Drug, bio-affecting and body treating compositions inventions 07/09

20090191117 - anti-integrin antibodies, compositions, methods and uses: The present invention relates to at least one novel anti-alpha-V subunit antibodies, including isolated nucleic acids that encode at least one anti-alpha-V subunit antibody, alpha-V subunit, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.... Agent: Philip S. Johnson Johnson & Johnson

20090191119 - Cancerous disease modifying antibodies: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be... Agent: Mchale & Slavin, P.A.

20090191120 - Cancerous disease modifying antibodies: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be... Agent: Mchale & Slavin, P.A.

20090191118 - Cytotoxicity mediation of cells evidencing surface expression of trop-2: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be... Agent: Mchale & Slavin, P.A.

20090191121 - Targeting and imaging tumor vasculature using conjugates that bind to aminophospholipids: Disclosed is the surprising discovery that aminophospholipids, such as phosphatidyserine and phosphatidylethanolamine, are specific, accessible and stable markers of the luminal surface of tumor blood vessels. The present invention thus provides aminophospholipid-targeted diagnostic and therapeutic constructs for use in tumor intervention. Antibody-therapeutic agent conjugates and constructs that bind to aminophospholipids... Agent: Peregrine Pharmaceuticals, Inc.

20090191122 - Method for purification of 225ac from irradiated 226ra-targets: The present invention describes a method for purification of 225Ac from irradiated 226Ra-targets provided on a support, comprising a leaching treatment of the 226Ra-targets for leaching essentially the entirety of 225Ac and 226Ra with nitric or hydrochloric acid, followed by a first extraction chromatography for separating 225Ac from 226Ra and... Agent: Wilmerhale/new York

20090191123 - Novel imaging agents: The present invention provides a novel imaging agent suitable for the non-invasive visualization of fibrosis. A precursor for the preparation of the imaging agent is also provided by the invention, as well as a pharmaceutical composition comprising the imaging agent and a kit for the preparation of the pharmaceutical composition.... Agent: Ge Healthcare, Inc.

20090191124 - Pdgf-rbeta binders: Provided herein are PDGF-Rβ imaging agents that are polypeptides labeled with a signal generator (e.g., paramagnetic label, a radionuclide, or a fluorophore), wherein the imaging agents bind specifically to PDGFR-β. Also provided are in vivo imaging methods using the imaging agents.... Agent: General Electric Company Global Research

20090191125 - Diagnostic and therapeutic alkyl piperidine/piperazine compounds and process: o

20090191126 - Peptide and multivalent peptide conjugate for diagnosis and treatment of vascular plaques: This invention encompasses compositions and methods for treating and imaging vulnerable plaque and other inflamed regions in a subject.... Agent: Morgan, Lewis & Bockius LLP (sf)

20090191127 - Omentum and use thereof: In some embodiments, mammalian omentum and methods of using the same for treating symptoms and/or conditions related to dementia are provided. In addition, a composition comprising the omentum tissue and/or the extract thereof is described in some embodiments. In some other embodiments, methods of formulating and administering the composition are... Agent: Knobbe Martens Olson & Bear LLP

20090191131 - Use of particulate contrast agents in diagnostic imaging for studying physiological paramaters: The present invention relates to a method of imaging of an animate human or non-human animal body, which method comprises: administering parenterally to said body a particulate material comprising a matrix or membrane material and at least one contrast generating species, which matrix or membrane material is responsive to a... Agent: Ge Healthcare, Inc.

20090191128 - Core-shell nanoparticles for thearapy and imaging purposes: The invention relates to nanoparticles coated with an inorganic nanoscale material herein referred to as core-shell nanoparticle, in which the core material has a wider band gap than the shell material. The described core-shell nanoparticles are very suitable for the application in photodynamic therapy due to their enhanced energy transfer... Agent: Philips Intellectual Property & Standards

20090191129 - Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors: This invention relates to novel compounds suitable for labelling or already labelled by 18F, methods of preparing such a compound, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for diagnostic imaging by positron emission tomography (PET).... Agent: Millen, White, Zelano & Branigan, P.C.

20090191130 - De novo synthesis of bacteriochlorins: to produce the bacteriochlorin, wherein R is an acetal or aldehyde group. The condensing may be carried out in an organic solvent, preferably in the presence of an acid. The bacteriochlorins are useful for a variety of purposes such as active agents in photodynamic therapy, luminescent compounds in flow cytometry,... Agent: Myers Bigel Sibley & Sajovec

20090191132 - Coded medication and methods of preparing same for identification and distinguishment: A selected substance is dissolved into a given injectable fluid medication having an initial clear visual appearance. The selected substance is selected from a group of substances which, when dissolved in the injectable fluid medication, will alter the clear appearance to produce a non-clear or altered visual appearance. The altered... Agent: J. Bruce Hoofnagle

20090191135 - Methods for the dispersion of water-soluable or hydrophilic substances in a supercritically pressurized fluid: A method for encapsulating an active principle by dispersing the active principle in a supercritical fluid by adding a surfactant to the fluid. The surfactant is a block copolymer having at least one CO2-philic block and at least one nonionic hydrophilic block.... Agent: Foley And Lardner LLP Suite 500

20090191134 - Stable aerosol pharmaceutical formulations: The present invention provides a stable aerosol pharmaceutical formulation of a beta-agonist, an anticholinergic, or a combination thereof in combination with a cosolvent and optionally a surfactant. The invention also provides a method of making the stable aerosol pharmaceutical formulation and methods of treating bronchoconstriction, asthma and related conditions with... Agent: Conley Rose, P.C.

20090191136 - Use of active substance complexes of panthenol, glycerol, citrate and/or bisabolol against pollen allergies: A cosmetic or dermatological preparation for combating or substantially preventing pollen allergies. The preparation comprises panthenol, glycerol and at least one of citrate and bisabolol and has at least one of (i) a pH of from about 4.6 to about 5.4, (ii) a mass ratio of panthenol to citrate of... Agent: Greenblum & Bernstein, P.L.C

20090191137 - Method and material for controlling or eliminating potentially harmful, contaminating or nuisance micro-organisms or cells: A method is shown for reducing or eliminating the levels or activities of potentially harmful or contaminating organisms or cells by applying nanophase manganese (VII) oxide to solutions, surfaces or materials to eliminate, reduce or prevent the growth of potentially harmful, contaminating or undesirable microorganisms, such as algae and bacteria.... Agent: Whitaker, Chalk, Swindle & Sawyer, LLP

20090191138 - Novel topical formulations for improving the appearance of nails: A method is provided for improving the appearance of nails of a patient wherein a composition is topically applying to the patient's nail(s) exhibiting symptoms of at least one condition selected from the group consisting of onycholysis, onychoschizia or onychorrhexis and wherein the composition contains one or more biocompatible organic... Agent: Connolly Bove Lodge & Hutz LLP

20090191140 - Make-up powder, and process for its preparation: m

20090191139 - Water base slurry composition for cosmetic products and methods of use: This invention relates to water based slurry compositions of cosmetic and personal care products and methods of making and using water based slurry compositions for cosmetic and personal care products such as foundations, eye shadows, lotions, and creams.... Agent: Pillsbury Winthrop Shaw Pittman, LLP

20090191141 - Hair care compositions and methods of treating hair using same: The present invention provides kits and methods for treating hair on the scalp comprising non-toxic compositions providing beneficial effects on hair without employing high temperatures, free radical initiators or rinsing hair after applying the compositions.... Agent: Fitzpatrick Cella Harper & Scinto

20090191142 - Process for lightening direct dyeing or oxidation dyeing in the presence of at least one organic amine, device therefor and anhydrous composition: A process for dyeing human keratin fibers in the presence of at least one oxidizing agent, comprising applying to the fibers at least one anhydrous composition (A) comprising at least one fatty substance and at least one surfactant, at least one composition (B) comprising at least one oxidizing agent, and... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090191143 - Hair shaping kiet and process comprising at least one non-hydroxide base: The disclosure provides ready-to-use cosmetic compositions for permanently shaping keratin fibers comprising, as permanent hair-shaping active agent, a base not belonging to the hydroxide family. The disclosure also provides kits comprising compartments to be placed in contact to form the ready-to-use compositions, and processes using these compositions.... Agent:

20090191144 - Use of lipid components against pollen allergies: A cosmetic or dermatological preparation for combating or substantially preventing pollen allergies. The preparation comprises or essentially consists of a lipid phase which comprises one or more lipids and has a spreading coefficient of less than about 800 mm2/10 min at 25° C. and a viscosity of from about 40... Agent: Greenblum & Bernstein, P.L.C

20090191145 - Adhesive systems containing polyisocyanate prepolymers and aspartate-ester curing agents, processes for preparing the same, medical uses therefor and dispensing systems for the same: wherein X represents an n-valent organic radical derived from a corresponding n-functional primary amine X(NH2)n, R1 and R2 each independently represent an organic radical having no Zerevitinov active hydrogens and n represents a whole number of at least 2; and (B2) an organic filler having a viscosity of 10 to... Agent: Connolly Bove Lodge & Hutz, LLP

20090191146 - Methods for the modulation of neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections: Described is the modulation of the neovascularization and/or growth of collateral arteries and/or other arteries from preexisting arteriolar connections. Methods are provided for enhancing neovascularization and/or the growth of collateral arteries and/or other arteries from preexisting arteriolar connections comprising contacting organs, tissue or cells with a colony stimulating factor (CSF)... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090191148 - Cytokine muteins: The present invention relates generally to the treatment of an interleukin-11 (IL-11)-mediated condition. More particularly, the present invention provides the use of modified forms of IL-11 which modulate IL-11 signaling in the treatment of IL-11-mediated conditions.... Agent: Scully Scott Murphy & Presser, PC

20090191149 - Il-1alpha immunization induces autoantibodies protective against atherosclerosis: Immunization of a mammal with IL-1α, which causes the mammal to generate IL-1α autoantibodies, can be used to reduce the risk and severity of, or to reduce progression of, an atherosclerosis-related disease in the mammal. Progression of atherosclerosis-related diseases such as peripheral ischemic heart disease, coronary artery disease, cerebrovascular disease,... Agent: Banner & Witcoff, Ltd.

20090191150 - Methods of treating infections using il-21: Methods for treating mammals with infections, particularly viral infections using molecules that have an IL-21 functional activity are described. The molecules having functional activities include polypeptides that have homology to the human IL-21 polypeptide sequence and proteins fused to a polypeptide with IL-21 functional activity. The molecules can be used... Agent: Zymogenetics, Inc. Intellectual Property Department

20090191147 - Use of interleukin-11 to prevent immune-mediated cytotoxicity: The use of interleukin-11 to prevent, to ameliorate, and to treat an immune-mediated disease in a mammal in need of such treatment is disclosed.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090191152 - Intralymphatic chemotherapy drug carriers: A chemotherapeutic composition can be configured for subcutaneous administration for preferential intralymphatic accumulation while also providing a therapeutic systemic concentration that is not toxic. The composition can include a pharmaceutically acceptable carrier, and a nanoconjugate configured for preferential intralymphatic accumulation after subcutaneous administration. The nanoconjugate can include a nanocarrier configured... Agent: Workman Nydegger 1000 Eagle Gate Tower

20090191151 - Triazole-containing macrocyclic hcv serine protease inhibitors: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned... Agent: Elmore Patent Law Group, PC

20090191154 - Assembly and folding of fc-interferon-beta fusion proteins: Disclosed are Fc-interferon-beta (Fc-IFN-β) fusion proteins and nucleic acid molecules encoding them. The Fc-IFN-β fusion proteins include variants of the interferon-beta (IFN-β) protein that are altered to achieve enhanced biological activity, prolonged circulating half-life and greater solubility. Also disclosed are methods of producing the fusion proteins and methods of using... Agent: Goodwin Procter LLP Patent Administrator

20090191153 - Oximyl macrocyclic derivatives: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned... Agent: Elmore Patent Law Group, PC

20090191155 - Compositions and methods for ameliorating myosin viia defects: The invention provides compositions and methods for ameliorating defects in myosin VIIa (MYO7A) expression and/or function, including providing vectors for myosin VIIa expression and formulations comprising them, and methods of using them, for treating human retinitis pigmentosa (or retinal degeneration), and blindness and deafness such as that found in Usher... Agent: Morrison & Foerster LLP

20090191156 - Gm-csf cosmeceutical compositions and methods of use thereof: It has been discovered that granulocyte macrophage colony stimulating factor (“GM-CSF”) promotes migration of activated (but not differentiating) keratinocytes to wound sites. It was also discovered that GM-CSF increases the quantity and improves the quality of collagen. This growth factor specifically increases migration of keratinocytes of the “wound” phenotype but... Agent: Pabst Patent Group LLP

20090191157 - Use of recombinant modified vaccinia virus ankara (mva) for the treatment of type 1 hypersensitivity in a living animal including humans: The present invention relates to the use of a recombinant modified vaccinia virus Ankara (MVA) comprising a heterologous nucleic acid for the production of a medicament for the prevention and/or treatment of type I hypersensitivity in a living animal including humans. The invention further relates to a recombinant modified vaccinia... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090191172 - Method of controlling administration of cancer antigen: The present invention is directed to mammalian bi-specific T cells and methods for using these bi-specific T cells. More specifically, the invention relates to a method of controlling administration of cancer antigen to a subject by providing bi-specific T cells that express a viral antigen T cell receptor and a... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090191169 - Methods for gene transfer to mammals: e

20090191170 - Nucleic acid compositions and methods of introducing nucleic acids into cells: The invention relates to a bifunctional nucleic acid which includes a first nucleic acid which comprises an aptamer bonded to a second nucleic acid that possesses a biological activity (herein referred to as a “biological effector sequence”) and which is not a nucleic acid ligand.... Agent: Edwards Angell Palmer & Dodge LLP

20090191171 - Reprogramming of differentiated progenitor or somatic cells using homologous recombination: The present invention provides methods and compositions for reprogramming somatic cells to a more primitive state, such as induced pluripotent stem cells, using homologous recombination. The induced pluripotent stem cells generated by the methods of the present invention are useful in a variety of therapeutic applications in the treatment and... Agent: Dla Piper LLP (us)

20090191158 - Defective interfering virus: Cloned, i.e. defined, defective interfering (DI) influenza A virus is produced in embryonated hens eggs using a method which generates large quantities of DI virus material. Cloned DI virus is then used in tests on mice and ferrets given a lethal challenge of wild-type influenza A virus. When cloned DI... Agent: Brooks Kushman P.C.

20090191167 - Adult sertoli cells and uses thereof: The invention relates, in part, to non-neonatal Sertoli cells derived from non-rodent animals, pharmaceutical compositions comprising such Sertoli cells, and uses thereof. The non-neonatal, non-rodent Sertoli cells express more FasL than neonatal Sertoli cells, and they provide greater immunoprivilege than neonatal Sertoli cells. In some embodiments the Sertoli cells are... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090191162 - Catecholamine receptor modulation: The invention relates to receptors of catecholamines and their role in stem cell development and function.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090191165 - Fibrin glue composition for repairing nerve damage and methods thereof: A fibrin glue composition is for repairing nerve damage, and/or enhancing the functional recovery of a damaged nerve which includes fibrin glue and an amount of bone marrow stem cells (BMSCs) effective for repairing the nerve damage and/or enhancing at least partially the functional recovery. A method is also for... Agent: Panitch Schwarze Belisario & Nadel LLP

20090191164 - Human hematopoietic multipotent progenitor cells: A substantially enriched human multipotent progenitor cell population is provided, which is characterized as a progenitor cell capable of giving rise to the multipotent lineage but which lacks certain long-term self-renewal properties of the hematopoietic stem cell. Methods are provided for the isolation and culture of these cells. The cell... Agent: Stanford University Office Of Technology Licensing Bozicevic, Field & Francis LLP

20090191160 - Methods of producing pluripotent stem-like cells: The instant invention provides methods and compositions for the production and use of pluripotent stem-like cells from somatic cells, e.g., fibroblasts.... Agent: Edwards Angell Palmer & Dodge LLP

20090191159 - Multipotent/pluripotent cells and methods: Described herein are multipotent stem cells, e.g., human and other mammalian pluripotent stem cells, and related methods.... Agent: Wilson Sonsini Goodrich & Rosati

20090191168 - Pregnancy-induced oligodendrocyte precursor cell proliferation regulated by prolactin: The present invention relates to a method to increase oligodendrocytes and oligodendrocyte precursor cells through administration of prolactin or a prolactin inducing agent.... Agent: Fish & Richardson P.C.

20090191163 - Primed tissue for tissue engineering and methods of priming tissue: Provided is a composition comprising a primed engineered tissue construct, methods of making the composition, methods of using the composition in dermatologic surgery, and a kit for supplying surgical tissue graft components.... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20090191166 - Screening and therapy for lymphatic disorders involving the flt4 receptor tyrosine kinase (vegfr-3): The present invention provides materials and methods for screening for and treating hereditary lymphedema in human subjects.... Agent: Marshall, Gerstein & Borun LLP

20090191161 - Tenocyte cell culturing method: The present invention relates to a method for culturing tenocytes. In particular the present invention relates to a method for culturing tenocytes comprising the step of incubating tenocytes in a culture medium comprising insulin or functional derivative.... Agent: Woodcock Washburn LLP

20090191173 - Induction of neurogenesis and stem cell therapy in combination with copolymer 1: A method for inducing and enhancing neurogenesis and/or oligodendrogenesis from endogenous as well as from exogenously administered stem cells comprises administering to an individual in need thereof an agent selected from the group consisting of Copolymer 1, a Copolymer 1-related polypeptide, a Copolymer 1-related peptide, and activated T cells which... Agent: Cooper & Dunham, LLP

20090191174 - Blood processing device and associated systems and methods: The present invention is directed to an environmentally closed cell processing device, for the aseptic processing of blood cells. The device includes a continuous flow centrifuge, fluid reservoirs and fluid handling systems. Blood cells are processed by the present device, to remove their immunodominant antigens. Seroconverted cells and methods of... Agent: Foley & Lardner LLP

20090191175 - Therapeutic methods using peg-conjugated agents and devices for performing the same: The present invention discloses methods and devices for selectively removing anti-PEG antibodies from a patient's blood prior to administration of a PEG-conjugated therapeutic agent so as to prevent immune reactions against the PEG-conjugated therapeutic agents when the agents are administered as a therapeutic regimen. Removal of anti-PEG antibodies may be... Agent: Hogan & Hartson L.L.P.

20090191176 - Chondroitin sulfate synthesis promoter: The invention provides a chondroitin sulfate synthesis promoter useful for the treatment of diseases such as articular disease and discopathy. The chondroitin sulfate synthesis promoter contains, as an active ingredient, chondroitin sulfate glucuronyltransferase protein and/or chondroitin sulfate N-acetylgalactosaminyltransferase-1 protein, or a gene encoding the enzyme protein(s).... Agent: Factor & Lake, Ltd

20090191177 - Enantiomerically pure (-) 2-[1-(7-methyl-2-(morpholin-4-yl)-4-oxo-4h-pyrido[1,2-a]pyrimidin-9-yl)ethylamino]benzoic acid, its use in medical therapy, and a pharmaceutical composition comprising it - 026: The present invention relates to enantiomerically pure (−) 2-[1-(7-methyl-2-(morpholin-4-yl)-4-oxo-4H-pyrido[1,2-a]pyrimidin-9-yl)ethylamino]benzoic acid or pharmaceutically acceptable salts thereof, it being in a solid state, its use in medical therapy, pharmaceutical composition comprising it, its use in the preparation of a medicament for use in a method for preventing or treating diseases, and its... Agent: Pepper Hamilton LLP

20090191178 - Manufacture of highly phosphorylated lysosomal enzymes and uses thereof: This invention provides compositions of highly phosphorylated lysosomal enzymes, their pharmaceutical compositions, methods of producing and purifying such lysosomal enzymes and compositions and their use in the diagnosis, prophylaxis, or treatment of diseases and conditions, including particularly lysosomal storage diseases.... Agent: Marshall, Gerstein & Borun LLP

20090191179 - Use of factor viia analogues with increased activity: The invention relates to methods for the treatment of a severely bleeding subject.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090191180 - Use of factor viia analogues with increased activity: The invention relates to methods for treatment of bleeding episodes in a subject with thrombocytopenia.... Agent: Novo Nordisk, Inc. Intellectual Property Department

20090191133 - Modulation of stat 6 expression for the treatment of airway hyperresponsiveness: Disclosed herein are compounds, compositions and methods for modulating the expression of STAT 6 in a cell, tissue, or animal. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders related to expression of STAT 6, airway hyperresponsiveness, and/or... Agent: Knobbe, Martens, Olson & Bear, LLP

20090191187 - Antibodies against interleukin-1 receptor and uses thereof: The present invention relates to antibodies against interleukin-1 receptor (IL-1R), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. The antibodies of the present invention are particularly useful for treating a variety of inflammatory diseases including, but not limited to, rheumatoid arthritis.... Agent: Hoffmann-la Roche Inc. Patent Law Department

20090191186 - Antibodies to the pcrv antigen of pseudomonas aeruginosa: The current invention provides high-affinity antibodies to the Pseudomonas aeruginosa PcrV protein that have reduced immunogenicity when administered to treat Pseudomonas aeruginosa infections.... Agent: Townsend And Townsend And Crew, LLP

20090191182 - Compositions, kits, and methods for the modulation of immune responses using galectin-1: The present invention is based, in part, on the discovery that galectin-1 (Gal1) plays a role in immune disorders, including Hodgkin lymphoma. Accordingly, the invention relates to compositions, kits, and methods for detecting, characterizing, modulating, preventing, and treating immune disorders, e.g., Hodgkin lymphoma.... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20090191184 - Dcr3 polypeptide, a tnfr homolog: A TNFR homolog, identified as DcR3, is provided. Nucleic acid molecules encoding DcR3, chimeric molecules and antibodies to DcR3 are also provided.... Agent: Genentech, Inc.

20090191188 - Immunostimulatory nucleic acids: The invention relates to immunostimulatory nucleic acid compositions and methods of using the compositions. The T-rich nucleic acids contain poly T sequences and/or have greater than 25% T nucleotide residues. The TG nucleic acids have TG dinucleotides. The C-rich nucleic acids have at least one poly-C region and/ore greater than... Agent: Wolf Greenfield & Sacks, P.C.

20090191181 - Methods of modulating smyd3 for treatment of cancer: The present invention features a method for determining the methyltransferase activity of a polypeptide and screening for modulators of methyltransferase activity, more particularly for modulators of the methylation of retinoblastoma by SMYD3. The invention further provides a method or pharmaceutical composition for prevention or treating of colorectal cancer, hepatocellular carcinoma,... Agent: Townsend And Townsend And Crew, LLP

20090191185 - Reducing cancer cell invasion using an inhibitor of toll like receptor signaling: Provided herein are methods and compositions for reducing the invasiveness of cancer cells. Such methods and compositions are particularly useful for cancer cells that express a member of the Toll Like Receptor9 (TLR9) subfamily and are useful in selecting the proper treatment for a subject with cancer.... Agent: Fish & Richardson P.C.

20090191189 - Replikin peptides in rapid replication of glioma cells and in influenza epidemics: Peptides of influenza virus hemagglutinin protein and Plasmodium falciparum malaria antigen, antibodies specific for the peptides, influenza vaccines, malaria vaccines and methods of stimulating the immune response of a subject to produce antibodies to influenza virus or malaria are disclosed. Also disclosed are methods for formulating vaccines for influenza virus.... Agent: Kenyon & Kenyon LLP

20090191183 - Substituted indoles: Disclosed herein are substituted indole cysteinyl leukotriene receptor modulators of Formula I, process of preparation thereof, pharmaceutical compositions thereof, and methods of use thereof.... Agent: Global Patent Group - Apx

20090191190 - Anti-abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using s: The present invention relates to anti-Aβ globulomer antibodies having a binding affinity to Aβ(20-42) globulomer that is greater than the binding affinity of the antibody to Aβ(1-42) globulomer, antigen-binding moieties thereof, hybridomas producing said antibodies, nucleic acids encoding said antibodies, vectors comprising said nucleic acids, host cells comprising said vectors,... Agent: Paul D. Yasger Abbott Laboratories

20090191193 - Aryl vinyl sulfides, sulfones, sulfoxides and sulfonamides, derivatives thereof and therapeutic uses thereof: e

20090191197 - Cancerous disease modifying antibodies: The present invention relates to a method for producing cancerous disease modifying antibodies using a novel paradigm of screening. By segregating the anti-cancer antibodies using cancer cell cytotoxicity as an end point, the process makes possible the production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be... Agent: Mchale & Slavin, P.A.

20090191195 - Combination of fcgammariib-specific antibodies and cd20-specific antibodies and methods of use thereof: The present invention relates to methods of treatment, prevention, management or amelioration of one or more symptoms of diseases or disorders associated with CD20 expression that encompass administration of a combination of: (A) one or more antibodies that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies... Agent: Edell, Shapiro & Finnan, LLC

20090191192 - Humanized anti-ccr2 antibodies and methods of use therefor: The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of... Agent: Lando & Anastasi, LLP

20090191194 - Inhibition of protein kinase c alpha for the treatment of cardiovascular diseases: The invention relates to the use of agents impeding the expression and/or activity of protein kinase C-alpha (PKC-α), especially for treatment of patients with diabetes and complications such as diabetic nephropathy, retinopathy or neuropathy.... Agent: Venable LLP

20090191198 - Methods for blocking the interaction between nkp80 and its ligands: The present invention relates to applications based on the findings of the interaction between NKp80 and its ligand AICL. A method of treating or preventing inflammatory diseases in a subject is disclosed, comprising administering a substance blocking the interaction between NKp80 and AICL, in particular for treating autoimmune diseases. Preferably,... Agent: Klarquist Sparkman, LLP

20090191191 - Methods for the modulation of il-13: The present invention is drawn to methods for modulating IL-13 expression and/or activity in a mammal comprising administering an effective amount of an agent which modulates the expression and/or activity of IL-9.... Agent: Morgan Lewis & Bockius LLP

20090191196 - Use: The invention describes the use of an antibody specific for serum amyloid P component, for the treatment or prophylaxis of amyloidosis, and the use of a compound which depletes serum amyloid P component from the circulation in combination with an antibody specific for serum amyloid P component.... Agent: Frommer Lawrence & Haug

20090191199 - Glycoengineered, recombinant antibody: The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for... Agent: Sughrue-265550

20090191200 - Method for the treatment of multiple sclerosis by inhibiting il-17 activity: The present invention provides a method for the treatment and/or prophylaxis of multiple sclerosis (MS) comprising administering a therapeutically effective amount of an inhibitor of IL-17 activity.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090191201 - Combination of the application of antibodies for immunostimulation together with glucocorticoids: The present invention relates to methods for reducing or eliminating the non-specific release of a cytokine associated with a disease comprising administering at least one glucocorticoid and an immunostimulating antibody. Additionally, the present invention relates to a pharmaceutical composition that contains at least one immunostimulating antibody and at least one... Agent: Mandel & Adriano

20090191202 - Methods for manipulating phagocytosis mediated by cd47: Methods are provided to manipulate phagocytosis of cells, including hematopoietic cells, e.g. circulating hematopoietic cells, bone marrow cells, etc.; and solid tumor cells. In some embodiments of the invention the circulating cells are hematopoietic stem cells, or hematopoietic progenitor cells, particularly in a transplantation context, where protection from phagocytosis is... Agent: Stanford University Office Of Technology Licensing Bozicevic, Field & Francis LLP

20090191204 - Anti-psgl-1 antibodies: Immunoglobulin chains or antibodies having light or heavy chain complementarity determining regions of antibodies that bind to P-Selectin Glycoprotein Ligand-1. Also disclosed are methods of inducing death of an activated T-cell and of modulating a T cell-mediated immune response in a subject.... Agent: Wolf Greenfield & Sacks, P.C.

20090191203 - Bcma polypeptides and uses thereof: The present invention relates to BCMA polypeptide variants and their uses, particularly for therapeutic or prophylactic treatment in human subjects. The invention also relates to nucleic acids encoding said polypeptides, vectors comprising such nucleic acids and recombinant cells containing the same. The invention further discloses methods of producing such polypeptides,... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090191205 - Compositions and methods for treating and diagnosing cancer: The present invention relates to compositions and methods for characterizing, diagnosing and treating cancer. In particular, the present invention identifies LGR5 as a protein over-expressed in solid tumor stem cell. The present invention further identifies an interaction between RSPO1 and LGR5 as an alternative pathway for the activation of beta-catenin... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090191208 - Antibodies against flagellin and uses thereof: The present invention provides a novel class of monoclonal antibodies which have a high affinity, broad spectrum neutralizing reactivity to flagellin from various Gram-negative bacteria including, but not limited to, E. coli, Salmonella, Serratia, Proteus, Enterobacter, Citrobacter, Campylobacter and Pseudomonas. The present invention further provides methods of treating inflammatory bowel... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090191207 - Compositions and methods for the prophylaxis or treatment of viral diseases: The invention relates to the use preferably of at least one active ingredient for the prophylaxis or therapy of a viral disease, wherein this active ingredient inhibits at least one component of the cellular signal transduction pathway for the activation of the transcription factor NF-kB such that virus multiplication is... Agent: Mayer & Williams PC

20090191206 - Human semen enhancer of viral infection peptides (sevi) and their use: Subject of the invention are peptides corresponding to a fragment of amino acids 240-290 of human prostatic acid phosphatase. The invention also relates to nucleic acids, antibodies, medicaments and diagnostics and their use and use of the peptides for the treatment and diagnosis of viral diseases, especially HIV disease.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090191209 - Methods and compositions for targeting polyubiquitin: Anti-K63-linked polyubiquitin monoclonal antibodies, and methods for using the antibodies, are provided.... Agent: Genentech, Inc.

20090191210 - Method for inhibiting tumor invasion or spreading in a subject: The present invention provides for a method for inhibiting tumor invasion or metastasis in a subject which comprises administering to the subject a therapeutically effective amount of a form of soluble Receptor for Advanced Glycation Endproducts (RAGE). The present invention also provides a method for evaluating the ability of an... Agent: Cooper & Dunham LLP

20090191211 - Methods for damaging cells using effector functions of anti-epha4 antibodies: The present invention relates to the use of cytoxicity based on the effector function of anti-EphA4 antibodies. Specifically, the present invention provides methods and pharmaceutical compositions that comprise an anti-EphA4 antibody as an active ingredient for damaging EphA4-expressing cells using antibody effector function. Since EphA4 is strongly expressed in pancreatic... Agent: Townsend And Townsend And Crew, LLP

20090191212 - Angiopoietin-2 specific binding agents: Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090191213 - Compositions and methods for regulating nk cell activity: The present invention relates to novel compositions and methods for regulating an immune response in a subject. More particularly, the invention relates to specific antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects. The invention also relates to fragments and... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090191214 - Anti-human il-21 monoclonal antibodies: Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinant IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases,... Agent: Zymogenetics, Inc. Intellectual Property Department

20090191215 - Treatment with anti-vegf antibodies: This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents.... Agent: Genentech, Inc.

20090191216 - Antibody or a fragment thereof, having neutralizing activity against hiv: The invention relates to a monoclonal antibody or a fragment thereof, recognizing a peptide of sequence set forth as SEQ ID NO 7 or an analogue thereof, wherein the complementarity determining region 3 (CDR3) of its H chain variable region comprises the peptide sequence set forth as SEQ ID NO... Agent: Oliff & Berridge, PLC

20090191217 - Anti-il-1r1 single domain antibodies and therapeutic uses: Disclosed is the use of an antagonist of Interleukin 1 receptor type 1 (IL-1R1) for the manufacture of a medicament treating, preventing or suppressing lung inflammation or a respiratory disease. In some embodiments of the described invention, the medicament is for local administration to pulmonary tissue. Also disclosed are methods... Agent: Mcdermott Will & Emery LLP

20090191218 - Dna vaccines and methods for the prevention of transplantation rejection: Methods for preventing, delaying the onset of, or treating rejection of an allograft using a DNA vaccine, where the vaccine can comprise a polynucleotide encoding a pro-apoptotic protein, like BAX and/or a polynucleotide encoding an autoantigen or donor antigen, like secreted glutamic acid decarboxylase 55. Administering one of the DNA... Agent: Sheldon Mak Rose & Anderson PC

20090191219 - Methods for diagnosing and treating obesity by modulating the activity of auto-antibodies against the melanocortin-4 receptor: Disclosed are biological markers for obesity and methods for diagnosing and treating obesity and related conditions by detecting and modulating the activity of auto-antibodies against the melanocortin-4 receptor or a portion of the melanocortin-4 receptor. Also disclosed are methods for discovering new therapeutics which modulate the activity of auto-antibodies against... Agent: Joyce Von Natzmer Pequignot + Myers LLC

20090191220 - Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists: The ratio of concentrations of pro-adrenomedullin (pro-ADM)/pro-endothelin (pro-END) immunoreactivity in body fluids of critically ill patients is used as for the diagnosis, course control and prognosis, including an assessment of the mortality risk, of severe life threatening diseases. Further, a treatment of critically ill patients having high levels of pro-ADM... Agent: Millen, White, Zelano & Branigan, P.C.

20090191221 - Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same: The present invention provides antibodies (such as chimeric and humanized antibodies) specifically bind to an epitope on CD43 and CEA expressed on nonhematopoietic cancer cells. In addition, the present invention also provides use of the antibodies described herein for diagnostic and therapeutic purposes.... Agent: Morrison & Foerster LLP

20090191222 - Metastatic human tumor associated molecule, methods to detect both activated gene and protein and to interfere with gene expression: This disclosure characterizes the function and the expression of the human protein encoded by tm9sf4. The protein is highly expressed in malignant tumor cells and therefore is a novel marker for malignancy. Moreover, the protein is involved in the phagocytotic character of tumor cells. This disclosure provides methods and tools... Agent: Dodds & Associates

20090191224 - Nucleolin-mediated cancer diagnostics and therapy: The present invention provides for diagnostic kits for identifying cancer patients who are more susceptible to cancer therapies employing endostatin and other angiogenesis inhibitors, based upon the discovery that Nucleolin is a specific receptor for Endostatin. In particular, the diagnostic kits include antibody molecules against Nucleolin, DNA or RNA molecules... Agent: Heslin Rothenberg Farley & Mesiti PC

20090191223 - Peptides that selectively home to heart vasculature and related conjugates and methods: The present invention provides a variety of isolated peptides and peptidomimetics, which can be useful, for example, in constructing the conjugates of the invention or, where the peptide itself has biological activity, in unconjugated form as a therapeutic for treating any of a variety of cardiovascular diseases as described below.... Agent: Mcdermott, Will & Emery

20090191225 - Stably tethered structures of defined compositions with multiple functions or binding specificities: The present invention concerns methods and compositions for stably tethered structures of defined compositions with multiple functionalities and/or binding specificities. Particular embodiments concern stably tethered structures comprising a homodimer of a first monomer, comprising a dimerization and docking domain attached to a first precursor, and a second monomer comprising an... Agent: Immunomedics, Inc.

20090191229 - Adjuvancy and immune potentiating properties of natural products of onchocerca volvulus: The present disclosure relates to a method for inducing an antigen-specific immune response to an antigen in a mammal in need thereof, or potentiating an immune response, by administering to the mammal an effective amount of an isolated Ov-ASP, or at least one subunit of Ov-ASP.... Agent: K&l Gates LLP

20090191227 - Compositions and methods for enhancing immune responses to vaccines: The disclosure provides adjuvants, immunogenic compositions, and methods useful for vaccination and immune response. In particular, the disclosure provides a class of adjuvants comprising cationic lipid:co-lipid mixtures and methods for delivering formulated compositions.... Agent: Dla Piper LLP (us)

20090191228 - Immunogenic compositions capable of activating t-cells: Provided is means and methods for producing and/or selecting immunogenic compositions capable of activating a T-cell and/or a T-cell response, comprising providing the composition with at least one cross-beta structure and testing at least one immunogenic property.... Agent: Traskbritt, P.C.

20090191226 - Adjuvant formulation comprising a submicron oil droplet emulsion: An adjuvant composition, comprising a metabolizable oil and an emulsifying agent, wherein the oil and the detergent are present in the form of an oil-in-water emulsion having oil droplets substantially all of which are less than 1 micron in diameter. In preferred embodiments, the emulsifying agent is also an immunostimulating... Agent: Novartis Vaccines And Diagnostics Inc.

20090191230 - Cascade: The invention provides the use of an enzyme and a prodrug in the manufacture of a medicament for use in inducing an anti-tumour immune response in a human patient.... Agent: Marshall, Gerstein & Borun LLP

20090191232 - Combination therapy for the treatment of tumors: The present invention relates to a combination therapy method for treating gastrin-dependent tumors. The method comprises the immunization of a patient with an anti-gastrin 17 immunogenic composition in combination with the administration of chemotherapeutic agents such as 5-fluorouracil and leucovorin.... Agent: K&l Gates LLP

20090191231 - Prevention and treatment of amyloidogenic disease: The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Such methods entail administering agents that induce a beneficial immunogenic response against the amyloid deposit. The methods are useful for prophylactic and therapeutic treatment of Alzheimer's disease.... Agent: Townsend And Townsend And Crew, LLP

20090191233 - Influenza antigen delivery vectors and constructs: The present invention relates to fluorocarbon vectors for the delivery of influenza antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-influenza antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals, including humans.... Agent: Goodwin Procter LLP Patent Administrator

20090191234 - Vaccine: This invention relates to three newly-identified, distinct groups of antigenic peptides [LB1(f) peptides] from the same region of the P5-like fimbrin protein discovered using sequence data from the fimbrin protein of many Haemophilus influenzae strains. The invention additionally provides chimeric polypeptides that carry one or more representatives of such peptides... Agent: Calfee Halter & Griswold, LLP

20090191235 - Conformationally stabilized hiv envelope immunogens and triggering hiv-1 envelope to reveal cryptic v3-loop epitopes: Stabilized forms of gp120 polypeptide, nucleic acids encoding these stabilized forms, vectors comprising these nucleic acids, and methods of using these polypeptides, nucleic acids, vectors and host cells are disclosed. Crystal structures and computer systems including atomic coordinates for stabilized forms of gp120, and gp120 with an extended V3 loop,... Agent: Klarquist Sparkman, LLP

20090191236 - Piroplasmid vaccine: The invention relates to a Piroplasmid protein or an immunogenic fragment of said protein, and to a nucleic acid encoding said Piroplasmid protein or said immunogenic fragment. Furthermore, the invention relates to cDNA fragments, recombinant DNA molecules and live recombinant carriers comprising said nucleic acid. Also the invention relates to... Agent: Intervet/schering-plough Animal Health Attn: Jill Corcoran

20090191237 - Methods and reagents for vaccination which generate a cd8 t cell immune response: New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumour antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090191238 - Method for producing yeast expressed hpv types 6 and 16 capsid proteins: Mosaic VLPs of viral capsid proteins from different virus types are described, as are methods of making the same. Specifically, a diploid yeast strain that coexpresses the L1 and L2 capsid proteins of both HPV-6 and HPV-16 as mosaic VLPs is described. The mosaic VLPs induced the production of conformational... Agent: Novartis Vaccines And Diagnostics Inc.

20090191239 - Recombinant infectious laryngotracheitis virus and uses thereof: s

20090191240 - Flavivirus vaccines: The invention provides flavivirus vaccines and methods of making and using these vaccines.... Agent: Clark & Elbing LLP

20090191241 - Method and compositions for immunization with the pseudomonas v antigen: A method of inhibiting, moderating or diagnosing Pseudomonas aeruginosa infection is disclosed. In one embodiment, this method comprises inoculating a patient with an effective amount of PcrV antigen.... Agent: Quarles & Brady LLP

20090191242 - Novel homeopathic strain comprising a nosode from a protozoon of the genus trypanosoma: m

20090191244 - Microbubbles and methods for oxygen delivery: Compositions containing a carrier and microbubles encapsulating one or more gases, preferably oxygen, and methods for making and using the compositions are described herein. The microbubbles contain a lipid envelope formed of at least one base lipid and at least one emulsifying agent. The compositions may be administered to a... Agent: Pabst Patent Group LLP

20090191243 - High unsaponifiables and methods of using the same and its derivatives and uses thereof: Materials with high levels of unsaponifiable matter, such as extracts from plants, result in Hydrolysates with unique properties. It has been found that the application of a hydrolysis process to materials, particularly materials with a high level of unsaponifiables (e.g., at least 6% by total weight of the material) produces... Agent: International Flora Technologies, Ltd. C/o Cpa Global

20090191246 - Method of producing scale-like composite particles: In a method of producing scale-like composite particles, a dispersion liquid is prepared to include scale-like inorganic particles coated with resin and spherical fine particles having an average particle diameter in a range from 0.1 to 3.0 μm. The scale-like inorganic particles coated with the resin and the spherical fine... Agent: Kanesaka Berner And Partners LLP

20090191245 - Reduced-irritant dermatological compositions comprising at least one naphthoic acid compound and benzoyl peroxide and treatment of keratinization disorders therewith: Topically applicable, reduced-irritant dermatological/cosmetic compositions useful for the prevention/treatment of a variety of keratinization disorders, for example acne vulgaris, contain at least one naphthoic acid compound and an amount of benzoyl peroxide encapsulated in a polymeric system of porous particles for increasing cutaneous penetration of the at least one naphthoic... Agent: Buchanan, Ingersoll & Rooney PC

20090191247 - Anti-viral uses of carbon and metal nanomaterial compositions: This invention generally relates to use of novel nanomaterials comprised of metals in anti-viral applications. Such nanomaterials, for example, can be produced using a high power, pulsed plasma process, which plasma process, optionally, can be performed on the metal with a precursor (i.e., a gaseous precursor, such as acetylene or... Agent: Dillon & Yudell, LLP

20090191248 - Hand health and hygiene system for hand health and infection control: The present disclosure is directed to a system and methods for maintaining or improving hand health and hygiene. More particularly, the system and methods prevent or overcome skin damage caused by frequent hand washing and use of hand sanitizers and/or cleansers. The hand care system comprises an article, such as... Agent: Christopher M. Goff (27839) Armstrong Teasdale LLP

20090191250 - Antimicrobial composite material and method for fluid treatment: Composite materials with broad spectrum antimicrobial properties and methods and devices for fluid treatment utilizing said materials are provided. The antimicrobial composite materials may include combinations of activated carbon and a biguanide hydrate. A particular composition includes a mixture of carbon particles and particles of chlorhexidine hydrate, which is useful... Agent: Sutherland Asbill & Brennan LLP

20090191249 - Sheet substrates impregnated with aromatic releasing compositions and a method of delivery of aromatic releasing compositions: An article of manufacture and a method directed to application of aromatic releasing compositions impregnated within substrates such as non-woven paper materials (e.g., wipes, paper towels) and dispensable cloth materials (e.g., gauze or a thin fabric of silk, linen, or cotton materials) for providing relief from cold, allergies, sinus and... Agent: Robert M. Downey, P.A.

20090191251 - Antimicrobial molded article, laminate, heat insulating material and synthetic leather product: An antimicrobial molding is prepared by mixing: an antimicrobial composition containing two organic antimicrobial agents selected solely from imidazole organic antimicrobial agent and an inorganic antimicrobial agent; and a curing material such as a thermoplastic resin, light-curing resin, resin cured by two-pack mixing to be formed as a sheet, film,... Agent: Millen, White, Zelano & Branigan, P.C.

20090191252 - Pesticide compositions: This invention is related to the field of compositions useful in the control of pests that eat cellulose, such as, termites, where said composition is compacted and where said composition comprises alpha-cellulose, water, and a pesticide.... Agent: Dow Agrosciences LLC

20090191255 - Bmp-1 procollagen c-proteinase for diagnosis and treatment of bone and soft tissue defects and disorders: Uses of BMP-1 isoforms for diagnosing and treating defects and disorders of bone and soft tissues are described. Also described is a newly isolated variant of the BMP-1 isoform BMP-1-3.... Agent: Leon R Yankwich Yankwich & Associates

20090191254 - Inhibition of biofilm formation using bacteriophage: Disclosed herein are indwelling medical devices suitable for introduction into the body of a subject, wherein the indwelling medical devices comprise one or more surfaces on which a bacterial biofilm can form, and an effective amount of a bacteriophage composition carried by one or more of the surfaces, wherein the... Agent: Klarquist Sparkman, LLP

20090191253 - Use of k-252a and kinase inhibitors for the prevention or treatment of hmgb1-associated pathologies: The present invention relates to the use of K-252a, a physiologically active substance produced by microorganisms, and of its salts or synthetic and/or chemically modified derivatives for the prevention or treatment of HMGB1 associated pathologies. More particularly, the present invention relates to the use of K-252a for the prevention or... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090191256 - High water content ophthalmic devices: An ophthalmic device is disclosed that is a polymerization product of a monomeric mixture comprising (a) a major amount of a non-silicone-containing hydrophilic monomer; (b) a hydrophobic monomer; and (c) a crosslinking agent, wherein the ophthalmic device has an equilibrium water content of at least about 70 weight percent and... Agent: Bausch & Lomb Incorporated

20090191257 - Pain relief lollipop compositions and methods: A pain relief lollipop comprises a candy matrix comprising (a) an opioid agonist, (b) an N-methyl-D-aspartate receptor antagonist different from the opioid agonist, (c) gabapentin, or a pharmaceutically acceptable salt thereof, and, optionally, a muscle relaxant, sedative, anxiolytic, and/or antidepressant. A patient can self-administer small amounts of the pain relief... Agent: Knobbe Martens Olson & Bear LLP

20090191258 - Iodine-containing compositions: Compositions provided according to embodiments of the present invention include an inorganic clay admixed with an iodine-containing substance. Suitable iodine-containing substances include I2 and/or one or more iodine salts. Methods of treating a condition or disorder are provided according to the present invention which include administration of a therapeutically effective... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20090191260 - Aerosol and use thereof: The invention relates to an aerosol, in which a phase containing a solid substance is dispersed into a gaseous dispersant. The aim of the invention is to achieve a particularly effective anti-inflammatory action for the treatment of respiratory diseases. According to the invention, a depot is contained in the dispersed... Agent: Pearne & Gordon LLP

20090191261 - Antibody fragment-targeted immunoliposomes for systemic gene delivery: Nucleic acid-immunoliposome compositions useful as therapeutic agents are disclosed. These compositions preferably comprise (i) cationic liposomes, (ii) a single chain antibody fragment which binds to a transferrin receptor, and (iii) a nucleic acid encoding a wild type p53. These compositions target cells which express transferrin receptors, e.g., cancer cells. These... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090191263 - Compositions and methods for sirna inhibition of hif-1 alpha: RNA interference using small interfering RNAs which target HIF-1 alpha mRNA inhibit expression of the HIF-1 alpha gene. As HIF-1 alpha is a transcriptional regulator of VEGF, expression of VEGF is also inhibited. Control of VEGF production through siRNA-mediated down-regulation of HIF-1 alpha can be used to inhibit angiogenesis, in... Agent: Pepper Hamilton LLP

20090191259 - Efficient liposomal encapsulation: The present invention concerns a method for preparing liposomes, said method comprising the following steps: (I) mixing at least one liposome-forming lipid, a water-miscible organic solvent and aqueous medium Y to form a gel or liquid containing gel particles without sonication; and thereafter (II) (a) mixing the gel or liquid... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20090191264 - Epothilone compositions: This invention provides liposomal compositions comprising an epothilone.... Agent: Novartis Corporate Intellectual Property

20090191262 - Use of compounds of formula a-r-xo pharmaceutically acceptable salts thereof for producing a pharmaceutically preparations: The invention relates to a compound of formula A-R-X or pharmaceutically acceptable salts thereof which can be used for producing a pharmaceutical preparation suitable for preventing or treating cancerous diseases, pathological consequences of alcohol abuse, viral hepatitis, steatohepatitis, acute and chronic pancreatitis, toxic renal diseases, hepatic insulin resistance in diabetes... Agent: Norris, Mclaughlin & Marcus, Pa

20090191265 - Capsule formulation of pirfenidone and pharmaceutically acceptable excipients: A capsule formulation of pirfenidone is provided that includes pharmaceutically acceptable excipients. In one embodiment, this capsule formulation is capable of sustaining desirable pharmacokinetic responses in a patient. Further provided are methods of treating fibrotic conditions and other cytokine-mediated disorders by administering pirfenidone capsules of such formulation to a patient... Agent: Marshall, Gerstein & Borun LLP

20090191266 - Pregelatinized starch in a controlled release formulation: The present invention concerns the use of pregelatinized starch to prevent dose-dumping from a hydrophilic controlled release formulation. It also concerns a hydrophilic controlled release formulation, more in particular a hydrophilic controlled release matrix formulation, and solid dosage forms prepared therefrom, preferably for once daily oral administration. The hydrophilic controlled... Agent: Woodcock Washburn LLP

20090191267 - Oral compositions containing a salivation inducing agent: Oral dosage forms, and particles used therein, containing salivation inducing agents are disclosed. The salivation agents may be in the core of the dosage form and/or in coatings applied thereto, or alternatively may be within particles and/or the matrix of such dosage forms, in coatings applied to such particles, or... Agent: Philip S. Johnson Johnson & Johnson

20090191268 - Allergy vaccines: The invention provides methods and materials related to vaccines against self polypeptides. For example, the invention provides compositions containing chimeric IgE polypeptides and adjuvants.... Agent: Fish & Richardson P.C.

20090191270 - Structure and method for releasing substance therefrom: A method for releasing a substance from the structure set forth comprises the steps of applying stimulation from outside to the structure, and cleaving at least one of the bonding between the connecting member and the capping member and the bonding between the connecting member and the porous member to... Agent: Fitzpatrick Cella Harper & Scinto

20090191269 - Use of gelatin and a cross-linking agent for producing a cross-linking therapeutic composition: A therapeutic composition comprising gelatin and a cross-linking agent, for use in biological regenerative methods, which composition can be administered to a target area of the body while ensuring that the suspended cells and/or the growth factors remain in the target area of the body and at the same time... Agent: Leydig Voit & Mayer, Ltd

20090191271 - Topical formulations: Saturated, monophasic solutions of drug in a solvent and propellant mixture, together with a film-forming agent, exhibit transdermal diffusion fluxes greater than those predicted by Fick's law when applied topically.... Agent: Greenlee Winner And Sullivan P C

20090191273 - Metal oxide dispersion: A dispersion contains particles of metal oxide having a median volume particle diameter in the range from 24 to 42 nm which are dispersed in a medium which includes a mixture of at least one polar material having an interfacial tension of less than 30 mNm−1 and at least one... Agent: Jones Day

20090191272 - Use of vegetable fine grain sized fibres for preparing a nutritional composition for reducing mycotoxin bioavailability: The invention relates to using substantially insoluble vegetable fibres embodied in the form of microparticles at least 90% in weight of which has a size less than 700 μm as ingredients for preparing a nutritional composition for reducing a mycotoxin bioavailability in a human being or an animal during ingestion... Agent: Alston & Bird LLP

20090191274 - Pharmaceutical composition of amlodipine maleate having enhanced stability: The present invention relates to a coated particle of amlodipine maleate and a pharmaceutical composition for cardiovascular disease (CVD) comprising the coated particle of amlodipine maleate. The pharmaceutical composition of the present invention has stable bioavailability due to sufficient dissolution rate and prevents decomposition reaction of amlodipine to thereby being... Agent: Sughrue Mion, PLLC

20090191275 - Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract: Provided herein are methods for preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.... Agent: Townsend And Townsend And Crew, LLP

20090191276 - Colloidosomes having tunable properties and methods for making colloidosomes having tunable properties: Colloidosomes having tunable properties, methods for making the same, and applications thereof are described. Colloidosomes described herein are responsive to certain external stimulus to alter one or more properties of the colloidosome. Methods for making colloidosomes include forming a shell of colloidal particles on a core material where the colloidal... Agent: Harvard University & Medical School C/o Wolf, Greenfield & Sacks, P.C.

20090191277 - Protein nanoparticles: It is an object of the present invention to provide a highly safe composition comprising minoxidil and having high transparency due to the small particle size and high permeability into scalp and hair follicles. The present invention provides a protein nanoparticle which comprises minoxidil.... Agent: Birch Stewart Kolasch & Birch

20090191278 - Homeopathy-based formulation: A formulation comprising a potentized mixture of triturated Lichen planus tissue with histamine in the ratio of about 1:2 to about 2:1 in a vehicle, where the ratio of the mixture to the vehicle, can be varied from 1:99 to 50:50.... Agent: Lucas & Mercanti, LLP

20090191279 - Fluoride varnish compositions including an organo phosphoric acid adhesion promoting agent: Fluoride varnish compositions for temporary application and adhesion to a person's teeth. The composition includes a carrier comprising a resin and an adhesion promoting agent comprising an alkyl phosphoric acid. A fluoride ion source (e.g., a fluoride salt such as sodium fluoride) is dispersed within the carrier so as to... Agent: Workman Nydegger 1000 Eagle Gate Tower

20090191280 - Hard tissue repairing material: A hard tissue repairing material includes zirconia as a base material. A surface of the base material has a hydrophilic group. The hydrophilic group is bonded to zirconium atom in the base material. The base material may contain at least an ionic component that is selected from a group consisting... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090191281 - Pharmaceutical composition, process for manufacturing the same and its medical device for the treatment of cutaneous lesions: Use, method of manufacturing a pharmaceutical composition, pharmaceutical composition for the treatment of skin ailments comprising a therapeutic quantity in aqueous solution of nitric acid of 5 to 15 mmol/ml of pharmaceutical composition, and also comprising a zinc salt at a concentration of 0.01 to 0.015 mg of Zn2+ ions/ml... Agent: Sughrue Mion, PLLC

20090191282 - Controlled release composition containing a strontium salt: A controlled release pharmaceutical composition comprising a strontium salt. The invention also relates to the use of a strontium salt for treating a male suffering from diseases and conditions affecting metabolism and/or structural integrity of cartilage and/or bone. The invention also relates to the use of a strontium-containing compound for... Agent: Jones Day

20090191283 - Treatment of headaches, neck pain, joint pain and inflammatory-type pain: The formulation provides a method of treating headaches, neck, joint and inflammatory-type pain in a mammalian subject by administering to the subject a therapeutically effective amount of a nitrate-containing compound and a therapeutically effective amount of a selenium-containing compound. The formulation also provides kits and systems for practicing the subject... Agent: Morrison & Foerster LLP

20090191284 - Use of nitroaniline derivatives for the production of nitric oxide: The present disclosure relates to the use of a nitroaniline derivative of Formula (I) for the production of nitric oxide and for the preparation of a medicament for the treatment of a disease wherein the administration of nitric oxide is beneficial. The present disclosure furthermore relates to a method for... Agent: Seed Intellectual Property Law Group PLLC

20090191285 - Moisturizing liquid liner for barrier layer: A moisturizing liquid liner composition comprising a hydrophobic moiety and an emulsifier is described. Further, a substrate comprising a barrier layer and a moisturizing liquid liner composition comprising a hydrophobic moiety and an emulsifier is described. The substrate may be incorporated into an article.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090191286 - Binding and rinse-off of quaternary ammonium compounds for cosmetic and personal care applications: The disclosed composition and method includes the use of non-polar unsaponifiable material and polar hydrophilic salts in conjunction with quaternary ammonium compounds to provide hair treatment preparations for cosmetic and personal care applications. Disclosed features and specifications may be variously controlled, adapted or otherwise optionally modified to improve substantivity and/or... Agent: International Flora Technologies, Ltd. C/o Cpa Global

20090191287 - Mitigation of inflammation-related injuries: The present invention comprises formulae and methods that mitigate post-trauma inflammation, thus reducing overall damage to a patient. The formulae includes a uric acid agent, preferably a uric acid inhibitor, along with at least one other compound that is an inflammatory response suppressor. One preferred inflammatory response suppressor is a... Agent: Boyle Fredrickson S.c.

20090191288 - Composition to treat herpes, pseudomonas, staph, hepatitis and other infectious diseases: An improved method (process) and medicinal composition is provided to treat herpes, pseudomonas, hepatitis, staph (staphylococci) and other infectious diseases The inexpensive medicinal composition can be self-administered and maintained for a prescribed time. The attractive medicinal composition can comprise a quaternary ammonium salt surfactant, a skin protectant and an alcohol.... Agent: Tolpin & Partners, PC

20090191289 - Antimicrobial compositions: The present invention also provides a product (preferably a product other than a foodstuff, pharmaceutical, or cosmetic) comprising a preservative effective amount of cinnamaldehyde or a mixture of cinnamaldehyde and one or more alkanol-dialkyl hydantoins.... Agent: Darby & Darby P.C.

20090191290 - Dietary supplements containing extracts of cinnamon and methods of using same to enhance creatine transport: Materials derived from cinnamon can be administered orally to humans or animals for the purpose of controlling blood glucose as well improving glucose tolerance. Controlling glucose metabolism is essential for those with impaired glucose metabolism as is the case for those with Type II diabetes where insulin function is not... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20090191291 - Cosmetology product for skin and hair: The invention provides compositions for external application to the skin and/or hair. The composition may be used to treat burns, particularly minor burns, sunburns, eczema, psoriasis, dry or bleeding cuticles, dry or rough skin, athletes foot, razor rash or razor burn, cold sores, dry or chapped lips, dry or frayed... Agent: Morriss Obryant Compagni, P.C.

20090191292 - High essential oil and eugenol yielding cultivar of ocimum sanctum 'cim-ayu': The present invention relates to the development of a novel high herb yielding essential oil herb variety of Krishna Tulsi (botanically known as Ocimum sanctum, from the Family—Lamiaceae, 2n=32), and hereinafter named as ‘CIM-AYU’. In particular, the invention is related to the development of a high eugenol yielding variety of... Agent: Foley And Lardner LLP Suite 500

20090191293 - Composition for enhancing immunity and reducing inflammation related to infections: A composition and method for enhancing immunity and reducing or inhibiting inflammation related innate immune system activation while affording the body of a user protection against known detrimental byproducts of immune-response is provided. The composition comprises at least a therapeutically effective amount of vitamin C and extract of Andrographis paniculata.... Agent: Iovate Health Science Research Inc.

20090191294 - Grape cane product, and method of making: An extract of the grape plant obtained from grape plant cane is a powerful anti-oxidant, and offers a unique combination of beneficial organic chemicals, including trans-resveratrol, trans-viniferin, and oligostiibines. The grape plant cane product is produced essentially exclusively from grape plant cane, which is often discarded by vintners. Methods of... Agent: Law Office Of Terry L. Miller

20090185973 - Methods, compositions, unit dosage forms, and kits for pharmacologic stress testing with reduced side effects: Methods are presented for concurrent or sequential administration of pharmaceutical compositions of adenosine, dipyridamole, or combinations thereof, at dosages below the respective single agent doses. Methods are provided for detecting the presence and/or assessing the severity of myocardial ischemia during pharmacologic stress tests. Methods include sequential administration of a dipyridamole... Agent: Dechert LLP

20090185974 - Chimeric, human and humanized anti-granulocyte antibodies and methods of use: The present invention provides humanized, chimeric and human MN3 antibodies, fusion proteins, and fragments thereof. The antibodies, fusion proteins, and fragments thereof, as well as combinations with other suitable antibodies, are useful for the treatment and diagnosis of granulocyte related disorders and diseases, such as leukemia.... Agent: Immunomedics, Inc.

20090185977 - Composition and method for imaging cells: The invention relates to compositions containing a polynucleotide encoding for a reporter gene, a selectable marker and a regulatory element, that provide a method for imaging cells in vivo.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090185975 - Diagnostic probe for conformation disease: The invention provides a probe compound useful for early diagnosis of conformation disease, a composition and a kit comprising it for diagnosis for conformation disease, and a medical composition for treatment and/or prevention of conformation disease.... Agent: Nixon Peabody, LLP

20090185979 - Integrin heterodimer and an alpha subunit thereof: A recombinant or isolated integrin heterodimer comprising a novel subunit α11 in association with a subunit β is described. The integrin or the subunit α11 can be used as marker or target of all types of cells. The integrin or subunit α11 thereof can be used as marker or target... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090185976 - Method for introducing a chemical agent into the systemic circulation: A method for introducing a drug, imaging agent and/or other chemical agent into the systemic circulation comprises providing a the drug, imaging agent and/or other chemical agent in liposomes having a mean diameter of less than about 200 nm, preferably less than about 80 nm, as determined by negative-staining transmission... Agent: Christie, Parker & Hale, LLP

20090185978 - Monoclonal antibody capable of binding integrin alpha 10 beta 1: The present invention provides a monoclonal antibody or a fragment thereof binding to the extracellular I-domain of integrin alpha10beta1 and a hybridoma cell line deposited at the Deutsche Sammlung von Microorganismen und Zellkulturen GmbH under the accession number DSM ACC2583. Furthermore, the present invention also provides a monoclonal antibody or... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090185980 - In vivo drug screening system: The present invention provides imaging devices. The present invention also provides in vivo drug screening systems. The present invention further provides a method for in vivo drug screening.... Agent: Wpat, PC Intellectual Property Attorneys

20090185981 - Methods and apparatus for dynamically allocating bandwidth to spectral, temporal, and spatial dimensions during a magnetic resonance imaging procedure: A system and method of dynamically allocating signal acquisition bandwidth in magnetic resonance imaging systems. The use of high spatial and high spectral resolution in MRI imaging can improve the clinical usefulness of the images. However, during uptake and washout of contrast agents, the use of high spatial and high... Agent: Michael Best & Friedrich LLP

20090185982 - Approach to the treatment of compartment syndrome: The present invention relates to the use of an antisecretory protein or a derivative, homologue, and/or fragment thereof, having antisecretory activity, and/or a pharmaceutically active salt thereof, for the manufacture of a pharmaceutical composition and/or a medical food for the treatment and/or prevention of compartment syndrome. A compartment syndrome may... Agent: Bingham Mccutchen LLP

20090185983 - Aqueous medicament preparations for the production of propellant gas-free aerosols: The present invention relates to pharmaceutical preparations in the form of aqueous solutions for the production of propellant-free aerosols.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090185984 - Colorants surface treated with urethanes and methods for making and using the same: Compositions including colorants surface-treated with silicone polyurethanes, and methods for making surface-treated colorant products, are provided. Cosmetic, . . . personal care, skin care, nail and hair products including the surface treated colorants are disclosed. Also provided are methods for improving the hydrophobicity, or the adherence to the surface of... Agent: Michael Best & Friedrich LLP

20090185985 - Large-particle cyclodextrin inclusion complexes and methods of preparing same: The present invention provides a cyclodextrin inclusion complex comprising a guest encapsulated by cyclodextrin, the complex being greater than about 400 microns in size and methods of making the same. The present invention also provides a method of imparting flavor to a product to form a flavored product, the method... Agent: Michael Best & Friedrich LLP

20090185986 - Application of natural mineral water with special qualities in prophylaxis, hygiene and treatment of teeth and paradontium: The invention refers to a new application of mineral water in prophylaxis of dental and paradontium diseases, when water has the following physiochemical and biological properties: Ph 7.6-8.1; electrolytic conductivity 180-210 μS/cm at 20° C., hardness 110-150 mg Ca CO3/l; chlorides 0.5-2.5-mg Cl/l; fluorides 0.01-0.03 mg F/l; sodium 0.6-1.6 mg... Agent: Horst M. Kasper

20090185987 - Herbal dental care composition, method of manufacturing the same and use thereof: Disclosed herein is a herbal dental care composition comprising extracts of herbs Punica granatum, Acacia Arabica, Terminalia chebula, Terminalia bellerica, Emblica officinalis and Embelia ribes, optionally extract of Azadirachta indica and pharmaceutical acceptable excipients. Also disclosed are the methods of making the composition, formulating the same into different delivery systems... Agent: Knobbe Martens Olson & Bear LLP

20090185990 - Bioactive compositions from theacea plants and processes for their production and use: The present invention relates to isolated bioactive compositions containing bioactive fractions derived from Theacea plants. The present invention also relates to bioactive topical formulations containing the bioactive compositions. The present invention further relates to methods of using the bioactive compositions of the present invention, including, for example, methods for inhibiting... Agent: Heslin Rothenberg Farley & Mesiti PC

20090185989 - Cosmetic sun protection product based on w/si-emulsions: The invention relates to a cosmetic sun protection product based on W/Si emulsions, which product has improved effectiveness and, despite high content of organic sun protection filters, a very good sensory profile and, in particular, a long-lasting soft touch. The sun protection product includes 22-32 wt. % of a volatile,... Agent: Akerman Senterfitt

20090185991 - Enhanced photoprotective compositions: A photoprotective composition including a synergistic triplet combination of zinc oxide, styrene/acrylate copolymer and glycol. As a result of the inclusion of the synergistic triplet combination in a photoprotective composition, an unexpected boost in SPF is observed, as compared to a composition without the synergistic triplet combination.... Agent: Michaud-duffy Group LLP

20090185988 - Polyvinyl ultraviolet light absorbers for personal care: UV-absorbing polymers and copolymers suitable for Composition into sunscreens for the protection of human skin. The UV-absorbing chromophoric monomers chosen are simple and easily synthesized. With the correct choice of chromophoric monomer or mixture of monomers, protection against UV-A radiation or against both UV-A and UV-B radiation can be achieved.... Agent: Brett L. Nelson Eastman Chemical Company

20090185992 - Process for producing iron oxide coated pearlescent pigments: A pearlescent pigment, wherein the pigment is an inorganic material and the color of a homogeneous coating of the pigment, measured over a black background has a CIELAB hue angle, hab, from about 40 to about 320 degrees, wherein L* is from about 35 to about 80, and the chroma... Agent: Frost Brown Todd, LLC

20090185994 - Conditioning and colouring composition for hair: p

20090185993 - Process for colouring and permanent shaping keratin fibres: e—an aqueous colouring composition based on at least one hair direct dye is optionally mixed with a composition comprising at least one oxidizing agent and applied onto hair and rinsed off from hair with water after processing 5 to 45 min at a temperature of 20 to 45° C. and... Agent: Norris, Mclaughlin & Marcus, P.A.

20090185995 - Lubricious, non-tacky personal lubricant: This invention relates to personal lubricant compositions that are relatively non-tacky while maintaining lubricity.... Agent: Philip S. Johnson Johnson & Johnson

20090185996 - Hydroxyethyl starch-containing polypeptide compositions: The invention provides compositions containing hydroxyethyl starch and polypeptides, including therapeutic polypeptides such as interleukin-11, that provide for enhanced stability of the polypeptide following storage at room temperature or elevated temperatures.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090185997 - Methods of suppressing microglial activation and systemic inflammatory responses: Methods of suppressing the activation of microglial cells in the Central Nervous System (CNS), methods of ameliorating or treating the neurological effects of cerebral ischemia or cerebral inflammation, and methods of combating specific diseases that affect the CNS by administering a compound that binds to microglial receptors and prevents or... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090185999 - Derivatives of gefitinib: This invention relates to novel quinazoline derivatives, their derivatives, pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by inhibiting cell surface tyrosine receptor kinases.... Agent: Edwards Angell Palmer & Dodge LLP

20090185998 - New activated poly(ethylene glycols) and related polymers and their applications: There are disclosed chemically active poly(ethylene glycols) and other hydrophilic polymers that are suitable for coupling to pharmaceutically or diagnostically active agents such as peptides, oligonucleotides, proteins or non-peptide molecules. The compounds are represented by the formula Poly-(X—NH—CO-A)n wherein, Poly is a hydrophilic polymer having a molecular weight of from... Agent: Darby & Darby P.C.

20090186000 - Use of thymosin alpha 1 for preparing a medicament for the treatment of stage iv malignant melanoma: It is described the use of thymosin alpha in combination with dacarbazine and optionally with Interferon alpha, for preparing a medicament for the treatment of malignant melanoma on stage IV characterized by distant unresectable metastases.... Agent: Lucas & Mercanti, LLP

20090186001 - Methods for treating ischemic tissue: Compositions and methods for treating ischemic tissue are provided herein.... Agent: Dechert LLP

20090186003 - Herpes simplex virus expressing foreign genes and method for treating cancers therewith: An anti-cancer pharmaceutical composition includes a herpes simplex virus (HSV) vector into which a nucleic acid sequence encoding for an anti-cancer agent selected from interleukin-12, GM-CSF, and CD has been inserted. A method of treatment of a patient suffering from cancer includes administering to the patient the anti-tumor pharmaceutical composition... Agent: Gifford, Krass, Sprinkle, Anderson & Citkowski, P.C.

20090186002 - Raav-delivered alpha-1-antitrypsin compositions and method for the treatment and prevention of diabetes: The subject invention concerns materials and methods for gene therapy. One aspect of the invention pertains to vectors which can be used to effect genetic therapy in animals or humans having genetic disorders where expression of high levels of a protein of interest are required to treat or correct the... Agent: Haynes And Boone, LLPIPSection

20090186007 - Use of cells derived from adipose tissue for the preparation of an anti-tumor medicament: Use of cells isolated from extramedullary white adipose tissue, selected from the group consisting of the stromal-vascular fraction and a subpopulation of said stromal-vascular fraction consisting of adherent cells, for the preparation of an anti-tumor medicament.... Agent: Alston & Bird LLP

20090186004 - Method for preparing an organ for transplantation: The present invention provides a method for preparing an organ, particularly a kidney, for transplantation into mammals. In detail, the present invention provides a method for preparing autotransplantation of autologous organs, particularly a kidney, wherein the isolated autologous mesenchymal stem cells are transplanted into an embryo inside a pregnant mammalian... Agent: Kilyk & Bowersox, P.l.l.c.

20090186005 - Methods and compositions for treating motor neuron diseases comprising mesenchymal stem cells: Disclosed herein are a composition for treating motor neuron diseases, particularly amyotrophic lateral sclerosis (ALS), using mesenchymal stem cells, and a method for treating motor neuron diseases using the composition. The composition and treatment method can provide effective therapy for motor neuron diseases, particularly for amyotrophic lateral sclerosis (ALS).... Agent: Sughrue Mion, PLLC

20090186006 - Placental vascular lobule stem cells: The present invention provides isolated populations of stem and progenitor cells from fetal vascular lobules of the placenta. The isolated populations of stem and progenitor cells of the invention express the markers CD144, CD105, and/or CD31 and lack expression of the hematopoietic-lineage marker CD45. Under specific conditions, cells of the... Agent: The Law Office Of Jane K. Babin Professional Corporation

20090186008 - Flea head, nerve cord, hindgut and malpighian tubule nucleic acid molecules, proteins and uses thereof: The present invention relates to flea head, nerve cord, hindgut and Malpighian tubule proteins; to flea head, nerve cord, hindgut and Malpighian tubule nucleic acid molecules, including those that encode such flea head, nerve cord, hindgut and Malpighian tubule proteins; to antibodies raised against such flea head, nerve cord, hindgut... Agent: Sheridan Ross P.C.

20090186009 - Solid matter containing coenzyme q: In the solid of the present invention, the disintegratability is suppressed in the stomach, and rapidly disintegrated in the intestine. Accordingly, coenzyme Q is more quickly absorbed from the intestine, which in turn enhances the absorbability of coenzyme Q from the intestine. In addition, the production method of the present... Agent: Sughrue Mion, PLLC

20090186010 - Methods for the identification of ikkalfa function and other genes useful for treatment of inflammatory diseases: The invention provides a method for identifying genes involved in the NF-κB pathway comprised of the steps of determining the level of expression of a gene in an experimental sample obtained from the cells having deficient levels of a component of the NF-κB pathway; determining the level of expression of... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090186011 - Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof: This invention provides compositions of active highly phosphorylated lysosomal sulfatase enzymes, their pharmaceutical compositions, methods of producing and purifying such lysosomal sulfatase enzymes and compositions and their use in the diagnosis, prophylaxis, or treatment of diseases and conditions, including particularly lysosomal storage diseases that are caused by, or associated with,... Agent: Marshall, Gerstein & Borun LLP

20090186012 - Plant extract: The present invention relates generally to plant extracts and/or components isolated therefrom which exhibit desirable properties in relation to therapy. More particularly, the present invention relates to extracts and components isolated thereof from the plant genus Zingiber and in particular from the rhizome of the species Zingiber officinale (also known... Agent: Knobbe Martens Olson & Bear LLP

20090186013 - Inorganic materials for hemostatic modulation and therapeutic wound healing: The invention provides compositions, methods and devices relating to a silaceous oxide that generates a reduced heat of hydration upon contact with blood. By reducing the heat of hydration, the compositions provide a hemostatic agent that attenuates a tissue burning side effect of conventional hemostatic agents without adversely affecting the... Agent: Bozicevic, Field & Francis LLP

20090186016 - Augmentation of endothelial thromboresistance: Stretch-induced increased hemodynamic load adversely affects endothelial cell function and is an important contributor to thromboembolus formation in heart failure, valvular heart disease, atrial fibrillation, venous insufficiency, and pulmonary hypertension, and in thrombus occluded vein grafts. Local thrombus formation and thromboenbolic events can be reduced by inhibiting the TGF-beta signaling... Agent: Banner & Witcoff, Ltd.

20090186014 - Method for treatment of pancreatitis: A method for treating acute or chronic pancreatitis in a subject comprises administering to the subject a therapeutically effective amount of an ACE2 inhibitor.... Agent: Harness, Dickey, & Pierce, P.l.c

20090186015 - Micrornas differentially expressed in lung diseases and uses thereof: The present invention concerns methods and compositions for identifying a miRNA profile for a particular condition, such as lung cancer, and using the profile in assessing the condition of a patient.... Agent: Fullbright & Jaworski L.L.P.

20090186017 - Graft-versus-host disease predicting marker and use thereof: A test method that provides data useful in predicting the probability of onset of acute graft-versus-host disease (GVHD) is described along with a kit for performing the method, and a pharmaceutical preparation and a molecular targeted therapy for treating or preventing GVHD. The test method includes measuring the blood DNAM-1... Agent: The Webb Law Firm, P.C.

20090186023 - Antibodies directed against hepatitis c virus e1e2 complex, compositions of hcv particles, and pharmaceutical compositions: New conformational antibodies are directed against HCV and more particularly to monoclonal antibodies. Described compositions of particles are liable to be recognized by the antibodies, as are pharmaceutical compositions containing them. Also described are HCV enveloped subviral particles or purified HCV enveloped complete viral particles, and the processes for preparing... Agent: Young & Thompson

20090186019 - Antigen binding molecules that bind egfr, vectors encoding same, and uses thereof: The present invention relates to antigen binding molecules (ABMs). In particular embodiments, the present invention relates to recombinant monoclonal antibodies, including chimeric, primatized or humanized antibodies specific for human EGFR. In addition, the present invention relates to nucleic acid molecules encoding such ABMs, and vectors and host cells comprising such... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090186018 - Compositions and methods for the treatment of rheumatoid arthritis: The present invention relates to compositions containing novel proteins and methods of using those compositions for the diagnosis and treatment of immune related diseases.... Agent: Genentech, Inc.

20090186020 - Melanocortin receptor binding mimetibodies, compositions, methods and uses: Melanocortin receptor binding mimetibody polypeptides are disclosed. Polynucleotides encoding these polypeptides, cells comprising these polynucleotides or expressing the mimetibodies, and methods of making and using the forgoing are also disclosed.... Agent: Philip S. Johnson Johnson & Johnson

20090186021 - Methods of preventing or treating inflammatory or autoimmune disorders by administering cd2 antagonists in combination with other prophylactic or therapeutic agents: The present invention provides to methods of preventing, treating or ameliorating an autoimmune or inflammatory disorder or one or more symptoms thereof utilizing combinatorial therapy. In particular, the present invention provides methods of preventing, treating, or ameliorating an autoimmune or inflammatory disorder or one or more symptoms thereof comprising administering... Agent: Jones Day

20090186022 - Organic compounds: The present invention relates to human thymic stromal lymphopoietin (hTSLP) antibodies and especially those which neutralize hTSLP activity. It further relates to methods for using anti-hTSLP antibody molecules in diagnosis or treatment of hTSLP related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis inflammatory bowel disease, and Hodgkin's lymphoma.... Agent: Novartis Institutes For Biomedical Research, Inc.

20090186026 - Ephrin and eph receptor agonists for modulation of bone formation and resorption: Compositions that stimulate bone formation and inhibit bone resorption through activation of both arms of EphrinB2-EphB4 signaling are provided. The composition comprises a bi-functional molecule having at least one EphB4 ligand-binding domain conjugated to an anti-EphB4 antibody.... Agent: Wyeth Patent Law Group

20090186025 - Fusion protein comprising an fc receptor binding polypeptide and an antigenic polypeptide for mediating an immune response: The present invention provides a fusion protein comprising an Fc receptor binding polypeptide and an antigenic polypeptide. The fusion peptide may further comprise a linker sequence or hinge portion which joins the Fc receptor biding polypeptide and the antigenic polypeptide. The Fc receptor binding polypeptide typically comprises the CH2 constant... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20090186024 - Gene expression signatures for oncogenic pathway deregulation: The disclosure relates to identifying deregulated pathways in cancer. In certain embodiments, the methods of the disclosure can be used to evaluate therapeutic agents for the treatment of cancer.... Agent: Michael Best & Friedrich LLP

20090186027 - Single chain antibodies against beta-amyloid peptide: Anti-AβP scFvs and single domain antibodies were generated, and when these antibodies were displayed on filamentous phage or as soluble protein molecules, stabilized by the maltose binding protein, they could prevent the fibrilization of Abp 1-40 and disaggregate Abp 1-40 fibrils generated in vitro. The anti-Aβp scFv antibodies also stained... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090186033 - Anti-amyloid immunogenic compositions, methods and uses: The present invention provides a recombinant immunogenic obtained by tandem multimerization of a B-cell epitope bearing fragment of Aβ42, within the active loop site of a carrier (display site), preferably bacterial thioredoxin (Trx). Polypeptides bearing multiple copies of Aβ42 fragments, preferably with an interposed amino acid linker, were constructed and... Agent: Young & Thompson

20090186030 - Antibodies that bind both bcma and taci: Molecules that interfere with the binding of a tumor necrosis factor receptor with its ligand, such as a soluble receptor or an anti-receptor antibody, have proven usefulness in both basic research and as therapeutics. The present invention provides antibodies that bind two tumor necrosis factor receptor family members: the transmembrane... Agent: Zymogenetics, Inc. Intellectual Property Department

20090186029 - Antibodies that specifically bind hedgehog-derived polypeptides: The present invention provides two novel polypeptides, referred to as the “N” and “C” fragments of hedgehog, or N-terminal and C-terminal fragments, respectively, which are derived after specific cleavage at a G′CF site recognized by the autoproteolytic domain in the native protein. Also included are sterol-modified hedgehog polypeptides and functional... Agent: Lisa A. Haile, J.d., Ph.d. Dla Piper US LLP

20090186032 - Bio-markers for diagnosing diabetic retinopathy: Disclosed herein are bio-markers for diagnosing diabetic retinopathy, a use of proteins, whose expression level down-regulated or up-regulated in the tears of a non-proliferative diabetic retinopathy (NPDR) patient, as bio-markers for diagnosing diabetic retinopathy, and a composition and kit for diagnosing diabetic retinopathy comprising antibodies against said proteins.... Agent: Sughrue Mion, PLLC

20090186031 - Compositions and methods for treating osteolytic disorders comprising mmp-14 binding proteins: Provided are methods and compositions for using MMP-14 or MMP-9 binding proteins alone or in combination with other therapeutic agents to treat osteolytic disorders such as osteotropic cancer and osteoporosis.... Agent: Lowrie, Lando & Anastasi, LLP

20090186028 - Detection of mutations in a gene associated with resistance to viral infection: A method for detecting a mutation related to the gene encoding LDLR. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the wild-type and mutated genes, or a polynucleotide... Agent: C. Rachal Winger

20090186035 - Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer: Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring... Agent: Dickstein Shapiro LLP

20090186034 - Gene expression markers for inflammatory bowel disease: The present invention relates to methods of gene expression profiling for inflammatory bowel disease pathogenesis, in which the differential expression in a test sample from a mammalian subject of one or more IBD markers relative to a control is determined, wherein the differential expression in the test sample is indicative... Agent: Goodwin Procter LLP Attn: Patent Administrator

20090186036 - Anti-alpha v beta 6 antibodies: Monoclonal antibodies that specifically bind to M.96. Also included are methods of using these antibodies to treat mammals having or at risk of having O06-mediated diseases, or to diagnose % Qmediated diseases.... Agent: Mcandrews Held & Malloy, Ltd

20090186037 - Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith: The present invention provides a method for inhibiting an immune response and a method for inhibiting rejection of transplanted tissues. This method comprises preventing an endogenous molecule on a cell selected from the group consisting of gp39 and CD40 antigens from binding its endogenous ligand and preventing an endogenous molecule... Agent: Louis J. Wille Bristol-myers Squibb Company

20090186038 - Methods of preventing or treating respiratory conditions: The present invention provides prophylactic an therapeutic protocols designed to prevent, manage, treat, or ameliorate a respiratory condition or one or more symptoms thereof. In particular, the present invention provides methods for preventing, managing, treating, or ameliorating a respiratory condition or one or symptoms caused by environmental factors or a... Agent: Medimmune, LLC Jonathan Klein-evans

20090186039 - Novel use of grp 94 in virus infection: A novel use of GRP 94 in treatment of virus infection is provided. More specifically, a method of inhibiting virus infection by inhibiting expression of GRP 94 and/or inactivating activity of GRP 94, and a method of developing drugs for preventing and/or treating virus infection and/or diseases caused by virus... Agent: Jhk Law

20090186040 - Dosing methods for treating autoimmune diseases using a taci-ig fusion protein such as atacicept: In various embodiments, the present invention provides methods, compositions, dosing, and administration schedules for treatment of autoimmune diseases, including systemic erythematosus (SLE), for example, comprising administering to a patient in need of such treatment a TACI-Ig fusion molecule such as atacicept. In one embodiment, the TACI-Ig fusion molecule is administered... Agent: Alston & Bird LLP

20090186041 - Anti-tsg101 antibodies and their uses for treatment of viral infections: The present invention provides antibodies that bind to the C-terminal region of TSG101. The invention also provides methods of using the TSG101 antibodies for the treatment of viral infections, including HIV and Ebola virus infection.... Agent: Steven B. Kelber

20090186042 - Identification and use of novopeptides for the treatment of cancer: Disclosed are compositions relating to novopeptides identified by the presence of frameshift mutations in tumor genes previously not identified as being oncogenic. The disclosed peptides can be used in the disclosed methods for the treatment of cancer.... Agent: Nixon Peabody, LLP

20090186043 - Method and compositions for preventing and treating streptococcus pneumoniae infection: A method of preventing and/or treating S. pneumoniae infection in mammalian subjects, wherein said method comprises administering to said subjects a composition comprising one or more agents that are capable of inhibiting the binding of the S. pneumoniae cell wall protein FBA to the respiratory tract cells of said subject.... Agent: Nixon & Vanderhye, PC

20090186044 - Type iv collagen-like immunoreactive peptide: A type IV collagen-like immunoreactive peptide immunologically reacts with an isolated, chronic nephritis-derived biological sample. Preferably, the type IV collagen-like immunoreactive peptide includes at least one member selected from the group consisting of at least one chain selected from alpha 1 to alpha 6 chains as a constituent alpha chain,... Agent: Sughrue Mion, PLLC

20090186047 - Hcv vaccinations: The invention relates to a method for preventing or treating Hepatitis C Virus (HCVi) infections, wherein a HCV vaccine comprising an effective amount of at least one HCV T-cell antigen and a polycationic compound comprising peptide bonds is administered to a human individual bi-weekly at least 3 times.... Agent: Fulbright & Jaworski L.L.P.

20090186046 - Hepatitis c virus non structural fusion protein: The present invention relates to an isolated fusion protein comprising at least three NS polypeptides originating from a hepatitis C virus which are configured in said fusion protein in an order which is distinct of the order in which they appear in the native configuration. The present invention also relates... Agent: Buchanan, Ingersoll & Rooney PC

20090186045 - Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants: The invention provides consensus sequences for hepatitis C virus 1a and 1b. Also provided are non-synonymous changes for each residue of the consensus sequences. These sequences are useful as compositions or vaccines for prophylactic use or treating HCV-infected individuals. Also provided are methods for lessening the chances for a HCV-infected... Agent: Banner & Witcoff, Ltd.

20090186048 - Tuberculosis vaccines comprising antigens expressed during the latent infection phase: The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing, boosting or treating infection caused by a species of the tuberculosis complex (M. tuberculosis, M. bovis, M. africanum, M. microti). The immunogenic composition, vaccine or pharmaceutical composition comprise a fusion polypeptide, which comprises one or more... Agent: Knobbe Martens Olson & Bear LLP

20090186049 - Method of treating mage positive cancer: The present invention relates to methods for treating a range of cancers, for example MAGE positive cancers, including, but not limited to melanoma and non-small cell lung cancer (NSCLC). The present invention relates to methods for treating cancer in the adjuvant (eg. post-operative) setting and the active disease setting.... Agent: Glaxosmithkline Corporate Intellectual Property, Mai B482

20090186050 - Live attenuated metapneumovirus strains and their use in vaccine formulations and chimeric metapneumovirus strains: The invention relates to an isolated mammalian negative strand RNA virus, metapneumovirus (MPV), within the sub-family Pneumoviridae, of the family Paramyxoviridae with one or more genetic modifications. The present invention also relates to the mutant components, i.e., nucleic acids and proteins, of these mutant mammalian MPVs. These mutant mMPV can... Agent: Jones Day

20090186051 - Compositions comprising hmw-maa and fragments thereof, and methods of use thereof: This invention provides recombinant polypeptides comprising a fragment of a High Molecular Weight Melanoma-Associated Antigen (HMW-MAA), recombinant Listeria strains comprising same, and methods of inducing an immune response and treating and impeding the growth of tumors, comprising administering same.... Agent: Pearl Cohen Zedek Latzer, LLP

20090186052 - Use of botulinum toxin for porlonged local desensitization: The invention concerns the use or a fragment of botulinum toxin having said toxin activity for preparing a medicine for reversibly desensitizing an area of the skin, said skin area being designed to receive injections. Said injections can be related, for example, to repeated delivery of insulin, growth hormones or... Agent: Hunton & Williams LLP Intellectual Property Department

20090186054 - Composition with controllable appearance: A composition intended to be applied on a surface and having an appearance controllable by an external field is disclosed. The composition comprises: a plurality of field responsive particles with a particle appearance, and a liquid with a liquid appearance, the liquid appearance being distinct from the particle appearance, the... Agent: Philips Intellectual Property & Standards

20090186055 - Makeup compositions for keratinous substances: c

20090186053 - Surface-modified non-metal/metal oxides coated with silicon dioxide: Surface-modified metal oxide particles coated with silicon dioxide and having a low structure are produced by adding a base dissolved in water, with stirring, to a dispersion consisting of a metal oxide, at least one compound of the type XnSi(OR)4−n and water, separating off, optionally washing with water, drying and... Agent: Smith, Gambrell & Russell

20090186056 - Compositions and methods for preventing infection: This invention relates to cholesterol-sequestering agents and methods of using cholesterol-sequestering agents to prevent infection. The compositions of the invention can be used to decontaminate skin and environmental surfaces that are contacted with microorganisms such as envelope viruses.... Agent: Knobbe Martens Olson & Bear LLP

20090186057 - Topical use of probiotic bacillus spores to prevent or control microbial infections: Compositions including an isolated Bacillus species, spores or an extracellular product of B. coagulans, suitable for topical application, for inhibiting growth of yeast, fungus, bacteria or Herpes simplex virus are disclosed. Methods of inhibiting growth of yeast, fungus, bacteria or Herpes simplex virus by topical application of compositions that include... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090186058 - Microencapsulation of biocides and antifouling agents: The present invention relates to microencapsulated compositions of isothiazolone derivatives and other water insoluble biocides or antifouling agents. In particular, the present invention relates to microencapsulated 4,5 dichloro 2 n-octyl-3(2H)-isothiazolone(DCOIT), useful in marine antifouling coatings and paints.... Agent: Thompson Hine L.L.P. Intellectual Property Group

20090186059 - Devices and methods for elution of nucleic acid delivery complexes: Embodiments of the invention include devices and methods for the controlled elution of nucleic acid delivery complexes. In an embodiment, the invention includes a method of making a medical device. The method can include complexing nucleic acids with a carrier agent to form a delivery complex solution, applying the delivery... Agent: Pauly, Devries Smith & Deffner, L.L.C.

20090186060 - Methods of enhancing radiation effects with metal nanoparticles: The present invention provides methods of using metal nanoparticles 0.5 to 400 nm in diameter to enhance the dose and effectiveness of x-rays or of other kinds of radiation in therapeutic regimes of ablating a target tissue, such as tumor. The metal nanoparticles can be administered intravenously, intra-arterially, or locally... Agent: Scully Scott Murphy & Presser, PC

20090186064 - Antimicrobial material and method for making the same: This invention provides a modified catheter biomaterial that provides both immediate, and long-term microbiocidal effects on otherwise antibiotic-resistant strains of microorganisms. The material, which exhibits good mechanical performance characteristics for medical devices, is composed of a hydrophobic polyurethane (PU), a hydrophilic polyethylene vinyl acetate (PEVA), a soluble silver salt and... Agent: Loginov & Associates, PLLC

20090186061 - Composition comprising polymeric, water-insoluble, anionic particles, processes and uses: The present invention relates to an injectable composition which comprises polymeric, water-insoluble, non-biodegradable, anionic particles, these particles having an irregular shape and a biocompatible carrier with a lubricated surface, a method for preparing the same, a method for treating a tissue in a patient which comprises injecting into the tissue... Agent: H. Jay Spiegel - H. Jay Spiegel & Associates

20090186065 - Isolating and purifying cells for therapy: The present invention provides methods and devices for isolating cells from a subject by circulating the subject's body fluid over an affinity moeity coupled matrix to isolate isolate cells from a subject either ex vivo or in vivo. One aspect of the invention is directed to connecting a subject to... Agent: Nutter Mcclennen & Fish LLP

20090186067 - Medical devices having improved mechanical performance: According to an aspect of the present invention, implantable or insertable medical devices are provided that contain at least one covalently crosslinked polymeric region, which contains at least one block copolymer comprising at least one low Tg block and at least one high Tg block.... Agent: Mayer & Williams PC

20090186066 - Method for production of chitosan-based films with enhanced cell adhering capacity, resulting product and applications: The method comprises, in general, the formation of a chitosan based film, the stabilization of said film and the activation of the cell adherence capacity by means of drying the stabilized and washed film. Additionally, the film may be biologically activated by means of fixing with a substance with biological... Agent: Moore & Van Allen PLLC

20090186062 - Method of repairing meniscal tears: A method of repairing a meniscal tear of a subject includes providing a sheet of collagen membrane material having on one side thereof a smooth barrier face which inhibits cell adhesion thereon and inhibits passage of cells therethrough. The sheet has a fibrous face opposite the smooth barrier face, the... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090186063 - Preparation for regeneration of postoperative, post-traumatic bone defects and method for implantation of this preparation: According to the invention preparation for regeneration of bone defects is employed in many branches of medicine, especially in orthopedics, dental surgery, reconstructive surgery, periodonthology and implantology. The preparation has been developed on the basis of inorganic chemical compound naturally occurring, i.e. deproteinized human bone, and on the basis of... Agent: Horst M. Kasper

20090186068 - Atomic plasma deposited coatings for drug release: Nanophase single or multiple layer time release coatings over drugs attached to metal surfaces are described. The coatings are deposited over a drug attached to a porous metal substrate using an atomic plasma deposition procedure. Porosity of the substrate and the number of APD deposited layers controls drug release when... Agent: Chameleon Scientific Corporation Aka Ionic Fusion Corporation

20090186069 - Coatings containing multiple drugs: A method for depositing a coating comprising a polymer and at least two pharmaceutical agents on a substrate, comprising the following steps: providing a stent framework; depositing on said stent framework a first layer comprising a first pharmaceutical agent; depositing a second layer comprising a second pharmaceutical agent; Wherein said... Agent: Wilson Sonsini Goodrich & Rosati

20090186070 - Particle immobilized coating and uses thereof: m

20090186071 - Clay-based hemostatic agents and devices for the delivery thereof: A device for promoting the clotting of blood comprises a clay material in particle form and a receptacle for containing the clay material. At least a portion of the receptacle is defined by a mesh. Another device comprises a gauze substrate and a clay material disposed on the gauze substrate.... Agent: Knobbe Martens Olson & Bear LLP

20090186072 - Operational status for active transdermal medicament patch: An active transdermal medicament patch includes a planar substrate with a therapeutic face releasably retainable against the skin of a patient. A return electrode and a medicament matrix susceptible to permeation by medicament are secured at separated locations on the therapeutic face and electrically conductively engage the skin. A detector... Agent: Kent S. Burningham Kent S. Burningham, P.C.

20090186076 - Combined use of tgf-beta signaling inhibitor and antitumor agent: The combined use of a TGF-β signaling inhibitor and an antitumor active substance or an imaging agent modified by a drug-encapsulating macromolecular micelle, or the like, is provided. The selective delivery capability of the antitumor active substance or the imaging agent to the target is improved, increasing the antitumoral activity... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090186075 - Composition: The present invention provides the use of a composition comprising an antigen recognizing molecule or fragment thereof and a lipid-based carrier for blocking an interaction between a ligand and a receptor.... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090186073 - Design of delivery vehicle based on rolling model: e

20090186074 - Lipid vesicles derived from olive oil fatty acids: Novel lipid vesicle compositions comprising lipids derived from olive oil fatty acids known as olivates, methods of their preparation, and methods of their use in cosmetics, food, dermatologics, and pharmaceuticals.... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090186079 - Oral and overall health by negating the biological effects of bacterial lipids: A method of treating an oral cavity condition, a topical composition for use in treating an oral cavity condition and a method of testing a potential agent for its ability to do the same are disclosed. When present in the oral cavity of an individual or animal, bacterial lipids cause... Agent: Alix Yale & Ristas LLP

20090186077 - Thermo-responsive materials: The invention is directed to, inter alia, injectable materials, which comprise a a zero-length cross-linking agent encapsulated in a thermo-responsive liposome dispersed in a polymer solution where the polymer and cross-linking agent are segregated at a first temperature, and non-segregated at a second temperature, and the material is injectable at... Agent: Pearl Cohen Zedek Latzer, LLP

20090186078 - Treatment of triple receptor negative breast cancer: The present invention relates to the use of a liposomal preparation for the manufacture of a pharmaceutical composition and the use of such a composition for the treatment of ‘triple receptor negative’ breast cancer.... Agent: Morgan Lewis & Bockius LLP

20090186080 - Methodology and apparatus for oral dual delivery of homeopathic products and non-homeopathic products: One possible embodiment of the invention may be an oral dosage apparatus comprising of a sealed, digestible container having an exterior that defines and seals a respective interior; the interior containing one or more non-homeopathic remedies; and the exterior presenting one or more homeopathic products. Another version of the invention... Agent: Long & Chybik

20090186081 - Disintegrating loadable tablets: A disintegrating loadable tablet product in compressed form comprising i) at least 60% w/w of a sorbent material having a specific surface area (BET surface area) of at least 50 m2/g as measured by gas adsorption or mixtures of such sorbent materials, and ii) a disintegrant or a mixture of... Agent: Edwards Angell Palmer & Dodge LLP

20090186082 - Method of manufacturing modified release dosage forms: In one embodiment, a dosage form comprises: (a) at least one active ingredient; (b) a molded core which is solid at room temperature; and (c) a shell which is in contact with at least a portion of the core, wherein the dosage form provides modified release of the active ingredient... Agent: Philip S. Johnson Johnson & Johnson

20090186084 - Form of administration of racecadotril: The present invention relates to a new racecadotril formulation in the form of tablets, the preparation process thereof and the use thereof to treat diarrhoea.... Agent: Stites & Harbison PLLC

20090186083 - Method for stabilization of isoxazole compound: 3-[(1S)-1-(2-fluorobiphenyl-4-yl)ethyl]-5-[[amino(morpholin-4-yl)methylene]amino]isoxazole is an isoxazole compound useful as a therapeutic agent for an autoimmune disease. The isoxazole compound can be stabilized by using an antioxidant such as a metabisulfite, bisulfite, sulfite or dibutylhydroxytoluene. A pharmaceutical composition for oral administration comprising the isoxazole compound and the antioxidant is an excellent pharmaceutical composition,... Agent: Sughrue Mion, PLLC

20090186085 - Methods and apparatus for determining formulation orientation of multi-layered pharmaceutical dosage forms: Rapid and accurate determination of the formulation orientation of multi-layer capsule-shaped tablets with respect to different internal formulation layers proximate to the opposite narrow and rounded ends of the tablets is required. By including an appropriate color scheme in multi-layer osmotic tablets, detection of the formulation orientation is achieved by... Agent: Woodcock Washburn LLP

20090186087 - Enteric sustained-release coated core and pharmaceutical dosage form and method for manufacturing the same: An enteric sustained-release coated core includes a drug-containing core and a coating film. The coating film includes 20%˜80% by weight of a hydrophobic polymer and 10%˜70% by weight of an enterosoluble material. The dissolution rate of the medical component in the drug-containing core is approximately less than 10% in hydrochloric... Agent: Rabin & Berdo, PC

20090186086 - Solid multilayer oral dosage forms: Provided are multilayer compressed oral dosage forms comprising naproxen or a pharmaceutically acceptable salt thereof and sumatriptan or a pharmaceutically acceptable salt thereof. Processes of making and using the oral dosage forms also are described.... Agent: Foley And Lardner LLP Suite 500

20090186089 - non-porous film for culturing cells: The invention relates to collagenous polypeptide films on which cells are cultivated. In particular the invention relates to such films that are used to treat wounds such as severe burns or physical or chemical injury. The invention also related to methods for producing such films.... Agent: Foley And Lardner LLP Suite 500

20090186088 - Inhalable drug: A process for preparation of particles of an inhalable drug is described. The process comprises combining a first liquid and a second liquid in a region of high shear, whereby the first liquid and the second liquid interact to form the particles of the drug. One of the first and... Agent: Townsend And Townsend And Crew, LLP

20090186091 - Methods of treating cardiovascular disorders associated with atherosclerosis: Layered phyllosilicates are useful for adsorbing and/or binding to cholesterol and, thereby, reducing blood cholesterol in a patient. Accordingly, provided herein is a method of reducing hypercholesteremia in a mammal comprising administering to said mammal a protonated and at least partially exfoliated layered phyllosilicate material alone and in combination with... Agent: Marshall, Gerstein & Borun LLP

20090186090 - Oral care composition to reduce or eliminate dental sensitivity: The invention includes an oral care composition that reduces and/or eliminates the perception of tooth sensitivity. The composition includes an adherent material and includes, in part, particles having a particle size of 2-5 microns. Also included within the scope of the invention are methods comprising the use of such compositions,... Agent: Colgate-palmolive Company

20090186092 - System and method for manufacturing oral osmotic drug delivery devices, and methods of administering same: A system and method for manufacturing oral osmotic drug delivery devices including the use of a mathematical model in deriving relationships between parameters used in manufacturing the devices for a desired release rate of the active drug substance contained therein. The derived relationship is then used to control the parameters... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090186093 - Methods for preparing core-shell composites having cross-linked shells and core-shell composites resulting therefrom: The present invention provides methods and compositions for the treatment of ion imbalances using core-shell composites and compositions comprising such core-shell composites. In particular, the invention provides core-shell particles and compositions comprising potassium binding polymers, and core-shell particles and compositions comprising sodium binding polymers, and in each case, pharmaceutical compositions... Agent: Senniger Powers LLP

20090186094 - Injectable and swellable microspheres for tissue bulking: The present invention relates to injectable compositions comprising biocompatible, swellable, hydrophilic, non-toxic and substantially spherical microspheres useful for tissue bulking. The invention also relates to methods of tissue bulking, particularly for the treatment of Gastro-esophageal reflux disease, urinary incontinence, or urinary reflux disease, using the injectable compositions.... Agent: Jones Day

20090186095 - Human hair root stimulator using emu oil to deliver specific therapeutic grade essential oils to the hair follicle: The invention utilizes the transdermal properties of oil from the Australian native Emu bird (Dromais Novae-Hollandiae) to deliver the specific therapeutic grade essential oil blend of Rosemary, Thyme, Lavender and Cedarwood through the human scalp to the hair root below, thus stimulating hair growth in live hair follicles.... Agent: Jennifer L. Bowers Bahney

20090186096 - Applications of microencapsulated essential oils: A new method for the preparation of microencapsulated essential oils is disclosed. The microcapsules containing essential oils or a formulation containing thereof may be used for various non-agricultural applications.... Agent: Nixon & Vanderhye, PC

20090186097 - Transgenic ungulates expressing ctla4-ig and uses thereof: The present invention provides ungulates, including pigs, expressing CTLA4-Ig, as well as tissue, organs, cells and cell lines derived from such animals. Such animals, tissues, organs and cells can be used in research and medical therapy, including xenotransplanation. In addition, methods are provided to prepare organs, tissues and cells expressing... Agent: King & Spalding

20090186098 - Sports drink composition: A composition having a high molecular weight carbohydrate with an average molecular weight greater than about 10,000. A hydrolyzed protein is also included in the composition, the protein having an average molecular weight less than about 10,000. The composition has an osmolality in solution that is less than the osmolality... Agent: Christopher & Weisberg, P.A.

20090186099 - Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system: Buccal aerosol sprays or capsules using polar and non-polar solvent have now been developed which provide biologically active compounds for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, active compound, and optional flavoring... Agent: Dickstein Shapiro LLP

20090186102 - Herbal medicine for osteoporosis and related conditions: A composition derived from six plant materials: ((i) Herba epimedii □□□ (Yin Yang Huo) (ii) Fructus Psoraleae (Psoralea coryfolia) □□□ (Bu Gu Zhi) (iii) Radix Rehmanniae preparatae (Rehmannia glutinosa) □□□ (Shu Di) (iv) Cortex Eucommiae □□ (Du Zhong) (v) Fructus Cnidii □□□ (She Chuang Zhi) (vi) Radix Astragali (Astragalus Membranaceus)... Agent: Stites & Harbison PLLC

20090186100 - Medicament for anti-aging skin care and wound healing and use thereof: A composition comprising Semen Lactucae sativae, Fructus oryzae and Resina Boswelliae carterii for prophylaxis or treatment of skin-aging, increasing skin hydration, improving wrinkle; and facilitating wound healing rate and improving wound quality.... Agent: Wpat, PC Intellectual Property Attorneys

20090186103 - Process for obtaining dried plant material: A process for obtaining dried plant material of plants from the Apocynaceae family, also known as Asclepiadaceae family, which contain steroidal glycosides having appetite suppressant activity. Said process covers (after harvesting and removing the roots a comminution step, a holding step of 1-36 hours in which moisture loss is limited,... Agent: Unilever Patent Group

20090186101 - Use of elderberry extract: The present invention relates to the field of viral therapy. More specifically, the present invention relates to the use of elderberry extract in the preparation of a pharmaceutical formulation for the treatment of an influenza viral infection. It also relates to a novel method of treatment of the avian flu... Agent: Fitzpatrick Cella Harper & Scinto

20090186104 - Herbal compositions for the treatment of mucosal lesions: The present invention provides therapeutic compositions comprising extracts of the plant species Echinacea purpurea and Sambucus nigra and the extract(s) of at least one further plant selected from the group consisting of Hypericum perforatum, Commiphora molmol and Centella asiatica. The compositions of the invention are of particular utility in the... Agent: Nixon & Vanderhye, PC

20090186105 - Device and composition for the delivery of a preservative-free balsamic cream: A device and composition for delivering menthol, camphor, eucalyptus essential oils, and other essential oils with balsamic benefits, to be used for the relief of symptoms of common cold.... Agent: Patent Correspondence Arnall Golden Gregory LLP

20090186106 - Pharmaceutical composition for use as a laxative: The invention relates to a pharmaceutical composition which is suitable in particular for use as purgative (cathartic), where the composition comprises in combination and in each case in pharmaceutically effective amounts (A) senna fruit dry extract and (B) plantago seeds (plantaginis ovatae semen). The composition can advantageously be manufactured by... Agent: Alston & Bird LLP

20090186107 - Orally administrable films and preparation thereof: The invention relates to an orally administrable mucoadhesive film which comprises one or more bioactive ingredients and, as a major film-forming polymer, at least one alginate which is capable of forming a low viscosity aqueous solution. Also provided is a process for preparing such films.... Agent: Nixon & Vanderhye, PC

20090186108 - Extract of herbal and composition containing the same: The present invention relates to herbal extracts of Sinapis Semen, Corydalis Tuber, Pharbitidis Seed, and Strychni Ignatii Semen, and a composition containing the same for treating and preventing gastrointestinal motility disorder. The extracts of the present invention have a remarkable effect of promoting gastrointestinal motility through HT3 receptor antagonism and/or... Agent: The Nath Law Group

20090186109 - Parthenolide free bioactive ingredients from feverfew (tanacetum parthenium) and processes for their production: The present invention relates to bioactive ingredients that include isolated bioactive fractions derived from cell juice of fresh biomass of a feverfew (Tanacetum parthenium) plant. The bioactive fractions are either free of or substantially free of α-unsaturated γ-lactones (e.g., parthenolide). Further, the bioactive fractions have anti-inflammatory and antioxidant activity. The... Agent: Heslin Rothenberg Farley & Mesiti PC

20090186110 - Guava extract: The present invention relates to the use of an extract of a plant selected from the group consisting of Psidium cattleianum, Psidium cattleianum ssp. Lucidum, Psidium guajava, Psidium guineense, Psidium littorale, Psidium molle and Psidium schiedeanum for the manufacture of a medicament for the treatment of a disease and/or condition... Agent: Fulbright & Jaworski L.L.P. Attn: MnIPDocket

20090186111 - Novel bacteria and pharmaceutically active products obtained therefrom: A substance obtainable from Staphylococcus Aureus bacteria or from a Staphylococcus Aureus bacteria culture, the substance characterized in having at least one of the following characteristics: (a) stimulates proliferation of bovine T-lymphocytes in vitro; (b) accelerates healing of skin wounds in mice and pigs; (c) prevents AIDS-like disease (ALD) in... Agent: Moore & Van Allen PLLC

20090180950 - Polychromatic, diversely-sized particles for angiography: The invention involves polychromatic particles of various sizes for assessing blood flow, blood barrier leakage and blood vessel leakage.... Agent: Schwegman, Lundberg & Woessner, P.A.

20090180951 - Inhibitors of integrin vla-4: e

20090180954 - Biokinetics of fast-clearing polypeptides: Provided herein are methods of reducing liver uptake in vivo of a polypeptide that specifically binds to a target comprising: (a) providing a polypeptide that specifically binds to a target; and (b) substituting at least one basic or at least one neutral amino acid residue of the native polypeptide from... Agent: General Electric Company Global Research

20090180953 - Invention concerning glp-1 and exendin: In the current invention peptides, which are derived from GLP-1 (glucagon-like peptide-1) and exendin-3 and/or exendin-4, are provided which bond to the GLP-receptor and can be used, labeled or unlabeled, for the production of an agent for diagnostic and therapy of benign and malignant diseases, in which GLP-1 receptor expression... Agent: Clark & Brody

20090180952 - Ligands binding the complex of urokinase-type plasminogen activator (uppa) and its receptor (upar) that inhibit downstream upar interactions: identification and use in diagnosis or therapy: Antibodies or other ligands specific for the binary uPA-uPAR complexes, for ternary complexes comprising uPA-uPAR and for complexes of uPAR and proteins other than uPA such as integrins inhibit the interaction of uPA and uPAR with additional molecules with which the complexed interact. Such antibodies or other ligands are used... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090180955 - Methods and compositions for detection of bacteria and treatment of diseases and disorders: Described herein are methods for detecting a bacteria in a subject and methods for detecting, imaging or diagnosing a site, disease, disorder or condition in a subject using bacteria. The methods can be used in conjunction with methods for treating a disease, disorder or condition. Such sites, diseases and disorders... Agent: K&l Gates LLP

20090180956 - Diagnostic for evaluating gastric evacuation function and/or small intestinal absorption function: The present invention provides a diagnostic agent for evaluating gastric emptying function and/or small intestinal absorptive capacity which imposes less burden to subjects and which is capable of obtaining objective test results in a short period of time. A diagnostic agent for evaluating gastric emptying function and/or small intestinal absorptive... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090180960 - Diagnosis and treatment of diseases involving platelet activation: Disclosed herein are compositions, methods, and kits for diagnosing or predicting a disease in a subject, for detecting activated platelets in a subject, and for treating a disease in a subject, wherein the diseases are mediated by platelet activation.... Agent: Clark & Elbing LLP

20090180958 - Diagnostic and therapeutic agents: The present invention relates to tumor targeting units comprising a peptide sequence X—R—Y—P—Zn, or a pharmaceutically or physiologically acceptable salt thereof. The invention further relates to tumor targeting agents comprising at least one targeting unit according to the present invention, directly or indirectly coupled to at least one effector unit.... Agent: Buchanan, Ingersoll & Rooney PC

20090180957 - Identification of a micro-rna that activates expression of beta-myosin heavy chain: The present invention relates to the identification of a microRNA, miR-208, that induces the expression of β-myosin heavy chain (β-MHC) and represses fast skeletal muscle contractile protein genes. Inhibition of this function is proposed as a treatment for cardiac fibrosis, hypertrophy and/or heart failure, and augmentation of this function can... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090180959 - Vdcc gamma-8 ion channel: VDCC γ-8 polypeptides comprising the amino acid sequence shown in SEQ ID NO. 3, SEQ ID NO. 5 or SEQ ID NO: 7, and homologues, variants and derivatives thereof are provided. Nucleic acids capable of encoding VDCC γ-8 polypeptide are also disclosed, in particular, those comprising the nucleic acid sequences... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090180962 - In vivo fluorescence sensors, systems, and related methods operating in conjunction with fluorescent analytes: C

20090180961 - Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs: The present invention is directed to methods for the identification and uses of a receptors that interact with anti-inflammatory compounds derived from eicosapentaenoic acid (EPA). The receptors are of the G-protein coupled receptor (GPCR) family, and are useful to screen candidate substances for anti-inflammatory activity, especially substances that are analogs... Agent: Fulbright & Jaworski L.L.P. Attn: MnIPDocket

20090180963 - Formulations for use in medical and diagnostic procedures: The present invention relates to formulations for use in medical or diagnostic procedures comprising a stabilizing agent alone or in combination with an osmotic agent. In one embodiment, the stabilizing agent is a natural hydrocolloid, preferably locust bean gum, and the osmotic agent is a sugar-based compound, preferably mannitol. The... Agent: Alston & Bird LLP

20090180965 - Methods for repair and regeneration of bone marrow: The invention is directed to a method for treating a tissue or organ in a subject by directly administering an effective amount of an exogenous, decellularized extracellular matrix or a mixture of extracellular matrix and mesenchymal stem cells into the intended site of activity, such as bone marrow cavity. In... Agent: Fulbright & Jaworski L.L.P.

20090180964 - Transmucosal delivery of optical, spect, multimodal,drug or biological cargo laden nanoparticle(s) in small animals or humans: A method is taught that provides for transmucosal delivery of a biological cargo and optical molecular imaging probes to a subject animal or human. At least one biological cargo-laden nanoparticle imaging probe is provided in a form that will be absorbed via mucosal tissue. The biological cargo-laden nanoparticle imaging probe... Agent: Carestream Health, Inc.

20090180966 - Cancer cell diagnosis by targeting delivery of nanodevices: Macromolecular contrast agents for magnetic resonance imaging are described. Biomolecules and their modified derivatives form stable complexes with paramagnetic ions thus increasing the molecular relaxivity of carriers. The synthesis of biomolecular based nanodevices for targeted delivery of MRI contrast agents are described. Nanoparticles (NP) have been constructed by self-assembling of... Agent: Thomas A. O'rourke Bodner & O'rourke, L.L.P.

20090180967 - Ultrsonically active microparticles and method of use: An ultrasonically active microparticle is taught that includes a porous interior particle having hydrophobic pores, a gas in the hydrophobic pores and a hydrophilic exterior shell surrounding the interior particle forming an ultrasonically active microparticle and allowing the microparticle to be suspended in an aqueous solution.... Agent: Robert A. Parsons

20090180968 - Metal coordination complexes of volatile drugs: The present disclosure provides a drug delivery device comprising a housing defining an airway, wherein the airway comprises at least one air inlet and a mouthpiece having at least one air outlet, at least one heated metal substrate disposed within the airway, at least one drug disposed on the at... Agent: Swanson & Bratschun, L.l.c

20090180969 - Pharmaceutical formulation comprising an anticholinergic drug: Pharmaceutical formulations suitable to be administered by pressurised metered dose inhalers (pMDIs) comprising a salt of 3-[[[(3-fluorophenyl)[(3,4,5-trifluoro phenyl)methyl]amino]carbonyl]oxy]-1-[2-oxo-2-(2-thienyl)ethyl]-1-azoniabicyclo[2.2.2]octane are effective for the prevention and/or treatment of an obstructive airways disease.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090180970 - Foamable composition combining a polar solvent and a hydrophobic carrier: a

20090180971 - Method for the prevention and/or activation of defense mechanisms in the human body against conditions, disorders or diseases relating to the presence of free radicals, such as: environmental pollution, aging or smoking: The invention provides a method for the prevention and/or activation of defense mechanisms in the human body against conditions, disorders or diseases relating to the presence of free radicals, such as; environmental pollution, aging or smoking by rising the administration to a mammal, namely a human being, of an effective... Agent: Furr Law Firm

20090180972 - Compositions of oxo-terpene derivatives and process for preparing the same: Described is to a process for augmenting, enhancing, modifying, or imparting a berry or citrus aroma or taste to a foodstuff or a beverage comprising the step of adding to a foodstuff or a beverage an aroma or taste augmenting, enhancing, modifying, or imparting quantity of at least an oxo-terpene... Agent: Joseph F. Leightner International Flavors & Fragrances Inc.

20090180973 - Compositions of oxo-terpene derivatives and process for preparing the same: Described is to a process for augmenting, enhancing, modifying, or imparting a berry or citrus aroma or taste to a foodstuff or a beverage comprising the step of adding to a foodstuff or a beverage an aroma or taste augmenting, enhancing, modifying, or imparting quantity of at least an oxo-terpene... Agent: Joseph F. Leightner International Flavors & Fragrances Inc.

20090180974 - Agent for protecting body cells: The invention relates to an agent or a composition for protecting body cells for the preventive and/or performance-enhancing influencing of body cells. The agent comprises a combination of herbal active substances and vitamins and amino acids, with one active substance consisting of polyphenols from green tea.... Agent: Fitch Even Tabin & Flannery

20090180977 - Controlled release compositions: A composition for controlled release of an active material such as a fragrance, sunscreen, vitamin or biocide in a product such as a hair shampoo, shower gel, another personal product such as an antiperspirant or deodorant, a household cleaning product such as a laundry detergent, hard surface cleaner or polishes,... Agent: Dow Corning Corporation Patent Department - C01232

20090180975 - Polynucleotide fragments of an infectious human endogenous retrovirus: Nucleotide sequences and fragments which code for a human endogenous retrovirus which is infectious. “Fragments” according to the present invention relate also to specific fragments of the sequences inserted into the vector pCR4-Topo and deposited as MERV-env, MERV-gag, MERV-prt and MERV-pol as mentioned above. Additionally, methods of using such sequences,... Agent: Fulbright & Jaworski L.L.P.

20090180976 - Single step milling and surface coating process for preparing stable nanodispersions: A single step milling and surface coating process allows for production of a stable dispersion of surface coated nanoparticles in an efficient manner. The process comprises providing feed particles, providing a coating agent, and generating the stable dispersion of surface coated nanoparticles by milling the feed particles in an aqueous... Agent: Dunlap Codding, P.C.

20090180978 - Cosmetic composition: The present invention provides a cosmetic composition ideally formulated as a make-up concealer including the following ingredients: caprylic/capric triglyceride, octyldodecanol, euphorbia cerifera (candelilla) wax, copernicia cerifera (camauba) wax, jojoba esters, polyethylene, stearalkonium bentonite, dimethicone, allantoin, tocopheryl acetate, ascorbyl palmitate, titanium dioxide, and iron oxides.... Agent: Cislo & Thomas LLP

20090180979 - Composition for the oxidation dyeing of keratin fibers comprising at least one cellulose with hydrophobic substituents, at least one oxidation dye, and at least one long-chain fatty alcohol, and methods of use thereof: The present disclosure relates to a dye composition for keratin fibers, comprising, in a medium suitable for dyeing: at least one nonionic derivative of cellulose comprising at least one hydrophobic substituent containing from 8 to 30 carbon atoms; at least one oxidation dye, and at least one fatty alcohol containing... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090180980 - Anti-arenaviral compunds: Described herein are 4-methyl-piperazine-1-carbothioic acid amide derivatives and analogs, as well as compositions containing the same, for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by hemorrhagic fever viruses, such as Arenaviruses.... Agent: Kramer Levin Naftalis & Frankel LLP Intellectual Property Department

20090180981 - Quinoxalinyl derivatives: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned... Agent: Elmore Patent Law Group, PC

20090180982 - Vaccine immunotherapy for immune suppressed patients: A method of immunotherapy to treat cancer or a synergistic anti-cancer treatment by administering an effective amount of a natural cytokine mixture (NCM), an effective amount of cyclophosphamide (CY), or an effective amount of indomethacin (INDO), wherein the NCM, CY, or INDO are administered singly or in communications thereof. An... Agent: Kohn & Associates, PLLC

20090180983 - Bicyclic, c5-substituted proline derivatives as inhibitors of the hepatitis c virus ns3 protease: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned... Agent: Elmore Patent Law Group, PC

20090180985 - Bridged carbocyclic oxime hepatitis c virus serine protease inhibitors: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. More specifically, the invention relates to oxime compounds containing a carbocyclic... Agent: Elmore Patent Law Group, PC

20090180984 - Macrocyclic oximyl hepatitis c serine protease inhibitors: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned... Agent: Elmore Patent Law Group, PC

20090180986 - Treating unwanted ocular conditions using an ascomycin macrolactam: The present invention provides compositions and uses of an ascomycin macrolactam for the treatment of an unwanted ocular condition occurring in a patient undergoing treatment with a therapeutically active agent for the treatment of cancer.... Agent: Allergan, Inc.

20090180989 - Compositions and methods for delivering nucleotide sequences to vertebrates: The invention includes methods of producing viral particles which include introducing into avian cells a nucleotide sequence encoding a replication deficient retroviral vector and introducing into the avian cells nucleotide sequence encoding products required for replication of the replication deficient retroviral vector, harvesting the viral particles and can include administering... Agent: Synageva Biopharma Corp.

20090180988 - Id-1 and id-2 genes and products as therapeutic targets for treatment of breast cancer and other types of carcinoma: A method for treatment and amelioration of breast, cervical, ovarian, endometrial, squamous cells, prostate cancer and melanoma in a patient comprising targeting Id-1 or Id-2 gene expression with a delivery vehicle comprising a product which modulates Id-1 or Id-2 expression.... Agent: Lawrence Berkeley National Laboratory

20090180987 - Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders: Methods for detecting a microorganism or cell in a subject and methods for detecting, imaging or diagnosing a site, disease, disorder or condition in a subject using microorganisms or cells and methods that microorganisms or cells for treating a disease, disorder or condition are provided. Sites, diseases and disorders include... Agent: K&l Gates LLP

20090180990 - Composition for maintaining healthy kidney function: The present invention provides a composition comprising prebiotic and probiotic components and is used to reduce elevated levels of nitrogenous waste products and to promote a healthy bowel microenvironment.... Agent: Licata & Tyrrell P.C.

20090180999 - Method of preventing, controlling and ameliorating urinary tract infections using cranberry derivative and d-mannose composition: A method is disclosed that prevents, controls and ameliorates urinary tract infections caused by E-coli by administering a therapeutically effective amount of a human dietary supplement composition comprising a cranberry derivative or proanthocyandin containing concentrate and D-mannose combined in a form suitable for oral consumption. The cranberry derivative or proanthocyandin... Agent: Allen, Dyer, Doppelt, Milbrath & Gilchrist P.A.

20090181000 - Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption: The invention relates generally to digestive disorders, and in particular to methods for treating irritable bowel syndrome by increasing carbohydrate absorption by administering a composition containing a Bacillus coagulans bacterium.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090181001 - Method of producing dry yeast containing s-adenosyl-l-methionine and composition for oral intake: A method for producing a dry yeast containing S-adenosyl-L-methionine using a yeast having production capability of S-adenosyl-L-methionine, in which a yeast cell concentrate separated from a cell culture liquid of the yeast is subjected to at least one treatment of (1) a treatment of adding a mineral acid to adjust... Agent: Antonelli, Terry, Stout & Kraus, LLP

20090180993 - Administration of therapeutic viruses: Two or more desensitization doses of a therapeutic virus are administered, followed by one or more escalated doses of the virus. In addition, the rate at which a therapeutic virus is administered can be controlled.... Agent: Wellstat Management Company. LLC

20090180992 - Compositions and methods for the treatment, mitigation and remediation of biocorrosion: A method of reducing biocorrosion or biofilm blockage in by identifying a target suspected of comprising one or more biocorrosive organisms and delivering to the target suspected of comprising the biocorrosive organisms an effective amount of a composition comprising an infective virulent viral panel sufficient to reduce the amount of... Agent: Chalker Flores, LLP

20090180991 - Method for treating inflammation associated with amyloid deposits and brain inflammation involving activated microglia: Filamentous bacteriophage which does not display an antibody or a non-filamentous bacteriophage antigen on its surface is used to inhibit or treat brain inflammation associated with amyloid deposits and/or involving activated microglia, to inhibit the formation of amyloid deposits, and to disaggregate pre-formed amyloid deposits.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090180994 - Oncolytic virus therapy: A method of treating a human subject with cancer is disclosed. A pharmaceutical composition is administered to the subject, the pharmaceutical composition comprising human leukocytes and a replication-competent oncolytic virus in suspension in a physiologically acceptable solution. Alternatively the pharmaceutical composition comprises human leukocytes or platelets infected with an oncolytic... Agent: Wellstat Management Company. LLC

20090180996 - Epigenetic modification of cell phenotype, fate and/or function by rna transfer: The invention relates to methods for altering the fate or differentiation status of somatic cells by RNA transfer. These methods can be used to transdifferentiate or dedifferentiate somatic cells of one phenotype or lineage into pluripotent cells or into somatic cells of a different lineage or phenotype.... Agent: Hunton & Williams LLP Intellectual Property Department

20090180997 - Mesenchymal stem cells and uses therefor: Methods of treating autoimmune diseases, allergic responses, cancer, or inflammatory diseases in an animal, promoting would healing, and promoting anglogenesis in an organ or tissue of an animal by administering to the animal mesenchymal stem cells in an effective amount.... Agent: Mcandrews Held & Malloy, Ltd

20090180998 - Methods of isolating non-senescent cardiac stem cells and uses thereof: The invention describes the isolation and methods of use of a non-senescent pool of adult cardiac stem cells. Methods for repairing aged myocardium or damaged myocardium using the isolated non-senescent adult cardiac stem cells are also disclosed. In addition, the invention describes a method for preventing or treating heart failure.... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090180995 - Novel anticoagulant polypeptides and complex: This invention is in the field of snake venom and the invention provides two novel snake polypeptides and nucleic acids encoding the same. Also provided are various uses methods and compositions based on the discovery of the novel snake polypeptides and their ability to synergistically inhibit coagulation.... Agent: Patent Correspondence Arnall Golden Gregory LLP

20090181002 - Reduced coenzyme q10-containing composition which is stable against oxidation, and method for stabilization of reduced coenzyme q10: The present invention provides a method for stabilization of reduced coenzyme Q10 characterized by concurrently containing a propylene glycol fatty acid ester in a composition containing reduced coenzyme Q10, and a composition containing reduced coenzyme Q10 and a propylene glycol fatty acid ester as essential constituting ingredients. According to the... Agent: Sughrue Mion, PLLC

20090181003 - Regulation of s6 kinsase protein activity and related methods: The invention encompasses agents and their methods of use for modulating the activity of kinases by effecting their acetylation or their binding to nucleic acids. The invention thus encompasses the modulation of S6 kinase by effecting its acetylation by p300. The invention further encompasses the modulation of S6 kinase 2... Agent: Morgan Lewis & Bockius LLP

20090181004 - Modified beta-lactamase and method for its preparation: The invention relates to targeted post translational modifi-cation of metallo-beta-lactamase by truncation and inser-tion of a dipeptide at the amino terminal end to reduce amino terminal heterogeneity in a recombinant DNA pro-duction system. A protein K-T-E-ΔBL is expressed, and modified by host proteases to E-ΔBL. Appropriate nucleotide molecules, vectors and... Agent: Banner & Witcoff, Ltd.

20090181005 - Nucleic acid encoding proteins involved in protein degradation, products and methods related thereto: In accordance with the present invention, there are provided novel Siah-Mediated-Degradation-Proteins (SMDPS) and/or SCF-Complex Proteins (SCPs). Nucleic acid sequences encoding such proteins and assays employing same are also disclosed. The invention SMDPs and/or SCPs can be employed in a variety of ways, for example, for the production of anti-SMDP and/or... Agent: Techlaw LLP

20090181007 - Culture medium and pharmaceutical composition for regenerating cartilage tissue, a method, uses and products related thereto: A composition for in vitro use as a culture medium or in vivo use as a pharmaceutical composition or a medical device, capable of accelerating the differentiation of stem cells into cells with a chondrocytic phenotype and of restoring the original trophism of chondrocytes, is described. The composition comprises, in... Agent: Steinfl & Bruno

20090181006 - Methods for diagnosing and treating cerebrovascular events based on nr2 peptides: Methods and kits for diagnosing and treating cerebrovascular events, and for defining the time and anatomical location of an event, are provided based on the detection and quantification of bound or total and unbound NR2 peptides in biological fluids. The methods are optionally performed in conjunction with neurological scoring and... Agent: Patent Correspondence Arnall Golden Gregory LLP

20090181009 - Antibodies to ntb-a: Anti-NTB-A antibodies and antigen-binding fragments thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding fragments are described. Also described are methods of using such antibodies and antigen-binding regions to bind NTB-A and treat diseases, such as hematologic malignancies, which are characterized by expression of NTB-A.... Agent: Arca Biopharma, Inc

20090181010 - Arginase ii: a target for the prevention of atherosclerosis: The instant invention provides methods and compositions for the treatment of. atherosclerotic disease. Specifically, the invention provides methods and compositions for modulating the activity of Arginase II, the production of Arginase II or the amount of free Arginase II for the treatment of atherosclerotic disease.... Agent: Edwards Angell Palmer & Dodge LLP

20090181011 - Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors: Immunomodulating agents comprising at least one Fc receptor ligand and at least one immunosuppressive factor are provided as are methods for their manufacture and use. The immunomodulating agents may be in the form of polypeptides or chimeric antibodies and preferably incorporate an immunosuppressive factor comprising a T cell receptor antagonist.... Agent: Townsend And Townsend And Crew, LLP

20090181012 - Method for detecting regulatory t cells using expression of folate receptor 4 as indicator, method for treating diseases using the detection method, pharmaceutical composition for immunostimulation, and method for treating diseases using the compostion: In the method of the present invention, Treg cells are detected from test cells containing (i) regulatory T cells and (ii) at least one type of cell selected from the group consisting of naive T cells and activated T cells, wherein expressions of folate receptor 4 on the surfaces of... Agent: Sughrue Mion, PLLC

20090181008 - Methods of treating alzheimer's disease: The invention provides biomarkers that are modulated in Alzheimer's disease including IL-1α, PDGF-BB, TNF-α, M-CSF, G-CSF, GNDF, eotaxin 2, MCP-3, PARC, AgRP, MSP-α, and BTC. Described are methods for preventing, treating, alleviating symptoms of, or delaying the development of Alzheimer's Disease (AD) in an individual diagnosed with Alzheimer's Disease or... Agent: Morrison & Foerster LLP

20090181013 - Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof: The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties... Agent: K&l Gates LLP

20090181014 - Compositions and methods for the diagnosis and treatment of tumor: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.... Agent: Genentech, Inc.

20090181016 - Fcgamma polymorphisms for predicting disease and treatment outcome: The invention provides compositions and methods for determining the likelihood of successful treatment with Cetuximab or other equivalent. The methods comprise determining the genomic polymorphism present in a predetermined region of the FcγRIIa gene at amino acid position 131 and/or alternatively the FcγRIIIa gene at amino acid position 158.... Agent: Foley & Lardner LLP

20090181015 - Humanized anti-cd40 antibodies and their methods of use: Provided are humanized anti-CD40 antibodies and antigen-binding fragments and methods for treating disease characterized by expression of CD40 antigen.... Agent: Seattle Genetics/fenwick

20090181018 - Humanized anti-ghrelin antibodies: Provided are humanized monoclonal antibodies, and antigen-binding portions thereof, which bind acylated and unacylated human ghrelin. Such antibodies are useful for neutralizing ghrelin activity and treating disorders in which ghrelin activity is detrimental, including obesity and related disorders, and various cancers.... Agent: Eli Lilly & Company

20090181019 - Methods for the treatment of gout: Disclosed are methods for the treatment and/or prevention of gout, comprising administering to a subject an effective amount of anti-IL-1β antibody or fragment thereof.... Agent: K&l Gates LLP

20090181020 - Methods of treating bone-loss disorders using a gm-csf antagonist: The invention is based on the discovery that GM-CSF antagonists can be used for the treatment of bone loss disorders, such as osteopenia. Accordingly, the invention provides methods of administering a GM-CSF antagonist, e.g., a GM-CSF antibody, to a patient that has a bone loss disorder and pharmaceutical compositions comprising... Agent: Townsend And Townsend And Crew, LLP

20090181017 - Prevention and treatment of complement-associated eye conditions: The invention concerns the prevention and treatment of complement-associated eye conditions, such as choroidal neovascularization (CNV) and age-related macular degeneration (AMD), by administration of Factor D antagonists.... Agent: Goodwin Procter LLP Attn: Patent Administrator

20090181021 - Ctsp cancer-testis antigens: The invention relates to CTSP polypeptides and the nucleic acid molecules that encode them. The invention further relates to the use of the nucleic acid molecules, polypeptides and fragments thereof in methods and compositions for the diagnosis, prognosis and treatment of diseases, such as cancer. More specifically, the invention relates... Agent: Wolf Greenfield & Sacks, P.C.

20090181022 - Bispecific binding agents for modulating biological activity: Methods for improving the biological and pharmaceutical properties of bispecific binding agents are described herein where the bispecific binding agent are able to target cells by a high affinity binding domain to a first cell surface marker that does not induce a significant biological effect and a low affinity binding... Agent: Townsend And Townsend And Crew, LLP

20090181027 - Anti-il-12/23p40 antibodies, epitopes, formulations, compositions, methods and uses: An anti-IL-12/23p40 antibody that binds to a portion of the IL-12 or IL-23 protein corresponding to the p40 subunit of IL-12 or IL-23, including compositions, formulations, and methods of administration have applications in diagnostic and/or therapeutic uses and devices.... Agent: Philip S. Johnson Johnson & Johnson

20090181028 - B-cell epitope peptides of hsp 65, novel amino acid sequences, dna encoding the amino acid sequences of said peptides, antibodies directed against said peptides and different uses thereof in the treatment of inflammatory and autoimmune diseases: B-cell epitope peptides of HSP 65, particularly the peptides comprising the amino acid sequence substantially as denoted by SEQ ID: NOs. 1-5 and their biologically functional homologues and derivatives thereof. Also included are polyclonal and monoclonal antibodies directed against them and their compositions for passive immunization against inflammatory and autoimmune... Agent: Fleit Gibbons Gutman Bongini & Bianco Pl

20090181029 - Methods for treating interleukin-6 related diseases: A pharmaceutical composition for the treatment of interleukin-6 (IL-6) related diseases, comprising an interleukin-6 antagonist (IL-6 antagonist) and immunosuppressants. The IL-6 antagonist is preferably an antibody to an interleukin-6 receptor (IL-6R).... Agent: Foley And Lardner LLP Suite 500

20090181023 - Nogo-a binding with enhanced affinity and pharmaceutical use thereof: The present invention provides a binding molecule which is capable of binding to the human NogoA polypeptide or human NiG or human NiG-D20 or human NogoA_342-357 with a dissociation constant <1000 nM, a polynucleotide encoding such binding molecule; an expression vector comprising said polynucleotide; an expression system comprising a polynucleotide... Agent: Novartis Corporate Intellectual Property

20090181024 - Novel composition and methods for the treatment of immune related diseases: The present invention relates to compositions containing a novel protein and methods of using those compositions for the diagnosis and treatment of immune related diseases.... Agent: Genentech, Inc.

20090181025 - T cell adhesion molecule and antibody thereto: An object of the present invention is to provide a T cell adhesion molecule that is expressed on a dendritic cell. According to the present invention, there is provided a protein comprising the amino acid sequence of SEQ ID NO: 2, SEQ ID NO: 4, SEQ ID NO: 6, SEQ... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090181026 - Tomoregulin-2-antibody compositions and methods for the diagnosis and treatment of alzheimer's disease: The present invention is directed to methods which exploit the discovery of tomoregulin-2 (TR2) in amyloid plaques in Alzheimer's disease using TR2-sepcific antibodies; methods and compositions comprising TR2-specific antibodies for the diagnosis and treatment of Alzheimer's disease; methods and compositions comprising immunizing TR2 peptides to induce an immune response, thereby... Agent: Davidson, Davidson & Kappel, LLC

20090181030 - Use of a preparation based on an antibody directed against a tumor-associated glycosylation: The invention relates to the use of a preparation based on an antibody directed against a tumor-associated glycosylation for preparing a medicament for the prophylactic and/or therapeutic treatment for the reduction or inhibition, respectively, of the growth of tumor cells in a cancer patient, as well as to a pharmaceutical... Agent: Birch Stewart Kolasch & Birch

20090181033 - Antibodies for identifying and/or isolating at least one cell population: Monoclonal antibodies, or fragments thereof, are used for isolating and/or identifying at least one cell population. The cell population can include any of the following types of cells: haematopoietic stem cells, neuronal stem cells, neuronal progenitor cells, mesenchymal stem cells and mesenchymal progenitor cells. The antibodies, or fragments thereof, bind... Agent: Knobbe Martens Olson & Bear LLP

20090181031 - Antibodies to bufadienolides prevent inhibition of na/k atpase and prolong survival in shock: The present invention relates to compositions and methods of use thereof for treatment of clinical conditions manifested from and/or exacerbated by a decrease or an inhibition of Na/K ATPase activity. The invention relates to composition comprises monoclonal or polyclonal antibodies to bufalin and/or bufalin sulfate, or vaccination against bufalin and/or... Agent: Donald S. Gann

20090181032 - Soluble hyaluronidase glycoprotein (shasegp), process for preparing the same, uses and pharmaceutical compositions comprising thereof: The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties... Agent: K&l Gates LLP

20090181034 - Antibodies and related molecules that bind to psca proteins: Antibodies and molecules derived therefrom that bind to novel PSCA protein, and variants thereof, are described wherein PSCA exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, PSCA provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The... Agent: Agensys C/o Morrison & Foerster LLP

20090181035 - Plexind1 agonists and their use: The present invention relates to PLEXIND1 agonists and their use for the treatment of disorders associated with angiogenesis, including cancer.... Agent: Genentech, Inc.

20090181036 - Pharmaceutical compositions and articles of manufacture useful in reversal of a clinical episode of an incurable disease and methods of use thereof: A method of reversing a clinical episode of a disease which is generally considered incurable in a subject. The method includes providing an immune-globulin preparation containing a detectable titer of antibodies to the disease that is generally considered incurable and administering die immune-globulin preparation to the subject. Preferably, the immune... Agent: Curatolo Sidoti Co., Lpa

20090181039 - Conjugates with reduced adverse systemic effects: A conjugate of an active agent and a targeting moiety having affinity for a target cell, in which the active agent has been modified by attachment of a cell membranes impermeabilizing group so that, if the active agent so modified is cleaved from the conjugate in the blood plasma instead... Agent: Louis J. Wille Bristol-myers Squibb Company

20090181038 - Method of decreasing cytotoxic side-effects and improving efficacy of immunoconjugates: Disclosed are methods, compositions and kits for improving targeting, in particular tumor targeting, of immunoconjugates. The method and composition relies on the sequestration of non-target cells that also express the antigen the immunoconjugate targets. Sequestration of those non-target cells in a variety of ways is disclosed. The methods, compositions and... Agent: Joyce Von Natzmer Pequignot + Myers LLC

20090181037 - Semi-synthetic glp-1 peptide-fc fusion constructs, methods and uses: The invention relates to semi-synthetic biologic molecules which are conjugates of GLP-1 peptides and human multimeric proteins or protein fragments, such as an antibody Fc joined by a non-peptidyl bond. The constructs demonstrate biological activity and are useful making therapeutic compositions and therapeutic formulations for use in treating diseases characterized... Agent: Philip S. Johnson Johnson & Johnson

20090181043 - Method for producing human anti-thymocyte immunoglobulins: Methods for producing improved anti-human thymocyte immunoglobulins from specific-pathogen-free animals are provided, without the need for an adsorption step on human tissues and the consequent drawbacks of such a step.... Agent: King Spalding LLP

20090181042 - Novel peptides of the respiratory syncytial virus (rsv) g protein and their use in a vaccine: The present invention relates to the Respiratory Syncytial Virus, and more particularly to the identification of novel antigens which are useful in particular for the therapeutic and prophylactic treatment of conditions caused by this virus. The present invention relates to methods of generating and/or increasing an immunogenic response directed against... Agent: The Firm Of Hueschen And Sage

20090181041 - Production of proteins carrying oligomannose or human-like glycans in yeast and methods of use thereof: Cell lines having genetically modified glycosylation pathways that allow them to carry out a sequence of enzymatic reactions, which mimic the processing of glycoproteins in humans, have been developed. Recombinant proteins expressed in these engineered hosts yield glycoproteins more similar, if not substantially identical, to their human counterparts. The lower... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090181040 - Triazinone compounds for treating diseases resulting from infestation with parasitic protozoans: The present invention relates to the use of triazinones such as triazinediones and triazinetriones for triazinetriones for the preparation of compositions for treating animals, in particular treating animals prophylactically, against parasitic protozoans, and to these compositions.... Agent: Bayer Healthcare LLC

20090181044 - Novel flavivirus antigens: The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability to induce an immune response to flaviviruses. The polypeptides and polynucleotides of the invention are useful in methods of inducing immune response against flaviviruses, including dengue viruses. Compositions and methods for utilizing polynucleotides and polypeptides of... Agent: Maxygen, Inc. Intellectual Property Department

20090181045 - Tat-based vaccine compositions and methods of making and using same: A Tat-based vaccine composition comprising at least one antigen coupled to at least one immunostimulatory lentivirus trans-activator of transcription (Tat) molecule wherein the antigen is a cancer antigen an infectious disease antigen or a fragment thereof and methods to treat disease by administering the Tat-based vaccine composition. An additional Tat-based... Agent: K&l Gates LLP

20090181046 - Capsid proteins and uses therefore: The present invention provides methods for the use of viral capsid proteins and chaperone proteins to produce immunogenic macro-molecular structures as antigen carrier to carry desired epitopes or antigens, for enhancing the immunogenicity of the carried epitopes or antigens for therapeutic or prophylactic vaccination. The immunogenic macro-molecular structures may also... Agent: Yunxu Cao

20090181047 - Anti-inflammatory hydrolysate of c. versicolor: Methods and compositions for reducing and/or inhibiting inflammation by topical application of dermatocosmetic compositions comprising effective amounts of extracts of Coriolus versicolor that have been hydrolyzed by an acid protease, preferably Rhizomucor miehei, and thereafter rendered substantially devoid of acid-protease activity.... Agent: Louis C. Paul, Esq. Louis Paul & Associates, LLC

20090181048 - Cancer drug delivery using modified transferrin: The present invention provides transferrin (Tf) conjugates of anti-cancer agents with increased cellular association and increased cellular internalization. The present invention also provides methods of treating cancer comprising administration of a Tf conjugate with increased cellular association to a subject with cancer. The present invention additionally provides methods of making,... Agent: Townsend And Townsend And Crew, LLP

20090181049 - Capsular polysaccharide solubilisation and combination vaccines: Precipitated bacterial capsular polysaccharides can be efficiently re-solubilised using alcohols as solvents. The invention provides a process for purifying a bacterial capsular polysaccharide, comprising the steps of (a) precipitation of said polysaccharide, followed by (b) solubilisation of the precipitated polysaccharide using ethanol. CTAB can be used for step (a). The... Agent: Novartis Vaccines And Diagnostics Inc.

20090181050 - Manufacturing method of combined vaccine: The present invention relates to a method for manufacturing a combined vaccine capable of concurrently preventing multiple diseases such as diphtheria, tetanus, pertussis, and hepatitis B which should be prevented in an infant. The method for manufacturing a combined vaccine according to the present invention includes the steps of independently... Agent: Swanson & Bratschun, L.L.C.

20090181051 - N-linked glycosylation alteration in e1 glycoprotein of classical swine fever virus and novel classical swine fever virus vaccine: E1, along with Erns and E2 is one of the three envelope glycoproteins of Classical Swine Fever Virus (CSFV). Our previous studies indicated that glycosylation status of either E2 or Erns strongly influence viral virulence in swine. Here, we have investigated the role of E1 glycosylation of highly virulent CSFV... Agent: Usda, Ars, Ott

20090181052 - Vaccine: A method for prevention of HPV infection and/or disease, the method comprising delivery of a first HPV vaccine comprising an L1 protein or immunogenic fragment thereof from at least HPV 16 and HPV 18, and a second HPV vaccine which does not comprise the HPV 16 and HPV 18 L1... Agent: Smithkline Beecham Corporation Corporate Intellectual Property-us, Uw2220

20090181053 - Capsular polysaccharide solubilisation and combination vaccines: Precipitated bacterial capsular polysaccharides can be efficiently re-solubilised using alcohols as solvents. The invention provides a process for purifying a bacterial capsular polysaccharide, comprising the steps of (a) precipitation of said polysaccharide, followed by (b) solubilisation of the precipitated polysaccharide using ethanol. CTAB can be used for step (a). The... Agent: Novartis Vaccines And Diagnostics Inc.

20090181054 - Multivalent meningococcal derivatized polysaccharide-protein conjugates and vaccine: The present invention describes derivatized polysaccharide-protein conjugates, a composition comprising one or more of such derivatized polysaccharide-protein conjugates and methods of immunizing human patients with the same. The derivatized polysaccharide-protein conjugates are purified capsular polysaccharides from Neisseria meningitidis serogroups A, C, W-135, and Y, derivatized chemically activated and selectively attached... Agent: Thomas J. Bordner Sanofi Pasteur, Inc.

20090181055 - Pathogen for bacterial poultry disease: The invention belongs to the field of animal health and in particular the causative agent of a new bacterial poultry disease, Gallibacterium. The invention provides said Gallibacterium bacteria, vaccine comprising inactivated Gallibacterium, and a method of immunizing to prevent disease in poultry.... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090181056 - Toxoplasma gondii mutant with enhanced homologous recombination and uses thereof: The present invention relates to a mutant Toxoplasma gondii which exhibits enhanced homologous recombination. The mutant of the present invention is a knockout in the KU80-dependent nonhomologous end-joining pathway which finds application in generating T. gondii gene knockouts and gene replacements for use in vaccine and drug development.... Agent: Licata & Tyrrell P.C.

20090181058 - Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins: Methods of using an injectable or implantable rod-shaped formulation for delivery of osteogenic proteins to treat osteoporotic and/or osteopenic bone are disclosed. The formulation comprises hyaluronic acid derivatives and osteogenic proteins, and optional excipients and active ingredients such as a bone resorption inhibitor.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090181057 - Methods and compositions for the inhibition of thrombus formation: The present invention is directed to compositions comprising inhibitors of GPIb-IX-VWF binding and methods of treating or preventing thrombosis associated with sepsis or endotoxemia in a mammal.... Agent: Marshall, Gerstein & Borun LLP

20090181059 - Hair cosmetic composition: e

20090181060 - Skin-care compositions: In certain embodiments provided are composition suitable for cleansing or treating the skin, the composition comprising: (i) at least 90% water; (ii) a non-ionic surfactant; (iii) one or more hydrophobic emollients present in a concentration from about 200 parts per million (ppm) to about 4000 ppm, and wherein the composition... Agent: Philip S. Johnson Johnson & Johnson

20090181062 - Dispensing a bird repellant: A bird repellant dispensing process and system is disclosed. An exemplary embodiment pressurizes a bird repellant solution at a pressure of at least 85 psi, the bird repellant solution comprising Methyl Anthranilate oil and a propellant, and wherein the Methyl Anthranilate oil and a liquid portion of the propellant is... Agent: Black Lowe & Graham, PLLC

20090181061 - Microbial resistant composites: Microbial resistant composites and methods for providing microbial resistant composites are described herein. The microbial resistant composites may include a polymeric material in the form of a polymeric matrix and a naturally occurring antimicrobial material such as the bark from aspen trees, birch trees, poplar trees, and extracts thereof. The... Agent: Holland & Hart LLP

20090181067 - Immobilized biologically active entities having high biological activity following mechanical manipulation: The present invention is directed to immobilized biologically active entities that retain significant biological activity following mechanical manipulation of a substrate material to which the entities are immobilized.... Agent: Eric J Sheets W. L. Gore & Associates, Inc.

20090181066 - Immobilized biologically active entities having high biological activity folowing mechanical manipulation: The present invention is directed to immobilized biologically active entities that retain significant biological activity following mechanical manipulation of a substrate material to which the entities are immobilized.... Agent: Gore Enterprise Holdings, Inc.

20090181063 - Implantable medical device comprising a pro-healing poly(ester-amide): The present invention relates to implantable medical devices, in particular stents, comprising pro-healing poly(ester-amide)s.... Agent: Squire, Sanders & Dempsey LLP

20090181065 - Methods and devices for promoting endothelial morphogenesis: In one aspect, the present invention provides methods for promoting endothelial morphogenesis. The methods of this aspect of the invention include the step of providing to one or more endothelial cells an amount of an osteoprotegerin sufficient to promote endothelial morphogenesis. The methods of this aspect of the invention can... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20090181064 - Xenotransplant for cns therapy: A “supplementary choroid plexus” comprising preferably a xenotransplant of choroid plexus cells from a neonatal mammal provides a steady supply of trophic factors for administration to a central nervous system in need of treatment for a neurological disease. Choroid plexus cells manufacture a range of trophic factors, particularly during fetal... Agent: Haynes And Boone, LLPIPSection

20090181068 - Low viscosity liquid polymeric delivery system: Low viscosity biodegradable polymer solutions of a liquid biodegradable polymer and biocompatible solvent and methods of using the compositions to form a liquid polymer implant are provided.... Agent: Whyte Hirschboeck Dudek S C Intellectual Property Department

20090181069 - Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom: The invention relates to the film products and methods of their preparation that demonstrate a non-self-aggregating uniform heterogeneity. Desirably the films disintegrate in water and may be formed by a controlled drying process, or other process that maintains the required uniformity of the film.... Agent: Hoffmann & Baron, LLP

20090181070 - Emulsification systems, umulsions and wet wipes containing such emulsions: A method of making an oil-in-water emulsion is described in which an oil emulsifier and a polysaccharide emulsion stabiliser, which stabiliser comprises a Xanthan polysaccharide and a polyglucomannan polysaccharide, is dispersed in an oil. The oil-based dispersion so formed is then combined with water, preferably at low temperature and under... Agent: Jones Day

20090181071 - Oral care delivery system with microcrystalline wax: An oral care delivery system comprises a flexible substrate with a first side and a second side, with at least one oral care composition that is disposed adjacent the first side of the substrate, and at least one delivery layer that is disposed adjacent the second side of the substrate.... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090181072 - Methods for making a multicomponent hemostatic dressing: A method of making a pliable, bioabsorbable hemostatic dressing wherein the dressing is composed of fibers with at least one molecular-scale coating, which upon first contact with blood and due to a large area of contact with blood per unit weight of active ingredients, initiates and accelerates the biochemical blood... Agent: Louis Ventre, Jr

20090181073 - Method for treating irritation caused by hair removal: A method for relieving skin irritation caused by hair removal involves applying a chilled skim milk additive which to the irritated skin. The additive is applied to the skin on pads or similar carriers which are provided with a self-contained component that can be frozen or, when compressed and ruptured,... Agent: William W. Jones

20090181074 - Mucosal tissue dressing and method of use: A method and apparatus for reducing or eliminating pain after surgical procedures related to mucosal tissue, including tonsillectomy, adenoidectomy, or other pharyngeal operations. Certain embodiments provide a biodegradable film or covering that serves as a mechanical barrier to reduce pain caused, for example, by friction between solid food and healing... Agent: Mcandrews Held & Malloy, Ltd

20090181075 - Drospirenone containing transdermal drug delivery devices and methods of delivery thereof: A transdermal drug delivery device comprising an adhesive matrix, an effective amount of drospirenone, and an oligomeric adjuvant selected from an oligolactic acid, oligolactic acid derivatives, or mixtures thereof. Also, a transdermal drug delivery device comprising a backing film and an adhesive matrix which comprises an effective amount of drospirenone,... Agent: Millen, White, Zelano & Branigan, P.C.

20090181077 - Detection of pkc-iota as a biomarker for brain tumorigenesis: A method of detecting brain tumorigenesis in a subject, the method including the steps of (a) obtaining a sample from the brain of the human subject, (b) detecting quantitatively or semi-quantitatively in the sample a level of expression for PKC-iota and (c) comparing the expression level in (b) to a... Agent: Smith Hopen, Pa

20090181076 - Drug release from nanoparticle-coated capsules: Methods of producing a controlled release formulation for an active substance are disclosed, wherein the methods involve dispersing a discontinuous phase comprising an active substance into a continuous phase so as to form a two-phase liquid system comprising droplets of said discontinuous phase, and allowing nanoparticles provided to the two-phase... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090181078 - Vaccine composition containing synthetic adjuvant: Compositions and methods, including vaccines and pharmaceutical compositions for inducing or enhancing an immune response are disclosed based on the discovery of useful immunological adjuvant properties in a synthetic, glucopyranosyl lipid adjuvant (GLA) that is provided in substantially homogeneous form. Chemically defined, synthetic GLA offers a consistent vaccine component from... Agent: Seed Intellectual Property Law Group PLLC

20090181079 - Methods of making and using theaflavin, theaflavin-3-gallate, theaflavin-3'-gallate and theaflavin 3,3'-digallate and mixtures thereof: The present invention discloses methods of making a mixture of theaflavin, theaflavin-3-gallate, theaflavin-3′-gallate and theaflavin 3,3′-digallate, pharmaceutical compositions of the above mixture of theaflavins, diet supplement compositions of the above mixture of theaflavins and methods for using the above mixtures of theaflavin and pharmaceutical compositions thereof to treat or prevent... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090181080 - Oral cannabinnoid liquid formulations and methods of treatment: A room temperature stable aqueous cannabinoid formulation is disclosed. In preferred embodiments, the cannabinoid formulation comprises dronabinol in a mixture of buffer solution, and organic cosolvents such as ethanol, propylene glycol and polyethylene glycol.... Agent: Davidson, Davidson & Kappel, LLC

20090181081 - Systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance: Alterations of redox homeostasis in mammals underlie a host of symptoms, syndromes and diseases, including AIDS and cancer, which can be successfully treated by administration to a mammal of therapeutically-effective amounts of sulfide compounds and/or thiosulfate compounds and/or thionite compounds and/or sulfite compounds and/or thionate compounds and/or any organic, inorganic... Agent: Baker & Mckenzie LLP

20090181082 - Tablet: The present invention can retain the volume of a tablet large without increasing the thickness of the tablet or the like dimension and prevents a plurality of tablets from sticking to each other even if they are subjected to a film-coating or the like treatment, so as to improve the... Agent: Rankin, Hill & Clark LLP

20090181084 - Oral fast-disintegrating tablet including particles of slowly-releaseable ascorbic acid: An oral fast-disintegrating tablet includes many tiny particles of slowly-releasable ascorbic acid, and a fast-disintegrating ingredient mixed with the many tiny particles that are dispersedly mixed with the fast-disintegrating ingredient. Each tiny particle is composed of a nucleus, an ascorbic layer and a release-control layer. The nucleus is coated with... Agent: Rosenberg, Klein & Lee

20090181083 - Porous tablets as carriers for liquid formulations: A novel tablet product that in an easy, flexible and reproducible manner can be loaded with a relatively high amount of a pharmaceutically acceptable liquid formulation e.g. carrying a therapeutically, prophylactically and/or diagnostically active substance. The novel loadable tablet product may be produced in large-scale batches and stored until use... Agent: Edwards Angell Palmer & Dodge LLP

20090181085 - Utilization of dialkylfumarates: The present invention relates to the use of certain dialkyl fumarates for the preparation of pharmaceutical preparations for use in transplantation medicine or for the therapy of autoimmune diseases and said compositions in the form of micro-tablets or pellets. For this purpose, the dialkyl fumarates may also be used in... Agent: Biogen Idec / Finnegan Henderson, LLP

20090181086 - Rasagiline formulations, their preparation and use: Disclosed are formulations which are designed to release rasagiline mesylate while maintaining specific pharmacokinetic properties.... Agent: Cooper & Dunham, LLP

20090181092 - Methods for treating joints and discs with a carrier matrix and cells: Methods for enhancing pain relief and accelerating repair of painful disruptions associated with damaged and/or degenerated synovial joints and spinal discs are disclosed. These methods include injecting an effective amount of a biocompatible matrix or biocompatible polymeric compound, as well as a plurality of cells, into and/or around the damaged... Agent: Andrews Kurth LLP

20090181093 - Methods for treating soft tissue damage associated with a surgical procedure: Methods for treating soft tissue damage associated with a surgical procedure and enhancing pain relief by accelerating the repair of painful disruptions associated with damaged and/or degenerated synovial joints and spinal discs are disclosed. The methods include injecting an effective amount of a biocompatible matrix or biocompatible polymeric compound into... Agent: Andrews Kurth LLP

20090181089 - Ph-controlled pulsatile delivery system, methods for preparation and use thereof: The invention relates to delivery systems that allow for the pulsatile release of a substance, such as a drug, in response to a change in pH. More specifically, it relates to drug administration to the GI tract, in particular to site-specific intestinal drug delivery via the oral route. Provided is... Agent: Traskbritt, P.C.

20090181091 - Product and process to regulate a gene network involved in constitutive inflammation and early cancer progression: A recombinant construct arranged for expression of a specific hairpin microRNA which disrupts crosstalk between the two inflammatory pathways is described for intervening in early cancer progression events. Accordingly, the construct can be used as a molecular therapeutic approach to prevent cancer of epithelial origin in mammals, which include but... Agent: Ade & Company Inc.

20090181090 - Protein-based carrier system for overcoming resistance in tumour cells: Nanoparticles, the particle matrix of which is based on at least one protein and has at least one active agent embedded therein and methods of producing the nanoparticles with at least one active agent embedded in the protein matrix are disclosed. The use of the nanoparticles for the treatment of... Agent: D. Peter Hochberg Co. L.p.a.

20090181088 - Thermosensitive polyphosphazene-bioactive molecule conjugates, preparation method thereof and use thereof: The present invention relates to a poly(organophosphazene)-bioactive molecule conjugates in which biodegradable and thermosensitive poly(organophosphazene) with a functional group showing the sol-gel phase transition with change of temperature is combined with various bioactive molecules, such as drugs, a preparation method thereof, and a use thereof for delivery of bioactive molecules.... Agent: LexyoumeIPGroup, LLC

20090181087 - Use of human cord blood-derived pluripotent cells for the treatment of disease: The present invention features methods of organ tissue regeneration using pluripotent cells derived from umbilical cord blood, compositions of these pluripotent cells, methods for further transforming these cells, and uses for these transformed cells.... Agent: Clark & Elbing LLP

20090181094 - Molecular cage for sustained release control of pharmaceutical and cosmetic agents: A method of making and using molecular cages is provided to control the release of molecules entrapped or caged within a caging molecule. The caging molecule may be a polymer, cellulose, or an organic and inorganic molecule that exhibits structural swelling, phase transitions, or structural rearrangement by changing thermodynamic parameters... Agent: Eric Yueh-lang Sheu

20090181100 - Dry powder aerosols of nanoparticulate drugs: There invention discloses aqueous dispersions of nanoparticulate aerosol formulations, dry powder nanoparticulate aerosol formulation, propellant-based aerosol formulations, methods of using the formulations in aerosol delivery devices, and methods of making such formulations. The nanoparticles of the aqueous dispersions or dry powder formulations comprise insoluble drug particles having a surface modifier... Agent: Elan Drug Delivery, Inc. C/o Foley & Lardner

20090181098 - Hmg-co-a reductase inhibitor enhancement of bone and cartilage: Methods of enhancing skeletal framework tissue are provided by treating a site requiring enhancement with an HMG-CoA reductase inhibitor at a dosage and for a duration that enhances the tissue while avoiding excess of the inhibitor and degradation of the enhancement.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090181096 - Method of targeting sustained release formulations of therapeutic agents to treat lung diseases: The present invention relates to method of targeting therapeutic agents for treating lung diseases.... Agent: Squire, Sanders & Dempsey LLP

20090181095 - Oxidative stress inhibitor: An oxidative stress inhibitor comprising a spherical activated carbon as an effective component is disclosed. The present invention is effective in the prevention or the treatment of a disease caused by oxidative stress, such as a kidney disease, a circulatory disease (for example, cardiovascular disease), a cancer, a diabetes, a... Agent: Reed Smith LLP

20090181097 - Particles: The present invention provides a particle aggregate comprising particles linked to other particles via linkers that are capable of being cleaved by an enzyme. The particles may be linked directly to other particles by the linkers or may be linked indirectly by means of a binding moiety. The invention also... Agent: Choate, Hall & Stewart LLP

20090181099 - Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract: Provided herein are methods for preventing or alleviating the symptoms of and inflammation associated with inflammatory diseases and conditions of the gastrointestinal tract, for example, those involving the esophagus. Also provided herein are pharmaceutical compositions useful for the methods of the present invention.... Agent: Paul, Hastings, Janofsky & Walker LLP

20090181101 - Nanoparticles comprising antibacterial ligands: Materials and Methods are disclosed for producing nanoparticles linked to antibacterial ligands, including antibiotics and/or molecules which bind to bacterial markers, and for the use of the nanoparticles for the treatment of conditions treatable by the antibiotic ligands.... Agent: Dann, Dorfman, Herrell & Skillman

20090181102 - Process for obtaining high efficiency human albumin for use in detoxification therapy: A process for purifying and collecting albumin from plasma and plasma fractions involves diafiltration of an albumin-containing plasma fraction; stabilizing the resulting albumin fraction with sodium chloride and an amino acid in the absence of any added fatty acid; pasteurizing the stabilized albumin fraction; and diafiltering the pasteurized fraction to... Agent: Buchanan, Ingersoll & Rooney PC

20090181103 - Cholesterol-lowering dairy products and methods for their preparation: The invention relates to a concentrated or dried milk product having cholesterol-lowering effects and to methods for preparing the same. Provided is a process for the preparation of a milk concentrate or milk powder having a cholesterol-lowering effect, comprising :—preparing a milk liquid;—preparing a fat fraction comprising at least one... Agent: Hoffmann & Baron, LLP

20090181104 - Breast reconstruction or augmentation using computer-modeled deposition of processed adipose tissue: A tissue transfer method for reconstruction and augmentation of soft tissue. The method includes harvesting adipose tissue from a patient. The harvested tissue is processed via centrifugation to isolate a purified subset of the adipose tissue including separating and removing a substantial amount of triglycerides from the harvested adipose tissue.... Agent: Allergan, Inc.

20090181105 - Method of antioxidation, antioxidant-functioning water, and usage of the same: The objective of the present invention is to provide an antioxidation method and antioxidant-functioning water that can anticipate high benchmarks of safety on the antioxidation subject such as the human body and reduced environmental burden. An antioxidation method and antioxidant-functioning water that can transform or maintain an antioxidation subject, which... Agent: Arent Fox LLP

20090181106 - Compositions and methods for treating vaginal infections and pathogenic vaginal biofilms: The present invention generally relates to methods and compositions for treating pathogenic vaginal biofilms. More specifically, the invention relates to pharmaceutical compositions comprising a combination of boric acid and diethylaminetetracetic acid (EDTA) and to methods of using such compositions to treat or prevent biofilm formation associated with vaginal infections, such... Agent: Wood, Phillips, Katz, Clark & Mortimer

20090181107 - Solution having biocidal activity: A method and apparatus for the electrochemical treatment of an aqueous solution in an electrolytic cell is described. Output solution having a predetermined level of available free chlorine is produced by applying a substantially constant current across the cell between an anode and a cathode while passing a substantially constant... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090181108 - Use of bisphosphonates for otosclerosis: A method of treating otosclerosis in a human in need thereof by administering a bisphosphonate in a defined dosing schedule. The invention demonstrates an effective response and sustained benefit in the treatment of otosclerosis. Particularly, the method involves administration of a bisphosphonate in a stepped-up dosage amount, e.g., in a... Agent: Baker Botts L.L.P.

20090181109 - Nanoveson™: treatment, biomarkers and diagnostic tests for liver diseases and comorbid diseases: A method of treatment of liver diseases and comorbid diseases is disclosed wherein an oral dose of lipids in an amount effective to trigger the release of cholecystokinin (CCK) into the duodenum to generate a major release of bile phospholipids from remodeled stores of triglycerides (TAG) in the liver, is... Agent: Davidson, Davidson & Kappel, LLC

20090181110 - Compositions from garcinia as aromatase inhibitors for breast cancer chemoprevention and chemotherapy: Aromatase inhibitors (AIs) are disclosed which are useful in the treatment and prevention of post-menopausal breast cancer. New AIs derived from natural products are disclosed that are evaluated for clinical utility for treating post-menopausal breast cancer and may also act as chemopreventive agents for preventing breast cancer. Several pure compounds... Agent: Mueller And Smith, Lpa Mueller-smith Building

20090181111 - Saponin and preservative compositions for reduction of protozoa: The invention is related to methods and compositions for reducing protozoa populations in animals. In an embodiment, the invention includes a method for reducing protozoal populations including administering a first composition comprising an effective amount of saponins to the animal, and administering a second composition comprising an effective amount of... Agent: Pauly, Devries Smith & Deffner, L.L.C.

20090181112 - Tablet composition containing kampo extract: Provided is a tablet composition containing Kampo extract having more excellent disintegration and dissolution properties than ever before. The tablet composition containing Kampo extract contains a Kampo extract powder, croscarmellose sodium, and sodium hydrogen carbonate. The Kampo extract powder is preferably at least one extract powder selected from the group... Agent: Sughrue Mion, PLLC

20090181113 - Compositions for the reversal of stratum granulosum in keratinization disorders: Compositions that, when used topically in a therapeutically effective amount, are safe and effective for the regression of stratum granulosum in patients exhibiting keratinization disorders, such as psoriasis. The compositions, which can be formulated as ointments, oils, soaps and shampoos, comprise a non-aqueous extract of Wrightia tinctoria, an extract of... Agent: Bregen Technical Consultants L.L.C.

20090181114 - Chia seed beverage and related method: A beverage is disclosed that is effective for enhancing gastrointestinal regularity and heart health. It is formed by a liquid comprising fruit derived juices, water or naturally or artificially flavored water. A composition of matter is mixed within the liquid in a shelf stable pasteurized beverage form and formed from... Agent: Allen, Dyer, Doppelt, Milbrath & Gilchrist P.A.

20090181115 - Method of screening for compounds that alter skin and/or hair pigmentation: The invention provides a method of identifying compounds that either increase or decrease skin and/or hair pigmentation, the method comprising determining the ability of a test compound to modulate NCKX-mediated calcium ion movement across a membrane (e.g. NCKX5). The method may comprise the steps of exposing a membrane comprising a... Agent: Morgan Lewis & Bockius LLP

20090181116 - Axmi-031, axmi-039, axmi-040 and axmi-049, a family of novel delta-endotoxin genes and methods for their use: Compositions and methods for conferring pesticidal activity to bacteria, plants, plant cells, tissues and seeds are provided. Compositions comprising a coding sequence for a delta-endotoxin polypeptide are provided. The coding sequences can be used in DNA constructs or expression cassettes for transformation and expression in plants and bacteria. Compositions also... Agent: Alston & Bird LLP

20090175783 - Compounds and imaging methods: The present invention relates to methods of distinguishing between active and inactive blood clots in vivo, including assisting in the determination of whether it is appropriate or not to continue anticoagulant therapy for an individual patient with previously diagnosed venous thrombo-embolic disease (VTE).... Agent: Ge Healthcare, Inc.

20090175784 - Anti-alpha v immunoliposome composition, methods, and uses: An immunoliposome composition targeted to the alphaV-integrin subunit of integrin receptors comprised of ligand-targeted liposomes bearing at least one targeting-ligand derived from an antibody and having binding specificity for at least one integrin receptor comprising an alpha V subunit including αvβ1, αvβ3 αvβ5, αvβ6, or αvβ8 integrin cell receptors is... Agent: Philip S. Johnson Johnson & Johnson

20090175785 - Self-assembled fmoc-ff hydrogels: Novel peptide-based hydrogels, composed of short aromatic peptides (e.g., homodipeptides of aromatic amino acid residues) are disclosed. The hydrogels are characterized by remarkable rigidity and biocompatibility. Further disclosed are uses of these hydrogels in applications such as tissue engineering, drug delivery, cosmetics, implantation, packaging and the like. Further disclosed are... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090175786 - Gastrin releasing peptide compounds: Novel methods of treating prostate tumors or of delaying the progression of prostate tumors are also provided, including, methods of treating bone or soft tissue metastases of prostate cancer, methods for treating hormone sensitive and hormone refractory prostate cancer, methods for delaying the progression of hormone sensitive prostate cancer, for... Agent: Kramer Levin Naftalis & Frankel LLP

20090175787 - Use of fructose-based compounds for the diagnosis of cancer: This invention relates to compositions, methods utilizing fructose and other monosaccharides for the diagnosis of cancer. Cancer cells have shown a higher level of fructose utilization as compared to glucose. Further, cancer cells have shown a preferential use of fructose for nucleic acid synthesis. The present invention takes advantage of... Agent: Davis Wright Tremaine LLP/los Angeles

20090175788 - Radiolabelled ligand for the glycine 1 transporter: i

20090175791 - Anti-vegf antibody compositions and methods: Disclosed are human antibodies that specifically inhibit VEGF binding to only one (VEGFR2) of the two primary VEGF receptors. The antibodies effectively inhibit angiogenesis and induce tumor regression, and yet have improved safety due to their specificity. The present invention thus provides new human antibody-based compositions, methods and combined protocols... Agent: Peregrine Pharmaceuticals, Inc.

20090175789 - Antibody raised against the ldl receptor: The present invention relates to a monoclonal antibody raised against the human LDL (Low Density Lipoprotein) receptor, binding to the peptide corresponding to amino acids 195-222 (SEQ ID NO: 1) in the peptide sequence for the human LDL receptor; to the use thereof as a drug; to a pharmaceutical composition... Agent: Harness, Dickey & Pierce, P.L.C

20090175790 - Cardiac arrhythmia treatment methods and biological pacemaker: Disclosed are methods of preventing or treating cardiac arrhythmia. In one embodiment, the methods include administering to an amount of at least one polynucleotide that modulates an electrical property of the heart. The methods have a wide variety of important uses including treating cardiac arrhythmia. Also disclosed are methods and... Agent: Banner & Witcoff, Ltd.

20090175792 - Glycomimetic inhibitors of siglec-8: Compounds, compositions and methods are provided for detecting or modulating in vitro and in vivo processes mediated by Siglec-8 binding. More specifically, Siglec-8 modulators and their use are described, wherein the Siglec-8 modulators that modulate a Siglec-8-mediated function comprise particular glycomimetics alone or linked to a diagnostic or therapeutic agent.... Agent: Seed Intellectual Property Law Group PLLC

20090175794 - Inhibitors of carbonic anhydrase ix: Novel radiopharmaceuticals that are useful in diagnostic imaging and therapeutic treatment of disease characterized by over expression of CA-IX comprise a complex that contains a sulfonamide moiety which is capable of binding the active catalytic site of CA-IX, and a radionuclide adapted for radioimaging and/or radiotherapy:... Agent: Foley And Lardner LLP Suite 500

20090175793 - Treatment of male sexual dysfunction: A composition comprising a selective oxytocin antagonist for use in the treatment and/or prevention of a male ejaculatory disorder; which selective oxytocin antagonist is optionally admixed with a pharmaceutically acceptable carrier, diluent or excipient.... Agent: Pfizer Inc. Patent Department

20090175796 - Antibodies and related molecules that bind to 24p4c12 proteins: Antibodies and molecules derived therefrom that bind to 24P4C12 protein and variants thereof, are described wherein 24P4C12 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 24P4C12 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 24P4C12... Agent: Agensys C/o Morrison & Foerster LLP

20090175795 - Chimeric therapeutic agents: A fusion protein including (i) a first segment that is located at the amino terminus of the fusion protein and contains the sequence of a first biological active peptide or protein; and (ii) a second segment that is located at the carboxyl terminus of the fusion protein and contains the... Agent: Occhiuti Rohlicek & Tsao, LLP

20090175797 - Inflammation-inhibitory serum factors and uses thereof: Disclosed are methods of purifying compounds that reduce or prevent an inflammatory response in a mammal, use of such compounds in treating a mammal having or being at risk of developing inflammation, as well as serum containing such purified compounds. Also disclosed are animal models that are more representative of... Agent: Clark & Elbing LLP

20090175798 - Mycobacterial catalase-peroxidase in the diagnosis and treatment of sarcoidosis: Provided are diagnostic and therapeutic methods of treating sarcoidosis comprising the use of microbial catalase-peroxidase protein, its peptide fragments, or derivatives thereof.... Agent: Foley Hoag, LLP (w/jhv)

20090175799 - Colored or colorable topical composition foam: There is described a colored or colorable topical composition, comprising: a) a foamable base composition comprising, 1) a flowable carrier composition; 2) a color agent; wherein the color agent is effective to impart, increase, decrease or otherwise affect color of a foam produced from the foamable composition and wherein the... Agent: Wilmerhale/boston

20090175800 - Methods and compositions for p2x receptor calcium entry channels and other calcium entry mechanisms: This invention relates generally to a method of increasing cytosolic Ca2+ levels in mammalian cells comprising contacting P2X receptor Ca2+ entry channels or any and all other Ca2+ entry channels or mechanisms on the cell with an effective amount of a small molecule, and a composition comprising the small molecule... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20090175801 - Cns-tumor treatment method and composition: A method, aerosol composition, and aerosolizing device for treating a brain tumor in a subject are disclosed. The method includes intranasally administering to the subject, an amount of a telomerase inhibitor, such as an oligonucleotide telomerase inhibitor, effective to inhibit growth of the tumor in the subject.... Agent: King & Spalding LLP

20090175802 - Tiotropium containing hfc solution formulations: This invention relates to tiotropium containing stable pharmaceutical solution formulations suitable for aerosol administration. More particularly, this invention relates to tiotropium containing stable pharmaceutical solution formulations suitable for aerosol administration wherein either an inorganic acid or an organic acid is added to the aerosol solution formulation which contains a tiotropium... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090175803 - Method and compositions for administering resveratrol and pterostilbene: Resveratrol and/or pterostilbene are added to a chewable carrier, to enhance absorption of resveratrol and/or pterostilbene buccally or through the mucous membranes of the mouth. The composition containing the resveratrol and/or pterostilbene is designed to be retained in the mouth for at least 20 seconds and up to 20 minutes... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090175804 - Preparation of cationic terpolymers and personal care compositions comprising said terpolymers: The present invention is directed to cationic terpolymers, methods to make them, and the use of compositions containing said terpolymers in personal care compositions. The polymers are useful in personal care applications. The cationic terpolymers of this present invention provide the extra conditioning benefits required in a personal care product.... Agent: Joann Villamizar Ciba Corporation/patent Department

20090175805 - Neuraminidase inhibitors and uses thereof: The invention is related to various methods for inhibiting or reducing biofilm formation, treating a biofilm production-related disorder, preventing biofilm formation, and screening for neuraminidase inhibitors. The invention also encompasses a mutant bacterial strain with a deleted neuraminidase gene.... Agent: Wilmerhale/columbia University

20090175806 - Antimicrobial compositions containing low concentrations of botanicals: The present invention relates to a preservative or antimicrobial compositions with broad spectrum antimicrobial activity comprising low concentrations of essential oil (and/or one or more component thereof) and a botanical extract in synergistic combination with a fruit acid and alkanediol, and optionally a solvent. The compositions of the invention may... Agent: Baker Botts L.L.P.

20090175808 - Composition and uses thereof: Use of a composition comprising oil bodies in the preparation of a formulation for administration to a mammal wherein said composition comprises oil curd extracted from oleaginous plant tissue, said oil curd comprising an aqueous dispersion of oil bodies and associated extrinsic protein material. Preferably, the oil curd is extracted... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090175809 - Merocyanine derivatives for cosmetic use: e

20090175807 - Pest control, compositions, and methods and products utilizing same: Pest-combating compositions containing modified volatility pest-control actives are formulated for sustained test-combating efficacy, utilizing oleochemicals subjected to transesterification, methanolysis or conversion of fatty acids to alkyl esters as modified volatility components. In a specific formulation, the pest-combating composition includes soy methyl ester and 2-undecanone. The composition may be constituted as... Agent: Intellectual Property / Technology Law

20090175810 - Compositions and methods for treating diseases of the nail: Methods and compositions for treating disorders of the nail and nail bed. Such compositions contain a vehicle in which all components of the composition are dissolved, suspended, dispersed, or emulsified, a non-volatile solvent, a wetting agent, and a pharmaceutically active ingredient that is soluble in the non-volatile solvent and/or a... Agent: Howard Eisenberg, Esq.

20090175812 - Novel skin lightening agents, compositions and methods: t

20090175811 - Use of compound that inactivates protein kinase a in a composition containing a cosmetically acceptable medium for lightening the skin: A method of using a compound to lighten the skin by inactivating protein kinase A. The compound may be in a composition with either a pharmacologically or cosmetically acceptable medium. Depending upon the medium and concentration of the compound, the composition may be used either therapeutically or non-therapeutically.... Agent: Young & Thompson

20090175813 - Water based liquid makeup cosmetic: According to the formation for a water based liquid makeup cosmetic, obtained is a water based liquid makeup cosmetic which makes it easy to rehomogenize (redisperse) the cosmetic by slightly shaking even after turned into an uneven state with standing still during storage and which makes fine lines liable to... Agent: Buchanan, Ingersoll & Rooney PC

20090175814 - Nitrile derivatives as perfuming ingredients: The present invention concerns substituted benzylic nitriles substituted with lower linear alkyl or alkylene groups. These compounds are useful perfuming ingredients, and can impart odor notes of the floral-green type. The invention concerns also the perfuming compositions or perfumed articles associated with the compound.... Agent: Winston & Strawn LLP Patent Department

20090175815 - Antiperspirant or deodorant products: The photo-destruction of an ingredient that is susceptible to photo-destruction in a stick cosmetic product can be retarded by pigmenting the composition or/and the dispenser for the composition with an inhibiting pigment and preferably a matching pigment. The photo-destruction can be further retarded by employing a dispenser that inhibits the... Agent: Unilever Patent Group

20090175816 - Method and composition for reducing malodor in permanently waved hair: By formulating permanent wave compositions with chlorophyll derivatives of water soluble alkaline divalent cations selected from the group consisting of magnesium, manganese, calcium, copper, and zinc, an easily employed malodor reducing composition is achieved for use with conventional reducing agents employed for permanently waving hair. In accordance with the present... Agent: Melvin I. Stoltz

20090175817 - Personal care composition: A personal care composition comprising an alkylene oxide-lactone based polymer, the polymer comprising an alkylene oxide and a lactone in copolymerized form, is useful for treating hair and skin.... Agent: The Dow Chemical Company

20090175818 - Poly(potassium and sodium styrene sulfonate) its manufacture and its uses: Antibiotic-associated diarrhea, such as that caused by Clostridium difficile, represents a serious medical complication that can result from administering a broad-spectrum antibiotic to a subject. Such diarrhea leads to significant potassium loss from the subject. The present invention discloses a polymeric therapeutic agent that treats antibiotic-associated diarrhea and is physiologically... Agent: Christopher M. Beck, Phd Genzyme Corporation

20090175819 - Molecule and chimeric molecules thereof: The present invention relates generally to the fields of proteins, diagnostics, therapeutics and nutrition. More particularly, the present invention provides an isolated protein molecule that comprises a dimeric 4-helix bundle, such as IFN-a2B, IFN-b1, IFN-g, IL-10 or its receptor, such as IFNAR2, IL-10Ra or chimeric molecules thereof comprising at least... Agent: Seed Intellectual Property Law Group PLLC

20090175820 - Inhibitors of cytochrome p450: e

20090175821 - Modified therapeutic peptides with extended half-lives in vivo: A method for protecting a peptide from peptidase activity in vivo, the peptide being composed of between 2 and 50 amino acids and having a C-terminus and an N-terminus and a C-terminus amino acid and an N-terminus amino acid is described. In the first step of the method, the peptide... Agent: Jones Day

20090175822 - C5-substituted, proline-derived, macrocyclic hepatitis c serine protease inhibitors: which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned... Agent: Elmore Patent Law Group, PC

20090175823 - Method of treating autoimmune diseases with interferon-beta and il-2r antagonist: Disclosed is a method of administering an interleukin-2 receptor (IL-2R) antagonist to a subject to treat an autoimmune disease. In particular embodiments, the IL-2R antagonist is an anti-IL-2R monoclonal antibody specific for one or more chains of the IL-2R, such as the alpha-chain, for example daclizumab. In other particular embodiments... Agent: Klarquist Sparkman, LLP

20090175825 - Interferon alpha and antisense k-ras rna combination gene therapy: An antiproliferative effect of IFN-α gene transduction in pancreatic cancer cells. The invention relates to expression of IFN-α to effectively induce growth suppression and cell death in pancreatic cancer cells, an effect which appeared to be more prominent when compared with other types of cancers and normal cells. Another aspect... Agent: Greenblum & Bernstein, P.L.C

20090175824 - Peptides for the treatment of hcv infections: This invention relates to novel compounds that are peptides derivatives and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel peptides that are derivatives of boceprevir. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090175828 - Coagulation factor x polypeptides with modified activation properties: The present invention relates to modified cDNA sequences coding for factor X polypeptides, in particular human factor X and its derivatives which can bypass the need for either factor VIIIa/factor IXa or factor VIIa/tissue factor for activation. The invention relates further to recombinant expression vectors containing such modified cDNA sequences,... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090175826 - Genetically-engineered newcastle disease virus as an oncolytic agent, and methods of using same: Recombinant strains of avian paramyxovirus (APMV), such as Newcastle disease virus (NDV), are provided. Also provided are compositions comprising them, and methods of using them to lyse tumor cells and to treat cancer. In certain aspects, genetically-engineered viral strains that incorporate therapeutic transgenes are also provided. The recombinant viruses may... Agent: Arent Fox LLP

20090175827 - Mir-16 regulated genes and pathways as targets for therapeutic intervention: The present invention concerns methods and compositions for identifying genes or genetic pathways modulated by miR-16, using miR-16 to modulate a gene or gene pathway, using this profile in assessing the condition of a patient and/or treating the patient with an appropriate miRNA.... Agent: Fullbright & Jaworski L.L.P.

20090175830 - Oncolytic adenovirus armed with therapeutic genes: The present invention involves compositions and methods for treating cancer using a mutant adenovirus comprising a polynucleotide encoding a therapeutic polypeptide that is targeted to cells with a mutant retinoblastoma pathway. The mutant adenovirus is able to kill the tumor cells without harming cells with a wild type retinoblastoma pathway.... Agent: Fulbright & Jaworski L.L.P.

20090175829 - Salmonella cancer therapeutics and related therapeutic methods: Therapeutic methods for treatment of solid tumor cancer cell masses, as can be effected using therapeutic compositions comprising salmonella species/strains and related compositions.... Agent: Reinhart Boerner Van Deuren S.c. Attn: Linda Kasulke, Docket Coordinator

20090175837 - Method and agent for controlling plant disease using bacteria of genus bacillus: This invention provides a control agent or material for biologically controlling plant diseases caused by plant pathogenic bacteria, fungi, or viruses, a method for controlling plant diseases using the same, and bacteria that can be used therefor. Also, this invention relates to a control agent or material for plant diseases... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090175831 - Adaptable messenger ribonucleic acid medical treatment device to manage diabetes mellitus: Diabetes mellitus is a disease of elevated blood glucose, often directly related to a deficiency in insulin production or insulin receptor production. The innovative strategy of treatment described here utilizes modified viruses to act as a transport vehicle to deliver to target cells in the body, messenger RNA molecules. Delivering... Agent: Lane B. Scheiber

20090175835 - Composition for treating damage of central or peripheral nerve system: The present invention provides a composition for treating damage of central or peripheral nerve system comprising neural precursor cell derived from subcutaneous tissue; neuron obtained by differentiating the neural precursor cell; or oligodendrocyte or Schwann cell obtained by differentiating the neural precursor cell; a use of neural precursor cell derived... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090175832 - Isolated embryonic-like stem cells derived from human umbilical cord blood: The present invention is related generally to embryonic-like stem cells isolated from human umbilical cord blood, designated herein as cord blood-stem cells (CB-SC's), which display the characteristics of embryonic stem cells and hematopoietic cells. These cells have the capability of proliferation and are able to differentiate to multiple types of... Agent: Nutter Mcclennen & Fish LLP

20090175834 - Neuronal progenitor cells and methods of derivation and purification of neuronal progenitor cells from embryonic stem cells: The invention provides neuronal progenitor cells, populations and cultures of cells, cell compositions and methods of producing neuronal progenitor cells. Neuronal progenitor cells can be prepared from embryonic stem cells, such as human embryonic stem cells.... Agent: Pillsbury Winthrop Shaw Pittman LLP

20090175833 - Pericytes for use as stem cells: A method of promoting perictye differentiation by selectively culturing pericytes in an enriched environment containing a promoter specific to a type of differentiation. Isolated and purified multipotent pericytes or pericyte precursors are provided. A stem cell therapy replacement comprising isolated and purified multipotent pericytes. A treatment of disease comprising an... Agent: Kohn & Associates, PLLC

20090175836 - Prelamin a pre peptide as a universal stem cell differentiation signal: Disclosed is the use of prelamin A pre peptide and homologues or analogs thereof for the induction of cell differentiation and tissue or organ growth and repair processes. The invention extends to virtually any cell, including both embryonic and non-embryonic stem cells, such as stem cells that are progenitors for... Agent: Sheridan Ross PC

20090175838 - Methods of modulating immune function: The invention relates to methods for modulating the immune function through targeting of CLIP molecules as well as gamma delta T-cells. The result is wide range of new therapeutic regimens for treating, inhibiting the development of, or otherwise dealing with, a multitude of illnesses and conditions, including autoimmune disease, transplant... Agent: Fulbright & Jaworski L.L.P.

20090175839 - Proteins with an attached short peptide of acidic amino acids: Disclosed are a fusion protein comprising enzyme N-acetylgalactosamine-6-sulfate sulfatase and a short peptide consisting of 4-15 acidic amino acids attached to the enzyme on its N-terminal side, a pharmaceutical composition containing the fusion protein, and a method for treatment of type A Morquio disease using the fusion protein. Compared with... Agent: Millen, White, Zelano & Branigan, P.C.

20090175840 - Insulin formulations for insulin release as a function of tissue glucose levels: Injectable insulin formulations that are capable of modifying the amount of insulin released based on the patient's tissue glucose levels, methods for making and using these formulations are described herein. The formulation may be administered via subcutaneous, intradermal or intramuscular administration. In one preferred embodiment, the formulations are administered via... Agent: Pabst Patent Group LLP

20090175841 - Compounds for improving nutritional status, cognition and survival: The present invention concerns using a leptin protein, a variant fragment or mimic of a leptin protein, or an activator of the AMPK signal transduction pathway for preparing a medicament that can either be used to improve cognitive function or to treat treatment of undesirable manifestations of a nutritional stress... Agent: Nixon & Vanderhye, PC

20090175842 - Dietary anti-bacterial compositions: A synergistic dietary antibacterial composition comprising the combination of proteolytic enzymes and one or more antibiotics effective against Helicobacter pylori, useful for the prevention or treatment of gastrointestinal disorders like peptic ulcer, gastric cancers and gastritis in the intestine caused by the Helicobacter pylori is disclosed in the present invention.... Agent: Ladas & Parry LLP

20090175843 - Composition for prevention or treatment of urinary tract infection: Compositions particularly suitable for preventing or treating urinary tract infections in mammals, especially in humans, comprising a combination of components, the composition comprising an effective amount of: (A) cranberry concentrate, cranberry extract or both; (B) D-mannose; and at least one component selected from the group consisting of: (C) ascorbic acid;... Agent: Lerner, David, Littenberg, Krumholz & Mentlik

20090175851 - Bivalent, bispecific antibodies: The present invention relates to novel domain exchanged, bivalent, bispecific antibodies, their manufacture and use.... Agent: Hoffmann-la Roche Inc. Patent Law Department

20090175847 - Humanized antibodies to ab (20-42) globulomer and uses thereof: The present invention relates to binding proteins and, in particular, humanized antibodies that may be used, for example, in the diagnosis, treatment and prevention of Alzheimer's Disease and related conditions.... Agent: Paul D. Yasger Abbott Laboratories

20090175852 - Imidazopyrazines as protein kinase inhibitors: In its many embodiments, the present invention provides a novel class of imidazopyrazine compounds as inhibitors of protein and/or checkpoint kinases, methods of preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of preparing pharmaceutical formulations including one or more such compounds, and methods of treatment, prevention,... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20090175853 - Method for treating amyloid disease: Disclosed herein are methods for treating amyloid disease in humans by clearing amyloid peptides from one or more bodily fluids such as, e.g. blood, of a patient. In particular, the methods are based on the administration of compounds capable of binding to amyloid-beta (Aβ) or on dialysis of blood or... Agent: Darby & Darby P.C.

20090175844 - Method of diagnosing bladder cancer: Objective methods for detecting and diagnosing bladder cancer (BLC) are described herein. In one embodiment, the diagnostic method involves determining the expression level of a BLC-associated gene that discriminates between BLC cells and normal cells. The present invention further provides means for predicting and preventing bladder cancer metastasis using BLC-associated... Agent: Townsend And Townsend And Crew, LLP

20090175845 - Methods for identifying compounds that modulate phb domain protein activity and compositions thereof: The invention relates to the finding that PHB domain polypeptides can bind cholesterol and related compounds and are involved in the regulation of various cellular activities. Accordingly, the invention includes methods of identifying compounds that can bind to and/or modulate activity of a PHB domain polypeptide such as Podocin or... Agent: Wilmerhale/columbia University

20090175848 - Modulation of the cooperativity between the ion channels trpm5 and trpa1: The present invention is related to modulating TRPA1 ion channel activity by targeting the ion channel TRPM5. The cooperativity between the ion channels can be used to modulate pain, mechanosensation and taste responses triggered through TRPA1 by modulating the activity of TRPM5... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090175850 - Nogo receptor homologs: The invention relates generally to genes that encode proteins that inhibit axonal growth. The invention relates specifically to genes encoding NgR protein homologs in humans and mice. The invention also includes compositions and methods for modulating the expression and activity of Nogo and the NgR proteins. Specifically, the invention includes... Agent: Sterne, Kessler, Goldstein & Fox, P.l.l.c.

20090175849 - Notch inhibition in the treatment or prevention of atherosclerosis: The present invention is directed to methods of treating or preventing atherosclerosis and other cardiovascular diseases by administering agents that inhibit or modulate the NOTCH signaling pathway. In addition, the invention encompasses methods for assaying compounds for their ability to treat atherosclerosis based upon their effects on NOTCH signaling, and... Agent: Law Office Of Michael A. Sanzo, LLC

20090175846 - Oligodendrocyte-myelin glycoprotein compositions and methods of use thereof: The present invention is based on the discovery that oligodendrocyte-myelin glycoprotein (OMgp), which is ex-pressed by oligodendrocytes and CNS myelin, negatively regulates oligodendrocyte and neuronal differentiation and survival. Based on these discoveries, the invention relates generally to methods of promoting neuronal and oligodendrocyte survival and differentiation by administration of an... Agent: Sterne, Kessler, Goldstein & Fox, P.l.l.c.

20090175863 - Agents targeting cd138 and uses thereof: Disclosed is a human murine chimeric antibody which substantially retains the antigen binding region of its murine counterpart and displays improved binding affinities to the antigen and/or more homogenous binding to target cells.... Agent: Joyce Von Natzmer Pequignot + Myers LLC

20090175856 - Anti-proliferative combination therapy using certain platinum-based chemotherapeutic agents and egfr inhibitors or pyrimidine analogues: The present invention describes a method or uses of prevention and/or treatment of a cancer or a tumor, and in particular to a combination therapy, methods, compositions and pharmaceutical packages comprising an inhibitor of receptors of the EGFR family or a chemotherapeutically active pyrimidine analogue and certain platinum-based chemotherapeutic agents.... Agent: Leon R. Yankwich Yankwich & Associates

20090175862 - Combination therapy employing lymphotoxin beta receptor binding molecules in combination with second agents: This invention features combination therapies that include a composition that activates lymphotoxin-beta receptor signaling in combination with one or more other biologic agents, as well as therapeutic methods.... Agent: Lahive & Cockfield, LLP / Biogen Idec Floor 30, Suite 3000

20090175860 - Compositions and methods of use for antibodies of c-met: Antibodies and fragments that bind to the protein target c-Met, particularly to epitopes located in the c-Met extracellular domain, are provided, as are methods of use of the antibodies and kits, for treating an unwanted cell, in particular, a cell associated with a c-Met-related condition such as a cancer, a... Agent: Novartis Institutes For Biomedical Research, Inc.

20090175858 - Crystalline egfr - matuzumab complex and matuzumab mimetics obtained thereof: The invention relates to a crystal complex formed by the extracellular domain of EGF receptor (EGFR) and the Fab fragment of anti-EGFR antibody matuzumab (EMD 72000). Especially the invention relates to the identification of the epitope regions on said EGFR, which the antibody matuzumab recognizes as antigen an to which... Agent: Goodwin Procter LLP Patent Administrator

20090175865 - Cysteine engineered antibodies and conjugates: e

20090175857 - Human antibodies that bind human il-12 and methods for producing: Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody... Agent: Lahive & Cockfield, LLP/abbott Floor 30, Suite 3000

20090175864 - Igf-1 and igf-2 chimeric polypeptides and therapeutic uses thereof: Pharmaceutical compositions containing a chimeric protein comprising an IGF1 and an IGF2 component and optionally (F), a fusion component, and/or a signal sequence, are provided. The chimeric protein exhibits improved activity relative to the native IGF1 or IGF2 polypeptide. Further, therapeutic methods for treating IGF1 insufficiency diseases or conditions using... Agent: Regeneron Pharmaceuticals, Inc

20090175854 - Methods of using death receptor ligands and cd20 antibodies: Methods for using death receptor ligands, such as Apo-2 ligand/TRAIL polypeptides or death receptor antibodies, and CD20 antibodies to treat conditions such as cancer and immune related diseases are provided. Embodiments of the invention include methods of using Apo2L/TRAIL or death receptor antibodies such as DR5 antibodies and DR4 antibodies... Agent: Genentech, Inc.

20090175855 - Novel compositions and methods for the treatment of immune related diseases: The present invention relates to compositions containing a novel protein and methods of using those compositions for the diagnosis and treatment of immune related disease.... Agent: Genentech, Inc.

20090175859 - Tnfalpha antagonists and methotrexate in the treatment of tnf-mediated disease: Methods for treating and/or preventing a TNF-mediated disease in an individual are disclosed. Also disclosed is a composition comprising methotrexate and an anti-tumor necrosis factor antibody. TNF-mediated diseases include rheumatoid arthritis, Crohn's disease, and acute and chronic immune diseases associated with transplantation.... Agent: Cooper & Dunham, LLP

20090175861 - Use of a b-cell-depleting antibody for treatment of polyoma virus infections: The present invention relates to uses of a B-cell-depleting antibody for the treatment of a polyoma virus infection.... Agent: Pearl Cohen Zedek Latzer, LLP

20090175867 - Single-chain multivalent binding proteins with effector function: Multivalent binding peptides, including bi-specific binding peptides, having immunoglobulin effector function are provided, along with encoding nucleic acids, vectors and host cells as well as methods for making such peptides and methods for using such peptides to treat or prevent a variety of diseases, disorders or conditions, as well as... Agent: Seed Intelectuall Property Law Group PLLC

20090175866 - Treatment of b-cell malignancies: The present invention generally relates to a pharmaceutical composition and to an improved method of preventing, attenuating and treating multiple myeloma by administering to an individual in need thereof at least one antibody to fibroblast growth factor receptor 3 (FGFR3). In particular, the at least one FGR3 antibody induces apoptosis... Agent: Winston & Strawn LLP Patent Department

20090175868 - Igf-ir antagonists as adjuvants for treatment of prostate cancer: The present invention relates to a method of treating prostate cancer with androgen deprivation therapy and an insulin-like growth factor receptor (IGF-IR) antagonist. Although the response rate of prostate cancer to androgen deprivation therapy (ADT) is high, surviving cancer cells invariably become androgen independent (AI) and tumor growth follows. The... Agent: Eli Lilly & Company

20090175869 - Pulsatile dosing of gossypol for treatment of disease: This invention relates to pulsatile dose administration of gossypol, a gossypol-related compound or pharmaceutical compositions thereof for treating diseases, disorders and conditions responsive to gossypol or gossypol-related compound, inhibiting the activity of anti-apoptotic Bcl-2 family proteins, inducing apoptosis in cells and increasing the sensitivity of cells to inducers of apoptosis.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090175873 - Inhibiting tumor cell invasion, metastasis and angiogenesis: The present invention relates to new compositions and methods useful for preventing, treating and diagnosing metastatic and/or invasive cancer and undesirable angiogenesis. For example, the invention relates to inhibitors of proteases that are specifically expressed in tumors, prodrugs activated in the tumor microenvironment and methods for using those inhibitors and... Agent: Schwegman, Lundberg & Woessner, P.A.

20090175871 - Method for demonstrating presence or absence of markers associated with the presence and/or the chemosensitivity of tumors: A method for detecting presence or absence of a tumor in a mammal and/or its sensitivity to chemotherapies, including, on a biological sample from said mammal, detecting and/or quantifying: presence of an eEF1A1 protein, and/or presence of antibodies directed against an eEF1A1 protein or a fragment including at least one... Agent: Ip Group Of Dla Piper US LLP

20090175877 - Methods of inhibiting metastasis: Methods of inhibiting metastasis or maintenance of various cancers are provided. In particular, the method makes use of fact that certain trafficking of cancers depend upon identified proteins, which serve as markers. Additional methods of screening are also provided.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20090175876 - Methods of using phhla2 to co-stimulate t-cells: The invention provides pHHLA2 co-receptor polypeptides and functional fragments, antibodies to same, isolated polynucleotides encoding same, vectors containing the polynucleotides, cells containing the vectors. Methods of making and using these co-stimulatory pHHLA2 co-receptors molecules are also disclosed.... Agent: Zymogenetics, Inc. Intellectual Property Department

20090175875 - Molecules and methods for modulating complement component: Compositions that bind to C3b epitopes and methods of using the compositions are described herein.... Agent: Novartis Institutes For Biomedical Research, Inc.

20090175874 - Novel interleukin-1 receptor intracellular ligand proteins and inhibitors of ligand binding: Novel IL-1-R intracellular ligand proteins are disclosed. Polynucleotides encoding the IL-1-R intracellular ligand protein are also disclosed, along with vectors, host cells, and methods of making the IL-1-R intracellular ligand protein. Pharmaceutical compositions containing the IL-1-R intracellular ligand protein, methods of treating inflammatory conditions, and methods of inhibiting IL-1-R intracellular... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090175872 - Treatment of conditions involving demyelination: The invention provides methods of treating diseases, disorders or injuries involving demyelination and dysmyelination, including multiple sclerosis, by the administration of an Sp35 antagonist. Additional methods include methods for inhibiting the binding of the Sp35 polypeptide with the ErbB2 polypeptide and a method for increasing ErbB2 phosphorylation by contacting oligodendrocytes... Agent: Sterne, Kessler, Goldstein & Fox, P.l.l.c.

20090175870 - Ykl-40 monoclonal authority: The present invention relates to monoclonal anti-human YKL-antibodies which are capable to modulate biological processes in which YKL-40 plays a prominent role, e.g. inhibit the growth and/or inducing apoptosis of cells, in particular cancer cells. The invention also relates to pharmaceutical compositions comprising said antibodies and uses said antibodies and/or... Agent: Gifford, Krass, Sprinkle,anderson & Citkowski, P.c

20090175878 - Cerebral vasospasm inhibitor: An objective of the present invention is to provide a cerebral vasospasm inhibitor which is effective on cerebral vasospasm occurring after subarachnoid hemorrhage and has few side-effects. The cerebral vasospasm inhibitor of the invention is characterized in containing an anti-HMGB1 monoclonal antibody as an active ingredient.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090175879 - Novel target in the treatment of cytokine release syndrome: A novel therapeutic and diagnostic target in the treatment of Cytokine Release Syndrome is provided. More specifically, a novel target is disclosed in the treatment of CRS occurring with diseases such as bacterial and viral infection as well as adverse reaction in drug therapy.... Agent: Henry M Feiereisen, LLC Henry M Feiereisen

20090175880 - Antibodies that bind human dendritic and epithelial cell 205 (dec-205): Isolated monoclonal antibodies which bind to human DEC-205 and related antibody-based compositions and molecules are disclosed. Also disclosed are pharmaceutical compositions comprising the antibodies, as well as therapeutic and diagnostic methods for using the antib... Agent: Lahive & Cockfield, LLP Floor 30, Suite 3000

20090175881 - Antibodies to il-17a: Engineered antibodies to human IL-17A are provided, as well as uses thereof.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20090175882 - Methods and compositions for treating hyperalgesia: This invention provides compounds which specifically inhibit TRPA1 but not other members of the thermoTRP ion channel family. Also provided in the invention are methods of using TRPA1-specific inhibitors to treat or alleviate pains mediated by noxious mechanosensation.... Agent: Genomics Institute Of The Novartis Research Foundation

20090175883 - Stabilized anti-respiratory syncytial virus (rsv) antibody formulations: The present invention provides liquid formulations of antibodies or fragments thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of the antibodies or antibody fragments, even during long... Agent: Jones Day

20090175884 - Misfolded proteins in cancer treatment and diagnosis: Cancer cells are identified and inhibited using agents that bind to epitopes unique to misfolded forms of surface proteins presented by the cancer cells. In one embodiment, cancer cells are identified and treated using antibodies that bind to a YYX epitope available on the misfolded form of the prion protein,... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090175885 - Method of controlling insect pests in cotton: The specificity of the monoclonal antibody to gossypol also enables the production of nanoparticles having a conjugated monoclonal antibody which retains the ability to selectively bind gossypol. Accordingly, nanoparticles can be provided with additional target ligands, such as antibodies, so as to specifically attach to tumors or cancer cells thereby... Agent: J. Bennett Mullinax, LLC

20090175887 - Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof: The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and... Agent: Knobbe Martens Olson & Bear LLP

20090175886 - Monoclonal antibodies against cd30 lacking in fucosyl and xylosyl residues: The invention pertains to anti-CD30 antibodies that lack fucosyl and xylosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity, including the ability to lyse CD30-expressing cell lines that are not lysed by the fucosylated and xylosylated form of the antibodies. The invention also provides host... Agent: Lahive & Cockfield, LLP/medarex Floor 30, Suite 3000

20090175888 - Methods of treating cancer with an antibody-drug conjugate: The present invention provides analogues of duocarmycins that are potent cytotoxins. Also provided are peptidyl and disulfide linkers that are cleaved in vivo. The linkers are of use in forming prodrugs and conjugates of the cytotoxins of the invention as well as other diagnostic and therapeutic moieties. The invention provides... Agent: Medarex C/o Darby & Darby P.C.

20090175889 - Hiv vaccine: The invention provides a polynucleotide encoding an envelope protein comprising gp120 of human immunodeficiency virus-1 (HIV-1) having a mutation at amino acid residues 197-199 whereby a single N-linked glycan is removed. In a typical embodiment, the mutation replaces the asparagine (N) at residue 197 with another amino acid, such as... Agent: Karen S. Canady Canady & Lortz LLP

20090175891 - Preventive and therapeutic vaccine for huntington's disease: A method for producing therapeutic vaccine which consist of NMDA-NRI subunit expressed in insect cells to produce recombinant protein which was encapsulated in PLGA or poly(lactide-co-glycolic acid) microparticles by solvent exchange and used for oral immunization. Excitotoxicity (i.e., a process in which an excessive amount of extracellular glutamate overexcites glutamate... Agent: Jeeri R. Reddy

20090175890 - Use of immature dendritic cells to silence antigen specific cd8+ t cell function: This invention provides methods for silencing a pre-existing immune response in a mammal, as for example, in the setting of autoimmune diseases. The method comprises administering to a mammal immature dendritic cells which have been contacted in vitro with an antigen, or to target the antigen to immature dendritic cells... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20090175893 - Albumin-fused anti-angiogenesis peptides: The invention relates to proteins comprising angiogenesis inhibiting peptides, such as endostatin peptides (including, but not limited to, fragments and variants thereof), which exhibit anti-retroviral activity, fused or conjugated to albumin (including, but not limited to fragments or variants of albumin). These fusion proteins are herein collectively referred to as... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20090175892 - Polynucleotides encoding mhc class i-restricted htert epitopes, analogues thereof or polyepitopes: This invention relates to the field of anticancer therapy, and to the identification of immunogenic peptides derived from the human telomerase reverse transcriptase (hTERT). The present invention relates to polynucleotides encoding hTERT epitopes restricted to MHC class I molecule, analogues thereof and polyepitopes containing such epitopes and/or analogues. Are also... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090175894 - Methods and materials for producing a generic anti-amyloid immune response in mammals: Compositions containing fibrillar aggregates of amyloidogenic polypeptides and adjuvants are described as well as methods of using such compositions to induce generic anti-amyloid immune responses in mammals.... Agent: Fish & Richardson P.C.

20090175895 - Methods and compositions for treating and preventing malaria: The present invention provides compositions and methods useful in the treatment or prevention of a condition caused by or associated with infection by Plasmodium falciparum, such as malaria. The compositions include various antigens of Plasmodium falciparum, both alone and in combination. The invention further includes fragments of the antigens.... Agent: Birch Stewart Kolasch & Birch

20090175896 - Cat allergen conjugates and uses thereof: The present invention is in the fields of medicine, public health, immunology, molecular biology and virology. The invention provides compositions comprising a virus-like particle (VLP) or a virus particle and at least one antigen, particularly at least one feline antigen, and more particularly at least one feline antigen that is... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090175898 - Influenza hemagglutinin and neuraminidase variants: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.... Agent: Medimmune, LLC Jonathan Klein-evans

20090175900 - Methods for packaging propagation-defective vesicular stomatitis virus vectors: A method of producing propagation-defective Vesicular Stomatitis Virus (VSV) in a cell culture is provided. The method involves introducing a plasmid vector encoding an optimized VSV G gene into a cell; expressing VSV G protein from the optimized VSV G gene; and introducing a propagation-defective VSV into the cell expressing... Agent: Wyeth Patent Law Group

20090175899 - Recombinant rsv virus expression systems and vaccines: The present invention relates to genetically engineered recombinant RS viruses and viral vectors which contain heterologous genes which for the use as vaccines. In accordance with the present invention, the recombinant RS viral vectors and viruses are engineered to contain heterologous genes, including genes of other viruses, pathogens, cellular genes,... Agent: Medimmune, LLC Jonathan Klein-evans

20090175897 - System for rapid production of high-titer and replication-competent adenovirus-free recombinant adenovirus vectors: The present invention relates generally to the fields of gene therapy, immunology, and vaccine technology. More specifically, the invention relates to a novel system that can rapidly generate high titers of adenovirus vectors that are free of replication-competent adenovirus (RCA). Also provided are methods of generating these RCA-free adenoviral vectors,... Agent: Frommer Lawrence & Haug

20090175901 - Immunostimulatory recombinant intracellular pathogen immunogenic compositions and methods of use: Immunogenic compositions comprising recombinant intracellular pathogens that have been transformed to express recombinant immunogenic antigens of the same or other intracellular pathogens and immunostimulatory molecules are provided. Exemplary immunogenic compositions include, but are not limited to, recombinant BCG expressing Mycobacteria major extracellular proteins and immunostimulatory molecules.... Agent: K&l Gates LLP

20090175902 - Immunogenic substances comprising a polyinosinic acid-polycytidilic acid based adjuvant: The present invention provides a polynucleotide adjuvant (PICKCa) composition and methods of use in eliciting an immune response, in particular a mucosal immune response. The polynucleotide adjuvant comprises of a polyriboinosinic-polyribocytidylic acid (PIC), at least one antibiotic and at least one positive ion. The present invention also provides an immunogenic... Agent: Bozicevic, Field & Francis LLP

20090175903 - Measles subunit vaccine: Compositions and methods for making and using therapeutic formulations of measles virus antigens with a Proteosome-based adjuvant are provided. The measles virus antigens may be derived from a variety of sources, such as from recombinant production or from a split antigen preparation. The measles vaccine formulations may be used, for... Agent: Seed Intellectual Property Law Group PLLC

20090175904 - Expressing hepatitis b virus surface antigen for vaccine preparation: HBsAg is expressed in a Saccharomyces cerevisiae host, carrying a plasmid having a HBsAg coding sequence, wherein the plasmid includes: (1) an upstream promoter from a glyceraldehyde-3-phosphate dehydrogenase gene, for controlling expression of the HBsAg coding sequence; and (2) an ARG3 transcription terminator downstream of the HBsAg coding sequence. The... Agent: Novartis Vaccines And Diagnostics Inc.

20090175906 - Genetically modified attenuated vesicular stomatitis virus, compositions and methods of use thereof: The present invention relates to methods for generating genetically modified and attenuated strains of vesicular stomatitis virus (VSV) for use in the preparation of immunogenic compositions. More particularly, the invention relates to the identification of particular genetic modifications of attenuated VSV that result in an increased yield of virus and... Agent: Wyeth Patent Law Group

20090175905 - Transfection reagent and method for enhancing transfection efficiency: A transfection reagent and a method for enhancing transfection efficiency are described. A nucleic acid is provided, and a disaccharide is added as a transfection reagent. The disaccharide is composed of two identical monosaccharides. The transfection reagent is then applied to cells to introduce the nucleic acid into the cells.... Agent: Jianq Chyun Intellectual Property Office

20090175908 - Influenza hemagglutinin and neuraminidase variants: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.... Agent: Medimmune, LLC Jonathan Klein-evans

20090175909 - Influenza hemagglutinin and neuraminidase variants: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.... Agent: Medimmune, LLC Jonathan Klein-evans

20090175907 - Multi plasmid system for the production of influenza virus: Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid influenza virus expression system are provided. Additionally, the invention provides methods of producing influenza viruses with enhanced ability to replicate in embryonated chicken... Agent: Medimmune, LLC Jonathan Klein-evans

20090175910 - Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization: Modified HIV Env, Gag, Pol, or Nef DNA with improved ability to elicit antibody and CTL responses to HIV antigens have been identified as prototype immunogens for the treatment and prevention of HIV infections.... Agent: Knobbe, Martens, Olson & Bear, LLP

20090175911 - Bacterial production of carotenoids: The present invention is based on a Bacillus the spores and vegetative cells forms of which are a different colour because of differential presence of at least one carotenoid in the spore and vegetative cell forms of the Bacillus. The Bacillus may therefore be used in detection methods and biosensors.... Agent: Nixon & Vanderhye, PC

20090175912 - Haemophilus influenza outer membrane protein and use thereof in vaccination: This invention relates to recombinant bacterial outer membrane proteins comprising one or more LB1(f) peptides from surface-exposed loop 3 of MOMP P5 of non-typeable H. influenzae. Polynucleotides encoding these recombinant proteins are also covered. The invention also relates to a method of isolating the recombinant proteins and a vaccine composition... Agent: Calfee Halter & Griswold, LLP

20090175913 - Ammendola/salmonella enterica strains of reduced pathogenicity, method for their preparation and uses thereof: The invention concerns novel Salmonella enterica attenuated strains, characterized in that they are inactivated at the level of the znuABC operon through mutation in at least one of the znuA, znuB, znuC genes of such operon, for uses in medical or veterinary fields as vaccines.... Agent: NeifeldIPLaw, PC

20090175914 - Salts or complexes of methyl donors with phytic acid or its derivatives and method for the synthesis thereof: e

20090175915 - Nanoparticle compositions providing enhanced color for cosmetic formulations: The present invention relates to cosmetic, dermatological, and pharmaceutical compositions that deliver, in an acceptable vehicle or carrier comprising a film former or wax and an effective amount of nanoparticles and one or more pigments and methods for improving the appearance of a biological surface by altering the optical properties... Agent: Charles J. Zeler, Esq. Avon Products, Inc.

20090175916 - Sheet-shaped cosmetic product: A sheet-shaped cosmetic product of the invention has a sheet and a stratified cosmetic cake disposed on the sheet with an adhesive layer sandwiched therebetween, and the adhesive layer and the cosmetic cake form a bonding zone in cooperation with each other, the bonding zone in which the adhesive layer... Agent: Cohen, Pontani, Lieberman & Pavane LLP

20090175917 - Tooth bleaching agent: The invention relates to “tooth-bleaching agent” compositions and to their applications in whitening teeth. The dental bleaching agent of the present invention comprises apatite, especially preferably in particle sizes in the nano range, likewise especially preferably in the form of fluorapatite. The tooth-bleaching agent can have a desensitising action and... Agent: Edwards Angell Palmer & Dodge LLP

20090175918 - Ultra-passivation of chromium-containing alloy and methods of producing same: The invention concerns article having a surface oxide layer up to 20 nm thick, the surface oxide layer comprising chromium and cobalt oxides where the atomic ratio of Cr/Co is more than 3. The invention also concerns methods for treating a chromium containing material, said method comprising contacting said material... Agent: Woodcock Washburn LLP

20090175920 - Biomaterial for osteosynthesis: The present invention relates to a biomaterial for the manufacture of osteosynthesis articles with dynamic mechanical properties analogous to calcified tissue, comprising a semi-aromatic polyamide matrix and at least one reinforcing means.... Agent: Young & Thompson

20090175921 - Chain extenders: The present invention relates to chain extenders, processes for their preparation and their use in the preparation of biocompatible biodegradable polyurethanes and polyurethane ureas for biomedical applications such as stents, scaffolds for tissue engineering. The chain extenders comprise a compound of formula (I)... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20090175919 - Chemical composition of hydrogels for use as articulating surfaces: The present invention provides a hydrogel composition comprising at least one polymer with functional groups including alcohol groups, acid groups, and amide groups and where the ratio of the functional alcohol groups to functional acid groups in the hydrogel composition ranges from about 16:1 to about 3:2. The present invention... Agent: Lowrie, Lando & Anastasi, LLP

20090175924 - Coated stent: A method of implanting a stent whereby the risk of restenosis is reduced, the method including the step of implanting into a patient susceptible to post-implant restenosis a stent coated with a therapeutically effective amount of a compound for reducing the onset or severity of restenosis, the compound containing a... Agent: Morrison & Foerster LLP

20090175923 - Humanized anti-amyloid beta antibodies: Humanized anti-Aβ antibodies derived from a murine antibody directed to a N-terminal epitope of Aβ are described. The humanized antibodies have reduced or no human T cell epitopes and bind Aβ with an affinity similar to that of the murine antibody.... Agent: Campbell Nelson Whipps, LLC

20090175922 - Three dimensional purified collagen matrices: Cell culture scaffolds presenting a more biologically relevant microenvironment are disclosed. More particularly, these cell culture scaffolds comprise three-dimensional matrices/biomaterials that are created from solubilized collagen compositions using controlled conditions to have the desired microstructure and mechanical properties. The engineered purified collagen based matrix compositions of the present invention can... Agent: Barnes & Thornburg LLP

20090175925 - Passive time released solute treatment: Devices and methods for delivery of a solute to increase blood sugar levels between certain hours in a form that allows for gradual delivery. One variation includes devices and methods for the timed release of a solute of carbohydrate, typically dextrose.... Agent: Levine Bagade Han LLP

20090175926 - Topical burn treatment: In some embodiments, a method of reducing the possibility of infection in a burn may include one or more of the following steps: (a) identifying a burn wound, (b) applying topically a molecular sieve agent to the burn wound, and (c) allowing the burn wound to scab over due to... Agent: Nikolai & Mersereau, P.A.

20090175927 - Administration of cells and cellular extracts for rejuvenation: The invention describes methods and agents for improving cosmetic appearance, for promoting, improving or restoring health of cells and tissues, preferably skin, and more preferably, for restoring aged or damaged skin to a healthy appearance. This invention relates to the use of cells and cellular extracts in rejuvenation and healing... Agent: Casimir Jones, S.c.

20090175928 - Lip plaster: The invention relates to a self-adhesive lip plaster which comprises at least one single-layered matrix and which contains at least one antiviral active medical substance for using in the event of Herpes labialis. Said matrix is arranged on a flexible carrier film which is hydrophobic and also permeable to vapor.... Agent: Friedrich Kueffner

20090175929 - Transdermally absorbable donepezil preparation: Disclosed is a donepezil-containing transdermally absorbable preparation which develops reduced adverse side effects and shows a satisfactory level of therapeutic effect. The preparation comprises an adhesive and a donepezil component (containing crystalline donepezil having type-B crystal polymorphism) and/or a salt thereof, wherein the donepezil component or the salt thereof is... Agent: Edwards Angell Palmer & Dodge LLP

20090175930 - Composition suppressing the expression of target gene in eyeball and medicament for treating of disease in eyeball: There is provided a composition comprising an RNA-encapsulated liposome, the RNA comprising a sequence being of 15 to 30 contiguous nucleotides of mRNA of a target gene associated with a disease in an eyeball, and a sequence complementary to the sequence, wherein the liposome is capable of reaching an eyeball,... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090175931 - Compositions and methods for modulating hemostasis: Factor Xa variants and methods of use thereof are disclosed.... Agent: Dann, Dorfman, Herrell & Skillman

20090175932 - Micelle assemblies: The invention encompasses micelle assemblies, compositions having micelle assemblies, and methods for preparing micelle assemblies and compositions thereof. Also, the invention encompasses compounds of the formula: A-X-Y-Z-R1 wherein A is a carboxy group or is absent; X is a polyol, Y is —C(═O)—, —C(═S)—, or is absent; Z is O,... Agent: Viksnins Harris & Padys Pllp

20090175934 - Extended release pharmaceutical formulation of venlafaxine and method of manufacturing the same: Disclosed herein is an extended release pharmaceutical formulation suitable for once daily administration, comprising a highly water soluble core consisting essentially of about 30 to about 40% by weight of venlafaxine hydrochloride, about 50 to about 80% by weight of water soluble diluent and about 2 to about 10% of... Agent: Cohen, Pontani, Lieberman & Pavane LLP

20090175933 - Preparation for the treatment of diarrhoea: A preparation for the treatment of diarrhoea comprising a bulking agent and an anti-diarrhoeal agent wherein the anti-diarrhoeal agent is provided in the form of an anti-motility agent.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090175935 - Pharmaceutical compositions of duloxetine: The present invention relates to solid oral pharmaceutical compositions of duloxetine, process for preparing such compositions and method of using such compositions. Preferably, the invention relates to a delayed release composition of duloxetine comprising a core comprising duloxetine, optional separating coat and an enteric coat, wherein the enteric coat comprises... Agent: Price Heneveld Cooper Dewitt & Litton, LLP

20090175936 - Microtablet-based pharmaceutical preparation: A pharmaceutical preparation consisting of various microtablets containing ingredients. The microtablets have the same form and the same weight.... Agent: D. Peter Hochberg Co. L.p.a.

20090175937 - Misuse preventative, controlled release formulation: Disclosed is a misuse preventative, controlled release formulation comprising a core comprising a superabsorbent material (for example, polycarbophil), a controlled release coat surrounding the core, and a plurality of controlled release microparticles having a pharmaceutically active agent (for example, an opioid analgesic) disposed within the core, the coat, or both... Agent: Goodwin Procter LLP Patent Administrator

20090175938 - Controlled release flurbiprofen and muscle relaxant combinations: This invention is a novel controlled release (CR) flurbiprofen and muscle relaxant combinations for oral administration with anti-inflammatory, analgesic, myorelaxant activity and methods of its manufacture. The pharmaceutical composition of the present invention is administered orally in tablet, multilayer tablet, multicoated tablet and capsule form.... Agent: Arent Fox LLP

20090175939 - Pharmaceutical compositions: Methods and compositions are provided which comprise effective amounts of analgesic to treat a subject, including reducing or eliminating an adverse effect associated with the analgesic.... Agent: Wilson Sonsini Goodrich & Rosati

20090175940 - Solubilized ibuprofen: A process for producing a solubilized ibuprofen, preferably in the form of a granulate, the process comprising the steps of: providing a mixture comprising solid ibuprofen and a first base selected from the group consisting of sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium glycinate, potassium glycinate and tribasic... Agent: Hoxie & Associates LLC

20090175941 - Tablet-form slow-release preparation for vertigo: The invention describes a pharmaceutical composition of a slow-release preparation in the form of tablets for the treatment of vertigo of any genesis. A pharmaceutical composition is described that contains cinnarizine and dimenhydrinate, wherein the release of active ingredients is slowed down. For this purpose, the pharmaceutical composition additionally contains... Agent: Kriegsman & Kriegsman

20090175942 - Solid dosage form of olmesartan medoxomil and amlodipine: The invention relates to a stable solid dosage form comprising olmesartan medoxomil and amlodipine or a pharmacologically acceptable salt thereof. In particular, it relates to solid dosage forms free from reducing sugars. The stable solid dosage form may optionally further comprise hydrochlorothiazide or a pharmacologically acceptable salt thereof.... Agent: King & Spalding

20090175944 - Gel suitable for implantation and delivery system: The invention concerns a dried form of a porous polymer gel material which may be rehydrated and placed under pressure or compression to induce salvation, thereby forming a high concentration gel, in the form of an injectable viscous putty or dough, which may be implantated in the body.... Agent: Kensey Nash Corporation

20090175945 - Systems, methods, and formulations for topically treating nail fungal infections and nail psoriasis: The present invention is drawn to systems, methods, and formulations for treating nail disorders. The system comprises an active agent formulation and a first barrier film. The active agent formulation includes an active agent and an aqueous liquid component. The first barrier film is configured to form a sheath over... Agent: Thorpe North & Western, LLP.

20090175943 - Transdiscal administration of specific inhibitors of pro-inflammatory cytokines: The present invention relates to injecting a high specificity cytokine antagonist into a diseased intervertebral disc.... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090175946 - Use of gelatin and a cross-linking agent for producing cross-linking medical glues: The invention relates to the use of gelatin and a cross-linking agent to provide a medical glue which forms a cross-linked gelatin gel in an area of application of the human or animal body. According to the invention, (i) the gelatin and the cross-linking agent are mixed with each other... Agent: Leydig Voit & Mayer, Ltd

20090175947 - Pharmaceutical composition for injectional particularly targeted local administration: The invention relates to a pharmaceutical composition for injectional, in particular targeted local administration, characterized in that it comprises a sterile suspension of platinum complex of general formula (I), wherein A and A′ independently of one another are an NH3 group or an amino or diamino group containing 1 to... Agent: Notaro & Michalos P.C.

20090175948 - Aerosol method for nano silver-silica composite anti-microbial agent: A method of forming and resulting nano-structured composite includes atomizing a mixture of an amount of each of aminopropyltriethoxysilane, AgNO3, DI water, and ethanol in a carrier gas; heating the atomized droplets at a selected temperature for a time sufficient to reduce the Ag to its elemental form in a... Agent: Mh2 Technology Law Group, LLP

20090175949 - Microparticles for delivery to cells and/or tissues: Delivery of bioactive molecules (BAMs) to organelles, cells, tissues, or animals with high efficiency is desirable. Novel compositions for highly efficient delivery of bioactive molecules by biolistic methods are described. The novel compositions include novel microparticle cores, microparticle core/BAM complexes, microparticle core/nanoparticle complexes and multilayer-microparticle core/BAM complexes. Any one of... Agent: Baker Donelson Bearman, Caldwell & Berkowitz, PC

20090175950 - Pharmaceutical safety dosage forms: Pharmaceutical safety dosage forms are provided which include a pharmaceutical and an antagonist to the pharmaceutical. The safety dosage forms are such that the antagonist has no significant bioavailability when the pharmaceutical safety dosage form is administered as intended. However, the antagonist is released and becomes bioavailable if the dosage... Agent: Cantor Colburn, LLP

20090175951 - Nanoparticulate compositions of immunosuppressive agents: Methods for stabilizing chemical compounds, particularly pharmaceutical agents, using nanoparticulate compositions are described. The nanoparticulate compositions comprise a chemical compound, such as a pharmaceutical agent, and at least one surface stabilizer. The component chemical compound exhibits chemical stability, even following prolonged storage, repeated freezing-thawing cycles, exposure to elevated temperatures, or... Agent: Elan Drug Delivery, Inc. C/o Foley & Lardner

20090175952 - Cefuroxime axetil granule and process for the preparation thereof: A cefuroxime axetil granule composition comprising a non-crystalline cefuroxime axetil solid dispersion or a substantially amorphous cefuroxime axetil, sucrose fatty acid ester, methacrylic acid-ethylacrylate copolymer and a disintegrating agent has highly desirable performance characteristics in terms of masking the bitterness of cefuroxime axetil, as well as high bioavailability and stability... Agent: Sughrue Mion, PLLC

20090175953 - Nanodispersions: The invention provides process for making contra-soluble nano-dispersions of at most sparingly-soluble materials in a soluble carrier material comprising the steps of: (i) providing a single phase mixture of: a) a solvent or a mixture of miscible solvents, b) at least one carrier material soluble in solvent (a), said carrier... Agent: Unilever Patent Group

20090175954 - Sheet-like composition: A sheet-shaped composition is provided which has an improved preservability and handling readiness, as well as a high flexibility in use. Amnion with trehalose added thereto is utilized. Addition of trehalose improves the flexibility of the amnion, and prevents basal membrane and stratum compactum from being damaged during lyophilization process.... Agent: Edwards Angell Palmer & Dodge LLP

20090175955 - Hydroperoxylapatite and compositions thereof: This invention relates to a compound of general formula Ca5(PO4)3(OOH)x(OH)1-x wherein 0<x<1, and compositions thereof.... Agent: Notaro & Michalos P.C.

20090175956 - Method of preparation and composition of antimicrobial ice: Composition and method for production of peroxycarboxylic acid solutions for various disinfection and cleaning compositions that utilizes non-equilibrium peroxycarboxylic acid. More specifically compositions comprise peracetic acid (PAA) and methods for making non-equilibrium PAA are provided. Frozen compositions useful as antimicrobial ice are provided.... Agent: Greenlee Winner And Sullivan P C

20090175957 - Acidic composition: A composition is provided which comprises an acidic component, generally fulvic acid, having a molecular weight not exceeding 20,000 Daltons and a low content of the elements aluminium, mercury, cadmium, chromium and lead. The acidic component is preferably carbohydrate derived and preferably using a wet oxidation process.... Agent: Birch Stewart Kolasch & Birch

20090175958 - Methods for deactivating allergens and preventing disease: This invention relates to articles of manufacture containing liquid compositions of hypohalous acid or hypohalous acid salt for deactivating allergens and preventing diseases on hard surfaces, soft surfaces and in the air. The articles of manufacture contain usage instructions with health claims. This invention also includes methods of instructing the... Agent: The Clorox Company

20090175959 - Controlled release solid preparation: The present invention provides a controlled release solid preparation superior in the stability of an active ingredient, which can exhibit pharmacological effects steadily and rapidly after administration, and shows a sustained pharmacological effect for a prolonged period of time: a controlled release solid preparation containing (1) an antacid, (2) an... Agent: Hamre, Schumann, Mueller & Larson, P.C.

20090175960 - Process for producing carbon dioxide solution, production apparatus, and carbonated water: A first aqueous solution filled in an electrolytic cell (2) is electrolyzed by applying DC voltage between the electrodes 7a and 7b in said electrolytic cell 2, to form an oxidation field short of electrons in said aqueous solution; and then, a second aqueous solution with carboxylic acid dissolved in... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090175961 - Dietary supplement compositions: Dietary supplements are disclosed herein. For example, dietary supplements containing a combination of tripeptides, potassium, pomegranate, and passionflower are provided.... Agent: Fish & Richardson P.C.

20090175962 - Process for the preparation of concentrated solutions of stabilized hypobromites: The invention provides stabilized concentrated aqueous solutions of alkali hypobromites, as well as a process for the preparation of said stabilized concentrated solutions at low temperatures, comprising reacting a concentrated alkali hydroxide aqueous solution with bromine, adding to the non-stabilized reaction product an aqueous solution of a sulfamic compound to... Agent: Kevin D. Mccarthy Roach Brown Mccarthy & Gruber, P.C.

20090175963 - Antiviral composition comprising lycoris squamigera extracts: Antiviral compositions including Lycoris squamigera extracts are described as useful for preventing or treating diseases caused by influenza virus infection of humans and other mammalian and avian subjects (e.g., pigs, horses, birds, and the like). Lycoris squamigera extracts in such use exhibit low toxicity in normal cell environments, and excellent... Agent: Intellectual Property / Technology Law

20090175964 - Composition for enhancing immunity: Disclosed is an edible composition for enhanced immunity comprising theanine or a source of theanine and a herb selected from Shankhpushpi, Shatavari, or a mixture thereof.... Agent: Unilever Patent Group

20090175965 - Use of unsaponifiable components of vegetable oils for preparing a cosmetic and related treatments: s

20090175966 - Antimicrobial compositions: The present invention also provides a product (preferably a product other than a foodstuff, pharmaceutical, or cosmetic) comprising a preservative effective amount of cinnamaldehyde or a mixture of cinnamaldehyde and one or more alkanol-dialkyl hydantoins.... Agent: Darby & Darby P.C.

20090175967 - Methods for treatment of intestinal carcinogenesis with rice bran: The present invention provides a method for treating colorectal cancer and reducing adenoma development in mammals by administering rice bran.... Agent: Townsend And Townsend And Crew, LLP

20090175968 - Dietary compositions for promoting brain health: Dietary compositions are disclosed herein. For example, dietary compositions containing a combination of a phosphatidylserine, DHA, EPA, antioxidants, and Ginkgo Biloba are provided.... Agent: Fish & Richardson P.C.

20090175969 - Formulation for treating obesity and associated metabolic syndrome: A formulation for treating obesity and associated metabolic syndrome. The formulation is a combination of especially selected vegetable extracts: Green tea extract containing epigallocatechin galate (EGCG), Coleus forskholii extract, Betula alba extract, and Guarana or Yerba Maté extract. Based upon clinical in vivo and in vitro studies, use of the... Agent: Alfred J Mangels

20090175970 - Stabilized plant extract and its therapeutic use: A plant extract, obtainable by aqueous extraction, is stabilised by the presence of a water-soluble agent capable of chelating the extract or a component thereof.... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090175971 - Method of using composition comprising pomegranate extracts against the common cold: The composition of one or more embodiments of the invention may be used to treat a common cold viral infection, since the composition of the present invention has significant antiviral properties as demonstrated by the examples of this application. The composition of the present invention may also be used as... Agent: Dalina Law Group, P.C.

20090175972 - Synergistic herbal ophthalmic formulation for lowering intraocular pressure in case of glaucoma: The present invention relates to an herbal ophthalmic composition of Withania somnifera and Areca catechu, which reduces intra ocular pressure of eyes in a synergistic manner. A composition of Withania somnifera and Areca catechu acts synergistically with the other ingredients when formulated as a composition of the present invention.... Agent: Oliff & Berridge, PLC

20090175973 - Coffee cherry compositions and methods for their use in the treatment of diabetes and diabetes related disorders: Compositions of coffee cherry, methods for their use in the treatment of diabetes and diabetes-related complications, and methods for manufacture of the compositions are disclosed. The compositions find use in the treatment of a variety of diabetes-related conditions including disorders relating to impaired vascular function. Methods for the treatment of... Agent: Stemedica Cell Technologies, Inc

20090175974 - Novel cadherin receptor peptide for potentiating bt biopesticides: Disclosed is a novel cadherin peptide that enhances the toxicity of Cry proteins. A novel insecticide composition comprising an effective amount of cadherin peptide having SEQ. ID. NO:2 and an effective amount of Bacillus thuringiensis Cry protein wherein the cadherin peptide comprises a Cry3Aa toxin binding region from the full-length... Agent: Usda-ars-office Of Technology Transfer National Ctr For Agricultural Utilization Research

20090169471 - Particles for injection and processes for forming the same: P

20090169472 - Methods and compositions for treating immune disorders: The present invention provides oligonucleotides, compositions comprising them and methods that use the oligonucleotides and compositions for stimulating cells expressing the TLR7 and/or TLR8 receptor. The oligonucleotides comprise for stimulating TLR7 comprise uracil-rich regions. The oligonucleotides for stimulating TLR8 comprise guanine-rich regions. The present methods and compositions are useful, inter... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090169473 - Diagnostic agent and therapeutic agent for disease associated with hepatocyte growth factor receptor: The diagnostic agent is for a disease associated with a hepatocyte growth factor receptor. wherein the drug includes: a labeled product of a partial polypeptide of hepatocyte growth factor containing a heparin-binding domain; or a labeled product of a polypeptide which consisting of an amino acid sequence in which one... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090169474 - Method for noninvasnely and quantitatively monitoring therapeutic and diagnostic transgene expression induced by ex vno and in vno gene targeting in organs, tissues and cells: An composition in a method for noninvasively monitoring the expression of therapeutic transgene delivered ex vivo and in vivo for the treatment of diseases includes the step of quantitatively imaging a reporter gene expression which is coupled to a therapeutic gene on a plasmid vector to infer levels, location, or... Agent: Law Offices Of Daniel L. Dawes

20090169475 - Radiolabeled derivatives of potent chymase inhibitors: Methods of imaging tissue of a mammal which expresses chymase include administering to the mammal an effective amount of a radiolabeled chymase inhibitor. Radiopharmaceuticals that may be used in diagnostic imaging and therapeutic treatment of disease characterized by expression of chymase have the structure of Formula I:... Agent: Foley And Lardner LLP Suite 500

20090169477 - Delaying or preventing onset of multiple sclerosis: Methods of treating persons at risk for relapsing MS are described.... Agent: Lowrie, Lando & Anastasi, LLP B2047

20090169476 - Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer: A novel gene 08P1D4 (also designated STEAP-1) and its encoded protein, and variants thereof, are described wherein STEAP-1 exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, STEAP-1 provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The... Agent: Goodwin Procter LLP Attn: Patent Administrator

20090169479 - Compounds comprising short aminoalcohol chains and metal complexes for medical imgaing: n

20090169480 - Dendritic polymers and magnetic resonance imaging contrast agent employing the same:

20090169481 - Dendritic polymers and magnetic resonance imaging contrast agent employing the same:

20090169478 - In vivo imaging and therapy with magnetic nanoparticle conjugates: A non-invasive in vivo technique is disclosed, useful for example in detecting cancers and micrometastases. The technique may be used to selectively deliver drugs to target cells such as tumors, metastases, micrometastases, and individual malignant cells. Ligands with specificity for a target cell receptor, and optionally drug molecules as well,... Agent: Patent Department Taylor, Porter, Brooks & Phillips, L.l.p

20090169484 - Iron-salen complex: The present invention provides a drug delivery system that overcomes conventional technical problems and that is readily put to practical use. Iron-salen complexes represented by General Formula (I) below. The invention renders iron-salen complexes magnetic, which can thus be used as drugs that can be delivered to affected areas in... Agent: Drinker Biddle & Reath LLP Attn: Patent Docket Dept.

20090169483 - Fluorescent photoprobe for the imaging of endothelin receptors: The present invention relates to a endothelin receptor antagonist conjugate of the formula (I) wherein R2 is an alkoxy group and one of R1 and R3 represents an alkoxy group and the other represents a group of the formula: (OCH2CH2)n—NH—X, wherein n is an integer of 1 to 100 and... Agent: Perkins Coie LLP

20090169482 - Silica-cored carrier particle: A nanoparticulate imaging probe with an oxide core, a biocompatible polymeric shell covalently attached to the oxide core, a dye, and a cleavable spacer that covalently binds the dye to the probe. When the spacer is cleaved, the dye is liberated from the probe. The emissions of the dye are... Agent: Carestream Health, Inc.

20090169486 - Biomedical foam articles: The present invention relates to biomedical foam articles for the wound sector which are formed by spraying a polymeric dispersion onto a wound. The polymeric dispersion being sprayed onto a wound surface forms a three-dimensional body which conforms to the spatial shape of the wound and which, as well as... Agent: Womble Carlyle Sandridge & Rice, PLLC

20090169487 - Essential oil diffusion: A method for treating and/or alleviating at least one symptom associated with impaired airway clearance of mucous, impaired oxygen intake, and/or infection in a patient suffering from a respiratory ailment and/or restrictive lung disease includes administering to the patient an effective amount of an essential oil composition including at least... Agent: Amin Talati, LLC

20090169485 - Gene therapy and pharmaceutical composition for prevention and treatment of lung cancer: Disclosed herein is a gene therapeutic agent and pharmaceutical composition for the prevention and treatment of lung cancer. For aerosol delivery, chemically synthesized polyester amine is used as a carrier in the gene therapeutic agent. The polyester amine/Akt1 siRNA complex is found to be effectively delivered to the lungs of... Agent: Birch Stewart Kolasch & Birch

20090169488 - Acidic solid oral compositons without erosive potential in saliva and method for determining erosive potential in saliva: Acidic oral compositions having calcium contents and effective pH-values in the area indicated by grey tone in FIG. 2 are non-erosive in saliva and capable of stimulating saliva production, even in “dry mouth” patients. A new multi-step test method for determining erosive potential in saliva has been used for identifying... Agent: Seed Intellectual Property Law Group PLLC

20090169489 - Cobalamin compositions and methods for treating or preventing mucositis: The present invention relates to troches, patches, gels, or viscous liquids for topical treatment or prevention of mucosal surfaces containing as an active ingredient molecules of cobalamin for the treatment of inflammatory, ulcerative and painful conditions of mucosal surfaces such as mucositis, stomatitis, vestibulitis, aphthous ulcerations, and Behcet's syndrome. For... Agent: Jeffrey T. Haley

20090169490 - Composition and method for weight loss: A weight loss composition consisting of 1 to 10 weight parts of L-hydroxy citric acid and 1 to 10 weight parts of L-carnitine tartrate as active components, and pharmaceutically or food-acceptable carrier is disclosed. The present composition can be made to tablet, capsule, oral juice or chewing gum which shows... Agent: Scihead Intellectual Property Law Group, Ltd

20090169491 - Peptides having activities of insulin like growth factor-1 and their uses: The present invention relates to a peptide having the activity of insulin like growth factor-1 (IGF-1) and derived from IGF-1, a composition for improving skin conditions or treating a periodontal disease comprising the peptide. The IGF-1 mimicking peptides of this invention have identical functions or actions to natural-occurring IGF-1 and... Agent: The Nath Law Group

20090169492 - Oral cavity composition: The object of the present invention is to provide an oral cavity composition which is nontoxic, excellent in plaque control, can prevent or treat onset of caries and periodontal disease caused by oral pathogens as well as can prevent or eliminate bad breath. The invention provides an oral cavity composition... Agent: Buchanan, Ingersoll & Rooney PC

20090169493 - Anti-senstivity, anti-caries, anti-staining, anti-plaque, ultra-mild oral hygiene agent: This invention relates to a composition useful as a dentifrice comprising a surfactant agent consisting essentially of monoalkyl and dialkyl phosphate esters, wherein the ratio of monoesters to diesters is greater than 1, and optionally an abrasive agent consisting essentially of siliceous materials.... Agent: Rhodia, Inc.

20090169496 - Dispersion of microparticulate titanium oxide and cosmetics containing the same: The present invention provides a dispersion of microparticulate titanium oxide that can generate a natural finish feeling, which includes a feeling of transparency, and has good long-term stability and an excellent UV protective effect in both UVA and UVB regions. The present invention is a dispersion of microparticulate titanium oxide... Agent: Rankin, Hill & Clark LLP

20090169495 - Merocyanine derivatives: Disclosed are merocyanine derivatives of formula (1), wherein R1 and R2 independently from each other are branched C4-C22alkyl; or branched C4-C12 alkenyl; R3 and R4 independently from each other are cyano; COR7, COOR7; CONR7R8; SO2(C6-C12)aryl; C2-C12alk-1-enyl; C3-C12cycloalk-1-enyl; C2-C12alk-1-inyl; C2-C12heteroalkyl; C3-C5heterocycloalkyl; C6-C10aryl; or C1-C9heteroaryl; wherein at least one of R3 and... Agent: Joann Villamizar Ciba Corporation/patent Department

20090169494 - Sunscreen cosmetic composition: s

20090169497 - Treatment and prevention of skin injury due to exposure to ultraviolet light: Photoprotective agents useful for the treatment or prevention of cell damage, particularly skin injury due to UV-light. Methods of prevention or treatment of cell damage and skin injury due to exposure to UV-light, particularly UVB-light. Methods include administration of an effective amount of one or more photoprotective N-mercaptoalkanoylcysteine derivatives of... Agent: Greenlee Winner And Sullivan P C

20090169498 - Controlled release gels: The invention relates to the field of gel-based delivery systems for a compound of interest, like a drug or cosmetic agent. Provided is a gel comprising at least one nonpolymeric gelator and at least one polymer, wherein the polymer content of said gel is more than 5 weight percent (wt... Agent: Traskbritt, P.C.

20090169499 - Interference pigments on the basis of silicon oxides: The present invention relates to pigments, the particles of which generally have a length of from 2 μm to 5 mm, a width of from 2 μm to 2 mm, and a thickness of from 20 nm to 2 μm, and a ratio of length to thickness of at least... Agent: Joann Villamizar, Patent Department Ciba Specialty Chemicals Corporation

20090169500 - Personal care compositions: This invention relates to personal care compositions containing polytrimethylene ether glycol in a variety of physical forms including solutions, gels, oil-in-water emulsions, water-in-oil emulsions, suspensions and solids. In a particularly preferred embodiment, the polytrimethylene ether glycol is derived predominantly from monomers obtained from renewable resources, making the personal care products... Agent: E I Du Pont De Nemours And Company Legal Patent Records Center

20090169501 - Mascara containing a sugar silicone surfactant: The invention relates to a mascara composition comprising at least one sugar silicone surfactant, as well as to methods of making and using such mascaras.... Agent: Oblon, Spivak, Mcclelland Maier & Neustadt, P.C.

20090169502 - Compositions and methods for treating keratinous substrates using polyamides: The disclosure relates to compositions and methods of using the compositions to treat keratinous substrates. The compositions provide a water resistant and non-transferable protective barrier on the substrate. For example, the compositions provide hair with improved shine, condition, manageability and color. The compositions contain at least one polyamide, at least... Agent: Connolly Bove Lodge & Hutz LLP Suite 1100

20090169504 - Compounds and pharmaceutical compositions for the treatment of viral infections: Provided herein are compounds, compositions and methods for the treatment of liver disorder, including HCV and/or HBV infections. Specifically, compound and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.... Agent: Jones Day

20090169503 - Dna-based vaccination of retroviral-infected individuals undergoing treatment: This invention provides DNA vaccines for the treatment of patients undergoing retroviral therapy. The vaccines are surprisingly effective at controlling viremia.... Agent: Townsend And Townsend And Crew, LLP

20090169505 - Novel vaccines against multiple subtypes of influenza virus: An aspect of the present invention is directed towards DNA plasmid vaccines capable of generating in a mammal an immune response against a plurality of influenza virus subtypes, comprising a DNA plasmid and a pharmaceutically acceptable excipient. The DNA plasmid is capable of expressing a consensus influenza antigen in a... Agent: Pepper Hamilton LLP

20090169506 - Use of gp130 activators in diabetic neuropathy: The invention relates to the use a substance signaling through gp130 for the manufacture of a medicament for the treatment and/or prevention of diabetic neuropathy. The use of IL-6 is preferred.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20090169508 - Opioid and opioid-like compounds and uses thereof: The present invention relates to opioid and opioid-like compounds, and pharmaceutical formulations thereof, and use thereof for prevention and treatment of disorders such as septic shock and organ damage.... Agent: Ladas & Parry LLP

20090169507 - Purine nucleoside analogues for treating flaviviridae including hepatitis c: This invention is directed to a method for treating a host, especially a human, infected with hepatitis C, flavivirus and/or pestivirus, comprising administering to that host an effective amount of an anti-HCV biologically active pentofuranonucleoside where the pentofuranonucleoside base is an optionally substituted 2-azapurine. The optionally substituted pentofuranonucleoside, or a... Agent: Jones Day

20090169511 - Mucosal bioadhesive slow release carrier for delivering active principles: A mucosal bioadhesive slow release carrier comprising an active principle and devoid of starch, lactose, which can release the active principal for a duration of longer than 20 hours. This bioadhesive carrier contains a diluent, an alkali metal alkylsulfate, a binding agent, at least one bioadhesive polymer and at least... Agent: Birch Stewart Kolasch & Birch

20090169510 - Novel macrocyclic inhibitors of hepatitis c virus replication: The embodiments provide compounds of the general Formulae I through general Formula VIII, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering... Agent: Knobbe Martens Olson & Bear LLP

20090169509 - O-linked glycosylation of peptides: The present invention provides polypeptides that include an O-linked glycosylation site that is not present in the wild-type peptide. The polypeptides of the invention include glycoconjugates in which a species such as a water-soluble polymer, a therapeutic agent of a biomolecule is covalently linked through an intact O-linked glycosyl residue... Agent: Morgan, Lewis & Bockius LLP (sf)

20090169515 - Canine probiotic bifidobacteria globosum: According to the invention there is provided a strain of lactic acid bacteria of the species Bifidobacteria pseudolongum obtainable by isolation from resected and washed canine gastrointestinal tract having a probiotic activity in animals. Methods of use and compositions comprising the Bifidobacteria pseudolongum of the present invention are also provided.... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090169513 - Expression of virus entry inhibitors and recombinant aav therefor: The present invention relates generally to the use of recombinant adeno-associated viruses (rAAV) for gene delivery and more specifically to the use of rAAV to deliver genes encoding human immunodeficiency virus entry inhibitors to target cells in mammals.... Agent: Marshall, Gerstein & Borun LLP

20090169514 - Expression vectors comprising the hs1 promoter of the vav1 oncogene and use thereof for the preparation of pharmaceutical compositions intended for somatic gene therapy: The present invention relates to the use of the HS1 promoter of the vav oncogene in the production of vectors selected from the groups of integrative vectors and non-integrative, non-plasmid vectors, for use in the preparation of pharmaceutical compositions intended for somatic gene therapy. By generating vectors that contain the... Agent: Ladas & Parry LLP

20090169516 - Method of constructing gene transport support: An object of the present invention is to provide a method of efficiently constructing a gene delivery carrier having a favorable activity and expression efficiency of a protein expressed by a gene introduced by transformation. Moreover, an object of the present invention is to provide a pharmaceutical composition comprising a... Agent: Jones Day

20090169512 - Vaccinia virus strains: The invention provides attenuated vaccinia virus vaccines that can be used in methods to prevent or treat small pox in patients, as well as methods of obtaining such vaccines.... Agent: Clark & Elbing LLP

20090169529 - Compositions and methods for immunostimulatory rna oligonucleotides: The present invention provides 4-nucleotide (4mer) RNA motifs that confer immunostimulatory activity, in particular, IFN-α-inducing activity to a RNA oligonucleotide. The present invention also provides RNA oligonucleotides, including siRNA, with high or low immunostimulatory activity. The present invention further provides the use of the RNA oligonucleotides of the invention for... Agent: Seed Intellectual Property Law Group PLLC

20090169517 - Compositions and methods for tumor-targeted delivery of effector molecules: The present application discloses the preparation and use of attenuated tumor-targeted bacteria vectors for the delivery of one or more primary effector molecule(s) to the site of a solid tumor. The primary effector molecule(s) of the invention is used in the methods of the invention to treat a solid tumor... Agent: Law Offices Of Albert Wai-kit Chan, PLLC

20090169530 - Plant disease controlling agent and controlling method: A plant disease controlling agent containing a lactic acid bacterium which is capable of controlling plant disease and a plant disease controlling method which comprises treating a plant and/or soil with the above-mentioned lactic acid bacterium. By using the lactic acid bacterium seemingly advantageous to human health, an agricultural crop... Agent: Jordan And Hamburg LLP

20090169531 - Use of symbiotic for the treatment of atopic dermatitis: The invention relates to the use of a product comprising a living Lactobacillus rhamnosus bacterium combined with lactose, particularly with a lactose-based medium, for the production of a medicament or a food supplement in order to treat a patient suffering from atopic dermatitis, in which said bacterium can ferment the... Agent: Cooper & Dunham, LLP

20090169518 - Pochonia chlamydosporia strain pcmr and method to use it in biological control of the root-knot-nematode (meloidogyne spp): This invention refers to isolation and utilization of the fungus Pochonia chlamydosporia var. chlamydosporia strain PcMR in biological control of nematodes, characterized in that it has a high virulence against Meloidogyne spp. in in-vitro microbiologic tests, pot tests and field tests. In these tests, the strain PcMR, isolated in Portugal,... Agent: Sughrue Mion, PLLC

20090169519 - Medicinal formulation containing a combination of hiv type i and hiv type ii: A novel medicinal formulation for the treatment of autoimmune diseases, said formulation comprising, combined serially diluted and potentized HIV TYPE I virus and HIV TYPE II virus, said dilution being effected in a vehicle selected from a group consisting of distilled water or ethyl alcohol and mixture of distilled water... Agent: Lucas & Mercanti, LLP

20090169526 - Bmp-6 estrogen responsive element and methods of use thereof: This invention is directed to a BMP-6 ERE nucleic acid sequence, vectors, cells and compositions comprising same. This invention also provides methods for identification of estrogen agonists, antagonists and therapeutic applications of same. This invention also provides methods of treating conditions, which are associated with estrogen insufficiency or with lack... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090169524 - Composites and methods of preparation and use thereof: The invention provides composites, methods for their preparation, composites prepared according to the methods, and methods for using the composites.... Agent: Viksnins Harris & Padys Pllp

20090169520 - Compounds, pharmaceutical compositions and therapeutic methods of preventing and treating diseases and disorders associated with amyloid fibril formation: Compounds, pharmaceutical compositions and methods for prevention and/or reversal of amyloid fibril formation and treating amyloid-related disorders are provided. Also provided a method of limiting and/or reducing inflammation.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090169523 - Hsc self-renewal: The invention is related to methods for culturing stem cells, more particularly hematopoietic stem cells (HSC). The invention relates to methods for HSC expansion and the use of RASSF8 to increase the retention and/or expansion of KLS cells in vitro. The invention is also directed to cells produced by the... Agent: Schwegman, Lundberg & Woessner, P.A.

20090169528 - Keratinocytes expressing exogenous angiogenic growth factors: The present invention relates to in vitro cultured skin tissue, and in particular to cultured skin tissue comprising exogenous genes encoding angiogenic growth factors. In some embodiments, the keratinocytes express exogenous angiopoietin-1 or a member of the VEGF family, preferably VEGF-A. In particularly preferred embodiments, the keratinocytes are incorporated into... Agent: Casimir Jones, S.c.

20090169527 - Materials from bone marrow stromal cells for use in forming blood vessels and producing angiogenic and trophic factors: A therapeutic for use in inducing angiogenesis and vasculogenesis, the therapeutic including angiogenesis and vasculogenesis inducing factors isolated from stem cells in conjunction with a pharmaceutically acceptable cell therapy. A method of amplifying the production of angiogenesis and vasculogenesis inducing factors secreted by exposing stem cells to and co-culturing the... Agent: Seed Intellectual Property Law Group PLLC

20090169522 - Mesenchymal stem cells expressing tnf-a receptor: Mesenchymal stem cells which express TNF-α receptor Type I in an amount of at least 13 pg/106 cells. Such mesenchymal stem cells inhibit the proliferation of lymphocytes and may be employed, in particular, in the treatment of graft-versus-host disease.... Agent: Mcandrews Held & Malloy, Ltd

20090169525 - Methods of reducing transplant rejection and cardiac allograft vasculopathy by implanting autologous stem cells: The invention provides novel methods of reducing transplant rejection and cardiac allograft vasculopathy in humans by employing the implantation of autologous progenitor cells into the transplanted donor heart. The autologous progenitor cells can be vascular progenitor cells (VPCs) and/or myocyte progenitor cells (MPCs) isolated from the recipient's explanted heart. Alternatively,... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090169521 - Vascularized cardiac tissue and methods of producing and using same: An isolated composition of matter is disclosed. The composition comprises a heterogeneous population of cells seeded on a scaffold, wherein the heterogeneous population of cells comprises cardiomyocytes, endothelial cells and fibroblast cells. Pharmaceutical compositions comprising same and uses thereof are also disclosed.... Agent: Martin D. Moynihan D/b/a Prtsi, Inc.

20090169532 - Curable bone cement: The present invention describes a curable bone cement. The cement comprises a curable polymeric binder and a filler, and is capable of curing without substantial evolution of heat on exposure to a curing agent. The binder comprises phenol groups which are capable of reacting in order to cure the cement.... Agent: Townsend And Townsend And Crew, LLP

20090169533 - Compositions and methods for treating neurodegenerative diseases: The present invention relates to compositions and methods for treating neurodegenerative diseases. In some embodiments, the present invention provides compositions for treating and preventing presbycusis.... Agent: Casimir Jones, S.c.

20090169534 - Variant forms of urate oxidase and use thereof: The present invention relates to genetically modified proteins with uricolytic activity. More specifically, the invention relates to proteins comprising truncated urate oxidases and methods for producing them, including PEGylated proteins comprising truncated urate oxidases.... Agent: Kramer Levin Naftalis & Frankel LLP Intellectual Property Department

20090169535 - Treatment of epilepsy by expressing st3gal-iii: The present invention provides methods of diagnosing epilepsy in a mammal by detecting ST3 β-galactoside α-2,3-sialyltransferase 3 (ST3Gal-III) activity or by detecting for one or more mutations in a ST3Gal-III gene that decrease that activity of a ST3Gal-III polypeptide. The invention further provides methods of treating an epileptic condition associated... Agent: Townsend And Townsend And Crew, LLP

20090169537 - Glutadon: The present invention relates to a pharmaceutical combination product for cancer therapy. The combination product comprises the two active ingredients glutaminase and 6-diazo-5-oxo-L-norleucine (DON). The invention further relates to the use of such a combination product for the treatment of cancers.... Agent: Morris Manning Martin LLP

20090169536 - Polypeptide having phytase activity and nucleotide sequence encoding the same: The invention relates to a recombinant DNA molecule, which, upon expression in a prokaryotic or eukaryotic host cell, encodes a polypeptide having phytase activity, wherein the recombinant DNA molecule comprises a DNA sequence selected from a) DNA sequences that have been obtained by variations of the mature wild-type E. coli... Agent: Edwards Angell Palmer & Dodge LLP

20090169538 - Methods of treating or preventing tissue damage caused by increased blood flow: A method of treating or preventing tissue damage occurring subsequent to affecting an increase in blood flow through a blood vessel which is in communication with the tissue, by administering an effective amount of a composition including a tissue damage-reducing or -preventing polypeptide including at least one of Thymosin beta... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20090169539 - Pdgf fusion proteins incorporated into fibrin foams: Compositions for wound healing, use of the compositions, and kits and methods of using thereof are described herein. In a preferred aspect, the compositions are suitable for use in a method for forming a fibrin matrix or foam that can be applied or injected at the site of need. In... Agent: Pabst Patent Group LLP

20090169545 - 5-ht4 receptor antagonists for the treatment of heart failure: This invention provides the use of a 5-HT4 receptor antagonist in the manufacture of a medicament for treating or preventing heart failure. Particular heart disorders to be treated are selected from the group comprising chronic heart failure, congestive heart failure, chronic congestive heart failure and heart failure resulting from ischaemic... Agent: Knobbe Martens Olson & Bear LLP

20090169544 - Formulation: A stable, aqueous pharmaceutical composition comprising an antibody having a heavy chain amino acid sequence of SEQ ID No: 3 and a light chain amino acid sequence of SEQ ID No: 4 and a pharmaceutically-acceptable adjuvant, diluent, carrier or excipient, wherein said composition has a pH of 4 to 6.... Agent: Fish & Richardson P.C.

20090169541 - Humanized anti-ccr2 antibodies and methods of use therefor: The present invention relates to a humanized antibody or functional fragment thereof which binds to a mammalian (e.g., human) CC-chemokine receptor 2 (CCR2) or a portion of the receptor and blocks binding of a ligand to the receptor. The invention further relates to a method of inhibiting the interaction of... Agent: Lowrie, Lando & Anastasi, LLP

20090169543 - Method for regulating immune function in primates using the foxp3 protein: Isolated nucleic acid molecules are provided which encode Fkhsf, as well as mutant forms thereof. Also provided are expression vectors suitable for expressing such nucleic acid molecules, and host cells containing such expression vectors. Also provided are pharmaceutical compounds and methods of identifying such compounds that can modulate the immune... Agent: Davis Wright Tremaine, LLP/seattle

20090169542 - Modulators of neuronal regeneration: The present invention provides methods and compositions related to CNS function and diseases.... Agent: Goodwin Procter LLP Attn: Patent Administrator

20090169540 - Use of an antagonist of epac for treating human cardiac hypertrophy: The present invention relates to the use of at least one Epac (Exchange Protein directly Activated by cAMP) antagonist for the manufacture of a medicament intended for the prevention or the treatment of pathologies selected from the list comprising cardiac hypertrophy, cardiac arrhythmias, valvulopathies, diastolic dysfunction, chronic heart failure, ischemic... Agent: Young & Thompson

20090169548 - Binding molecules: The present invention relates to the manufacture of mono, di and multivalent polypeptide binding complexes, also mono, di or multispecific polypeptide binding complexes and uses thereof. The invention also relates to the manufacture and use of a diverse repertoire of antigen specific VH binding domains derived from phage display libraries,... Agent: Cozen O'connor, P.C.

20090169549 - Conformational isomers of alpha-synuclein, antibodies thereto and methods of their manufacture and use: Conformational isomers of modified versions of α-Synuclein (αSyn), a protein that is associated with Parkinson's disease, have been designed and produced. These conformational isomers are produced by introducing cysteines into the α-Synuclein and scrambling the disulfide bonds to form stable and immunogenic isomers. These isomers are generically referred to as... Agent: Pabst Patent Group LLP

20090169546 - High affinity antibodies against hmgb1 and methods of use thereof: Compositions and methods are disclosed for inhibiting the release of a proinflammatory cytokine from a vertebrate cell, and for inhibiting an inflammatory cytokine cascade in a patient. The compositions comprise, for example, high affinity antibodies that specifically bind HMG1 and antigenic fragments thereof. The high affinity antibodies of the present... Agent: Medimmune, LLC Jonathan Klein-evans

20090169547 - Monoclonal antibodies against claudin-18 for treatment of cancer: The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing CLD18, including tumor-related diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder.... Agent: Mcandrews Held & Malloy, Ltd

20090169550 - Therapy of rituximab-refractory rheumatoid arthritis patients: A method is disclosed of treating a rituximab-refractory rheumatoid arthritis (RA) patient comprising administering an anti-CD20 antibody other than rituximab to the patient in an amount effective to treat the RA.... Agent: Genentech, Inc.

20090169551 - Methods and compositions for activating or inhibiting vegf-d and vegf-c: Methods for Activating endothelial growth factors VEGF-C or VEGF-D with plasmin, and methods of treatment comprising administering a pharmaceutical compositions comprising plasmin. Also disclosed are methods of screening for inhibitors of activation of the growth factors by plasmin, and method of treatment by blocking activation of VEGF-C/D activation by plasmin.... Agent: Marshall, Gerstein & Borun LLP

20090169552 - Negative immunomodulation of immune responses by erp5: The present invention relates to methods of treating immune disorders and cancers. In particular the invention provides methods of inhibiting the negative immunomodulatory effects of ERp-5 on T cells and dendritic cells, in conjunction with other surface receptors.... Agent: Fulbright & Jaworski L.L.P.

20090169555 - Mammalian sphingosine kinase type 2 isoforms, cloning, expression and methods of use thereof: Nucleic acids encoding mouse and human sphingosine kinase type 2 isoforms, methods for detecting agents or drugs which inhibit or promote sphingosine activity and therapeutic agents containing peptides or antibodies to peptides encoded by such nucleic acids.... Agent: Frishauf, Holtz, Goodman & Chick, PC

20090169553 - Novel protein fusion/tag technology: The present invention relates to fusion molecules comprising at least one first purification domain and a molecule of interest, wherein the purification domain is selected from the group consisting of a kringle domain and a staphylocoagulase D2 domain. The present invention further relates to methods of purifying a molecule of... Agent: Fitzpatrick Cella Harper & Scinto

20090169554 - Polypeptides of leishmania major and polynucleotides encoding same and vaccinal, therapeutical and diagnostic applications thereof: The present invention relates to new proteins of Leishmania major and to therapeutical and diagnostic applications thereof. More particularly, the present invention relates to excreted/secreted polypeptides and polynucleotides encoding same, compositions comprising the same, and methods of diagnosis, vaccination and treatment of Leishmaniasis.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20090169556 - Vascular endothelial cell growth factor antagonists: The present invention provides human vascular endothelial cell growth factor (hVEGF) antagonists, including monoclonal antibodies, hVEGF receptors, and hVEGF variants that are useful for the treatment of age-related macular degeneration, and other diseases and disorders characterized by undesirable or excessive neovascularization.... Agent: Genentech, Inc.

20090169558 - Bicyclic aromatic compounds useful as inhibitors of mitogen-activated protein kinase-activated protein kinase-2: e

20090169560 - Disulfide, sulfide, sulfoxide, and sulfone derivatives of cyclic sugars and uses thereof:

20090169559 - Parenteral formulations of peptides for the treatment of systemic lupus erythematosus: The subject invention provides a pharmaceutical composition comprising: an aqueous carrier; from 0.1 mg/ml to 20 mg/ml of the composition of a pharmaceutically acceptable salt of a) a peptide comprising at least 12 and at most 30 consecutive amino acids having a sequence corresponding to (i) a sequence of amino... Agent: John P. White Cooper & Dunham LLP

20090169557 - Whole glucan particles in combination with antibiotics, vaccines and viral monoclonal antibodies: The present invention relates to compositions and methods of using whole glucan particles and agents. Whole glucan particles enhance the tumoricidal activity of the innate immune system by binding to the C3 complement protein receptor CR3. This binding enhances innate immune system cytotoxicity, as well as stimulating the release of... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20090169561 - Anti-ip-10 antibodies and methods of use thereof: The invention relates to fully human antibodies, and fragments thereof, that bind to interferon-inducible-protein-10 (IP-10, CXCL10), thereby modulating the interaction between IP-10 and its receptor, CXCR3, and/or modulating the biological activities of IP-10. The invention also relates to the use of such anti-IP-10 antibodies in the prevention or treatment of... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20090169562 - Human binding molecules having killing activity against enterococci and uses thereof: The present invention provides human binding molecules specifically binding to enterococci and having killing activity against enterococci, nucleic acid molecules encoding the human binding molecules, compositions comprising the human binding molecules and methods of identifying or producing the human binding molecules. The human binding molecules can be used in the... Agent: Traskbritt, P.C.

20090169563 - Antibodies to cd40: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies... Agent: Ropes & Gray LLP

20090169564 - Stimulus inducible protein kinase complex and methods of use therefor: Compositions and methods are provided for treating NF-κB-related conditions. In particular, the invention provides a stimulus-inducible IKK signalsome, and components and variants thereof. An IKK signalsome or component thereof may be used, for example, to identify antibodies and other modulating agents that inhibit or activate signal transduction via the NF-κB... Agent: Jones Day

20090169565 - Neutrokine-alpha antibodies and methods of use thereof: The present invention relates to a Neutrokine-alpha antibody and a process for producing a Neutrokine-alpha antibody. The invention further relates to screening methods for identifying compounds that inhibit or enhance the action of Neutrokine-alpha. Also provided are diagnostic methods for detecting autoimmune disorders and therapeutic methods for treating autoimmune disorders... Agent: Leydig, Voit & Mayer Ltd.

20090169566 - Bioactive compositions: This invention relates to a bioactive composition comprising: (d) pH sensitive bioactive agent (e) an edible carboxylic acid containing moiety and (f) an edible alkalising moiety, wherein the proportion of said moieties and active agent provide pH control such that (i) when 400 mg of said composition is added to... Agent: Nixon Peabody LLP - Patent Group

20090169567 - Basic group-containing compound and use thereof: a salt thereof, a solvate thereof, or a prodrug thereof wherein all symbols are as defined in the specification has an antagonistic activity against CXCR4 and is therefore useful as a preventive and/or therapeutic agent for CXCR4-mediated diseases, for example, inflammatory and immune diseases (for example, rheumatoid arthritis, arthritis, systemic... Agent: Sughrue-265550

20090169568 - Antigenic complex for the diagnosis and treatment of porphyromonas gingivalis infection: The present invention provides a purified multimeric complex form P. gingivalis. The complex comprises at least one domain from each of RgpA, Kgp and HagA, and has a molecular weight greater than about 300 kDa.... Agent: Morrison & Foerster LLP

20090169569 - Apo-2l receptor agonist and cpt-11 synergism: Methods of using effective amounts of Apo-2L receptor agonists and CPT-11 to induce apoptosis and suppress growth of cancer cells are provided.... Agent: Genentech, Inc.

20090169570 - Methods and agents for improving targeting of cd138 expressing tumor cells: Disclosed are immunoconjugates having specificity for CD138 that diminish adhesion of CD138 expressing tumor cells to stroma cells and methods of using the same. This diminished adhesion renders the tumor cells not only susceptible to the immunoconjugate, but also to other agents, in particular cytotoxic agents.... Agent: Joyce Von Natzmer Pequignot + Myers LLC

20090169572 - Methods for damaging cells using effector functions of anti-cdh3 antibodies: The present invention relates to the use of cytotoxicity based on the effector function of anti-CDH3 antibodies. Specifically, the present invention provides methods and pharmaceutical compositions that comprise an anti-CDH3 antibody as an active ingredient for damaging CDH3-expressing cells using antibody effector function. Since CDH3 is strongly expressed in pancreatic,... Agent: Townsend And Townsend And Crew, LLP

20090169571 - Selected ma motifs to include cell death and/or apoptosis: The present application is directed to the use of dsRNA and/or ssRNA for the purpose of inducing apoptosis or cell death in proliferating cells. Specifically, low molecular weight and high molecular weight dsRNA and ssRNA are shown to induce apoptosis and/or cell death in proliferating cells, to arrest proliferation of... Agent: Townsend And Townsend And Crew, LLP

20090169574 - Heteroclitic analogs and related methods: Heteroclitic analogs of Class I epitopes are prepared by providing conservative or semi-conservative amino acid substitutions at positions 3 and/or 5 and/or 7 of these epitopes. The analogs are useful in eliciting immune responses with respect to the corresponding wildtype epitopes.... Agent: Sterne, Kessler, Goldstein & Fox P.l.l.c.

20090169575 - Proteins: The present invention provides methods and compositions for screening, diagnosis and prognosis of colorectal cancer, for monitoring the effectiveness of colorectal cancer treatment, and for drug development.... Agent: Klauber & Jackson

20090169573 - T-cell stimulatory peptides from the melanoma-associated chondroitin sulfate proteoglycan and their use: The present invention relates to melanoma-associated chondroitin sulfate proteoglycan (MCSP) epitopes recognized by T cells, especially by CD4+ T lymphocytes (short T-cells) and CD8+ T cells, on human melanoma cells. In more detail, the present invention relates to novel T-cell stimulatory tumour antigenic peptides corresponding to said epitopes (MCSP peptides);... Agent: Ballard Spahr Andrews & Ingersoll, LLP

20090169576 - Influenza combinatorial antigen vaccine: The invention provides a combinatorial influenza vaccine composition for use in providing prophylactic protection in humans against influenza viruses or animals, and a method of producing the vaccine.... Agent: King & Spalding LLP

20090169577 - Method for stimulating immune response against moraxella catarrhalis: Provided is a method for stimulating in an individual an immune response against M. catarrhalis. The method is performed by administering to an individual a composition that contains at least one isolated M. catarrhalis protein in an amount effective to stimulate an immune response against M. catarrhalis in the individual.... Agent: Hodgson Russ LLP The Guaranty Building

20090169578 - Tolerizing agents: Described herein is the development of fusion proteins useful for inducing tolerance in a subject. In particular embodiments, the tolerizing agents are useful for influence autoimmune, inflammatory, and/or allergic reactions. Example tolerizing fusion proteins contain a targeting portion (which delivers the fusion protein) and a toleragen or allergen or other... Agent: Klarquist Sparkman, LLP

20090169580 - Attenuated vaccines for non-segmented negative sense rna viruses: The invention relates to an attenuated non-segmented negative-sense RNA virus characterized by at least one mutation in the L gene wherein the mutation reduces viral replication, the methods of manufacturing and methods of use.... Agent: Foley & Lardner LLP

20090169579 - Modified vaccinia ankara virus avriant: The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus, wherein the MVA-BN virus, or a derivative thereof, induces at least substantially the same level of immunity in vaccinia virus prime/vaccina virus boost regimes when compared to DNA prime/vaccinia virus boost regimes. It further describes... Agent: Law Office Of Salvatore Arrigo

20090169581 - Stabilizing formulations for recombinant viruses: This invention relates to preparations of viruses, e.g. for vaccine or other pharmaceutical or research use, to their stabilization, and to processes of producing such preparations, as well as to their use, e.g. as vaccines or as virus vectors. The formulations comprise a sugar, a preservative, a dispersing agent, a... Agent: Mr. Reza Yacoob Aventis Pasteur Limited

20090169582 - Recombinant lactobacillus and use of the same: The invention relates to recombinant lactobacillus, use of the same and a pharmaceutical composition including the same. The recombinant lactobacillus includes a heterologous nucleic acid sequence. The heterologous nucleic acid sequence encodes at least an immunogenic fragment of the mite allergens Der p 1, Der p 2, or Blo t... Agent: Kenyon & Kenyon LLP

20090169587 - Chronotherapeutic dosage forms: A chronotherapeutic pharmaceutical formulation comprising a core containing an active agent (e.g., a drug) and a surfactant and a delayed release compression coating comprising a natural or synthetic gum applied onto the surface of the core.... Agent: Davidson, Davidson & Kappel, LLC

20090169585 - Resveratrol-containing compositions and their use in modulating gene product concentration or activity: The present invention relates to a resveratrol-containing composition capable of modulating gene expression to an extent greater than that observed with resveratrol alone or with calorie restriction. The invention particularly pertains to such resveratrol-containing compositions that comprise resveratrol, a chelator, hyaluronic acid, and/or vitamin D and which upon administration to... Agent: Edell, Shapiro & Finnan, LLC

20090169583 - Solid adsorbates of hydrophobic drugs: A solid pharmaceutical composition comprises a solid adsorbate comprising a hydrophobic drug, a lipophilic vehicle, and a porous substrate, wherein the hydrophobic drug and lipophilic vehicle are adsorbed to the porous substrate.... Agent: Chernoff, Vilhauer, Mcclung & Stenzel

20090169586 - Stable packaged dosage form and process therefor: A process for preparing a stable packaged dosage form, said dosage form comprising an oxidation-sensitive material, for example carotenes and carotenoids in whole dried algae of the genus Dunaliella. The invention also relates to a stable packaged oral dosage form comprising whole dried algae, but substantially no antioxidants exogenous to... Agent: Occhiuti Rohlicek & Tsao, LLP

20090169584 - Treatment of sleep disturbances: The present invention provides a new composition for treating pain-associated sleep disturbances, especially shortened sleep duration, comprising ibuprofen and diphenhydramine. The composition is further prepared as a bilayer tablet or caplet, or alternatively as a soft gelatin capsule composition, to prevent interaction between the active ingredients.... Agent: Wyeth Patent Law Group

20090169588 - Compositions containing proteins for the transfer/recycling of structurally modified lipids, and the applications thereof: The invention relates to compositions containing recycling/transfer proteins for structurally/functionally modified lipids, a lipid depot of structurally non-modified lipids, and non-transferable active ingredients. Such compositions can be used for the engineering of biomembranes, e.g. by external topical application, especially to the skin/mucous membranes. Structurally or functionally, especially oxidatively modified, lipids... Agent: Collard & Roe, P.C.

20090169589 - Filler pigments: Filler pigments based on platelet-shaped substrates, which are coated with barium sulfate and at least two metal oxides and/or metal hydroxides are highly suitable as filler pigments especially for cosmetic formulations.... Agent: Millen, White, Zelano & Branigan, P.C.

20090169590 - System for reducing the number of predator fish: The system includes a capsule member made from a material which is dissolvable in the digestive fluids of a predator fish and at a selected rate in water. The capsule contains a material which, following ingestion by a predator fish, results in death of the predator fish. A connecting element... Agent: Jensen + Puntigam, P.s.

20090169591 - Medical articles for the treatment of tumors: In accordance with one aspect of the invention, implantable and insertable medical articles are provided which are useful for the local treatment of tumors. These medical articles comprise one or more active agents that influence the local tumor environment in vivo, for example, decreasing the level of nutrients in the... Agent: Mayer & Williams PC

20090169594 - Carbon nanotube-based fibers, uses thereof and process for making same: A biocompatible and biodegradable carbon nanotube-based fiber capable of stimulating and sustaining cell proliferation and stimulating and sustaining nerve regeneration is disclosed herein. The biocompatible and biodegradable carbon nanotube-based fiber comprising at least one carbon nanotube; a biodegradable copolymer; and a coagulating polymer. The present disclosure also relates to a... Agent: Fulbright & Jaworski L.L.P.

20090169595 - Controlled release polymeric compositions of bone growth promoting compounds: The present invention is directed to an improved system for controlled release of a bone growth promoting compound and to a flowable composition for its formation. The flowable composition is composed of a bone growth promoting compound, a thermoplastic polymer and an organic solvent. The flowable composition is capable of... Agent: Pfizer Inc.

20090169596 - Device for spinal cord nerve regeneration: A method and a mould for manufacturing a nerve regeneration device specifically adapted to an individual injury in the spinal cord are proposed, which will allow axons in the damaged area to regenerate and restore function. The resulting device can be adapted to a specific wound in order to ascertain... Agent: Young & Thompson

20090169593 - Method of using and producing tropoelastin and tropoelastin biomaterials: A device implantable within a human body, and a method for producing the device, are provided. The device comprises a biocompatible coating on at least a portion of an outer surface of a substrate. The biocompatible coating comprises tropoelastin. A biocompatible coating is formed in situ on the outer surface... Agent: Marger Johnson & Mccollom, P.C.

20090169592 - Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects: Disclosed herein are improved osteogenic devices and methods of use thereof for repair of bone and cartilage defects. The devices and methods promote accelerated formation of repair tissue with enhanced stability using less osteogenic protein than devices in the art. Defects susceptible to repair with the instant invention include, but... Agent: Ropes & Gray LLP

20090169597 - Treatment of intervertebral disc degeneration using human umbilical cord tissue-derived cells: Methods for treating a patient having a disease or condition related to IVD degeneration are provided. The methods comprise administering cells obtained from human umbilical cord tissue, or administering pharmaceutical compositions comprising such cells or prepared from such cells. In some embodiments, administering the cells promotes repair and regeneration of... Agent: Patton Boggs LLP

20090169598 - Treatment of bacterial infections: The invention relates to polypeptides, comprising repeats of peptides derived from apolipoproteins, which exhibit antibacterial activity and to nucleic acids encoding the same. The invention further provides the use of such polypeptides, derivatives, analogues or nucleic acids as medicaments, and also their use in methods of preventing or treating bacterial... Agent: Davis Wright Tremaine LLP/los Angeles

20090169599 - Scientifically modulated and reprogrammed treatment (smart) fas/fasl virus technology intended to neutralize t-helper cells infected with the human immunodeficiency virus: Scientifically Modulated And Reprogrammed Treatment (SMART) Virus Fas/FasL technology is intended to terminate T-Helper cells infected with the Human Immunodeficiency Virus. The SMART-Fas/FasL Virus carrying Fas and FasL cell-surface receptors is capable of engaging a T-Helper cell infected by HIV that is expressing one or more FasL cell-surface receptors. When... Agent: Lane B. Scheiber

20090169600 - Hydrogen peroxide delivery system: A delivery system, e.g. a skin dressing, comprising an upper component, comprising hydrogen peroxide, and a lower component in hydrated condition, such that when the upper and lower components are placed in contact with each other, hydrogen peroxide migrates towards the lower component is provided.... Agent: Morgan Lewis & Bockius LLP

20090169603 - Adhesive pharmaceutical preparation: In the adhesive pharmaceutical preparation of the invention, a pressure-sensitive adhesive layer is laminated on one side of the backing. The pressure-sensitive adhesive layer contains a branched monoalcohol having from 12 to 28 carbon atoms, a drug which is liquid at room temperature or around room temperature (in which, free... Agent: Sughrue-265550

20090169604 - Adhesive pharmaceutical preparation containing bisoprolol: In the adhesive pharmaceutical preparation of the invention containing bisoprolol, a pressure-sensitive adhesive layer is laminated on one side of the backing. The pressure-sensitive adhesive layer contains a branched monoalcohol having from 12 to 28 carbon atoms, a free base of bisoprolol and a polyisobutylene pressure-sensitive adhesive. Accordingly, compatibility of... Agent: Sughrue-265550

20090169602 - Allergy treatment by epicutaneous allergen administration: The invention provides pharmaceutical compositions, kits, and methods for the treatment of allergy. The compositions are adapted for epicutaneous administration and comprise an allergen and at least one pharmaceutically acceptable excipient. They may be designed as adhesive patches, intradermal delivery devices, ointments, gels, sprays, or similar types of formulation suitable... Agent: Edwards Angell Palmer & Dodge LLP

20090169605 - Novel tape preparation: It is intended to provide a preparation for percutaneous administration of 2-(4-ethyl-1-piperazinyl)-4-(4-fluoro-phenyl)-5,6,7,8,9,10-hexahydrocycloocta[b]pyridine (Compound A), which inhibits the generation of a metabolite and is capable of continuously maintaining a blood drug level. Specifically, a tape preparation comprising an adhesive layer formed on one surface of a support, characterized in that the... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090169601 - Transdermal therapeutic system for administering lipophilic and/or sparingly skin- permeable active substances:

20090169606 - Low flexural strength transdermal tobacco alkaloid patch:

20090169615 - Collagen formulations for improved skin care: Compositions and methods for administering collagen to a human subject have been developed. The collagen-containing lipid vesicles of the invention provide a delivery system for human collagen which eliminates problems associated with chemical and physical instability of the collagen as well as immune responses to non-human collagen.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20090169611 - Gel-formulations of hydrophobic photosensitizers for mucosal applications: The present invention relates to improved methods of formulations of hydrophobic photosensitizers, and their precursors, for mucosal administration. The formulation of the invention comprises of hydrophobic photosensitizers which have been incorporated into suitably sized liposomes. Additionally, these formulations include the incorporation of PS-loaded liposomes into a copolymer matrix. The liposome... Agent: Bolesh J Skutnik Ceramoptec Industries

20090169610 - Liposome preparation: The present invention provides cancer treatment preparations of excellent targetability. The sugar chain-modified liposomes of the present invention, which contain an aromatase inhibitor, anti-androgenic agent, lyase inhibitor, GnRH agonist, GnRH antagonist, anti-angiogenic agent, tyrosine kinase inhibitor, serine-threonine kinase inhibitor, antibody having an anticancer activity, ansamitocin, capecitabine, celmoleukin, docetaxel hydrate, gemcitabine... Agent: Foley And Lardner LLP Suite 500

20090169614 - Methods of suppressing microglial activation and systemic inflammatory responses: Methods of suppressing the activation of microglial cells in the Central Nervous System (CNS), methods of ameliorating or treating the neurological effects of cerebral ischemia or cerebral inflammation, and methods of combating specific diseases that affect the CNS by administering a compound that binds to microglial receptors and prevents or... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090169607 - Pharmaceutical compositions comprising cyclosporin: The invention relates to liquid pharmaceutical compositions containing: a) a therapeutically effective dose of a cyclosporin; b) an aqueous carrier liquid; c) a first solubilizing substance selected among the group of phospholipids; and d) a second solubilizing substance selected among the group of non-ionic surfactants. Preferably, the cyclosporin is liposome... Agent: Edwards Angell Palmer & Dodge LLP

20090169609 - Pqs and its conjugates as adjuvants and their uses in pharmaceutical compositions: The present invention relates to new adjuvants and the uses in pharmaceutical compositions, like in vaccines. In particular, the present invention provides new compounds useful as adjuvants and/or immunomodulators for prophylactic and/or therapeutic vaccination in the treatment of infectious diseases, inflammatory diseases, autoimmune diseases, tumours, allergies as well as for... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20090169612 - Systemic immune activation method using nucleic acid-lipid complexes: This invention relates to a method for systemic immune activation which is effective for eliciting both a systemic, non-antigen specific immune response and a strong antigen-specific immune response in a mammal. The method is particularly effective for protecting a mammal from a disease including cancer, a disease associated with allergic... Agent: Dla Piper LLP (us)

20090169613 - Targeting of tumor stem cells through selective silencing of boris expression: The present invention provides compositions useful for the treatment of cancer that inhibit tumor stem cells through suppression of an activity or the expression of BORIS. The compositions target tumor stem cells through molecules that are specific to tumor stem cells. Specifically, the invention provides immunoliposomes specific to tumor stem... Agent: The Law Office Of Jane K. Babin Professional Corporation

20090169608 - Topically applicable composition for use as a skin bleaching agent: X is NH or a direct bond and n is 2, 3 or 4, preferably 2 or 3, and its use for lightening skin colour, for depigmenting liver spots and for evening out non-uniformities in skin colouration. The invention further relates to dermatologically effective compositions containing at least one disulfide... Agent: Hoffmann & Baron, LLP

20090169616 - Formulation and method for the release of paroxetine in the large intestine: The present invention provides a delayed and/or controlled release formulation of paroxetine or a pharmaceutically acceptable salt thereof that is formulated to release a substantial portion of the active ingredient (e.g., paroxetine) in the large intestine of an individual in need thereof. In one embodiment, the present invention provides a... Agent: Alston & Bird LLP

20090169619 - Carbamazepine extended release dosage form: Extended release pharmaceutical dosage forms of carbamazepine for oral administration to maintain a patient's blood concentration for at least a 12 hour period, methods of administering dosage forms and processes for the preparation of such dosage form.... Agent: Gibson & Dernier L.L.P.

20090169617 - Controlled release formulations comprising uncoated discrete unit(s) and an extended release matrix: A controlled-release formulation comprising one or more distinct and discrete units located in physical juxtaposition to enable administration to a patient in need of treatment in a single dose, characterised in that the or each unit comprise(s): (i) a unit dose of an active pharmaceutical ingredient or pharmaceutically acceptable salt... Agent: Summa, Additon & Ashe, P.A.

20090169618 - Zolpidem pharmaceutical compositions: The present invention provides extended release pharmaceutical compositions comprising zolpidem or a salt thereof.... Agent: Kenyon & Kenyon LLP

20090169620 - Orally disintegrating tablet compositions of temazepam: The compositions of the present invention are orally disintegrating tablet compositions comprising a therapeutically effective amount of at least one drug such as temazepam, 0.5-3% of an ODT binder polymer, a sugar alcohol and/or saccharide, and a disintegrant.... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090169621 - Pharmaceutical excipient having improved compressibility: A microcrystalline cellulose-based excipient having improved compressibility, whether utilized in direct compression, dry granulation or wet granulation formulations, is disclosed. The excipient is an agglomerate of microcrystalline cellulose particles and from about 0.1% to about 20% silicon dioxide particles, by weight of the microcrystalline cellulose, wherein the microcrystalline cellulose and... Agent: Davidson, Davidson & Kappel, LLC

20090169622 - Delayed-release oral pharmaceutical composition for treatment of colonic disorders: A timed or delayed release oral composition delivery system for the treatment of colonic disorders and diseases is provided. According to one aspect, a delayed release oral pharmaceutical composition includes an active core comprising a therapeutically effective amount of 5-amino salicylic acid (i.e., mesalamine); a primary coating composition disposed around... Agent: Michael P. Morris Boehringer Ingelheim Usa Corporation

20090169623 - Use of ginsenosides and extracts containing them: The present invention relates to the use of ginsenosides and a plant extract containing ginsenosides in a cosmetic or pharmaceutical composition or in a food supplement for the protection of the skin against deleterious effects of stress or irradiation e.g. sunlight or UV irradiation.... Agent: Barbara A. Shimei Director, Patents & Licensing

20090169625 - Electrostatically controlled hydrogels: The compositions and methods disclosed herein pertain to the manufacture and use of hydrogels. The disclosed compositions and methods pertain to hydrogels capable of induction by a variety of methodologies, such as by pH, salt and/or mixing. Such hydrogels are capable of self- or co-assembly and while doing so, may... Agent: The Mccallum Law Firm, P. C.

20090169624 - Nano-emulsion technology for drug elution: Embodiments of the invention provide to apparatuses and media used in drug elution studies and methods for making and using them. One embodiment of the invention is a drug elution method that can be used for in-vitro studies of a matrix impregnated with a compound such as a drug blended... Agent: Gates & Cooper LLP Howard Hughes Center

20090169627 - Particles for injection and processes for forming the same: In accordance with one aspect of the invention, injectable particles are provided which comprise (a) a first group of injectable particles comprising first polymeric particles loaded with a first therapeutic agent and (b) a second group of injectable particles comprising second polymeric particles loaded with a second therapeutic agent. The... Agent: Mayer & Williams PC

20090169626 - Tamper resistant dosage forms: Tamper resistant controlled release formulations.... Agent: Darby & Darby P.C.

20090169628 - Article and method for focused delivery of therapeutic and/or diagnostic materials: A microfiber extrudate and delivery process includes a bio-compatible polymer matrix forming a body of the microfiber extrudate, an exogenously excitable material arranged within the body, and an active load arranged within the body.... Agent: Mcnees Wallace & Nurick LLC

20090169630 - Methods and compositions for controlled and sustained production and delivery of peroxides and/or oxygen for biological and industrial applications: Methods and compositions for the controlled and sustained release of peroxides or oxygen to aqueous environments (e.g. a patient's body or circulatory system, or for other applications) or non-aqueous environments, include a material coating or encapsulating hydrogen peroxide, inorganic peroxides or peroxide adducts. In the case of peroxide adducts, and... Agent: Cooper & Dunham, LLP

20090169629 - Micellar compositions with ophthalmic applications: This invention relates to micellar compositions comprising at least one pharmaceutically active substance and a mixture of n-alkyl dimethyl benzyl ammonium chlorides, wherein the mixture comprises more than 30% n-alkyl dimethyl benzyl ammonium chlorides having a chain length superior or equal to C16. This invention also relates to ophthalmic compositions... Agent: Young & Thompson

20090169631 - Micronized opioid compositions, formulations and dosage forms and methods of making same: Novel compositions, formulations and dosage forms comprising stabilized micronized opioid particles are disclosed. Exemplary opioids include oxycodone, oxymorphone, hydrocodone, and hydromorphone, including as free bases or as salts. Stabilized micronized opioid particles having a Dv90 particle size distribution of less and or equal to 10μ or less than or equal... Agent: K&l Gates LLP

20090169633 - Oral particle including pseudoephedrine hydrochloride and cetirizine dihydrochloride: The present invention relates to an oral particle including pseudoephedrine hydrochloride and cetirizine dihydrochloride, which primarily includes a nucleus having a diameter ranging 25˜40 mesh, a pseudoephedrine-hydrochloride layer coated outside the nucleus with a coating solution composed of pseudoephedrine hydrochloride, a binder, a lubricant and pure water/alcohol, a release-control layer... Agent: Rosenberg, Klein & Lee

20090169632 - Sustained release composition and manufacturing method thereof: A sustained release composition comprising a polymer and manufacturing method thereof. The sustained release composition comprises a polymer, a bioactive agent, and a release rate determined agent, wherein the release rate determined agent is dispersed in the sustained release composition to control the release rate of the bioactive agent. The... Agent: Thomas, Kayden, Horstemeyer & Risley, LLP

20090169634 - Dna vaccine comprising il-6-encoding dna construct and applications thereof: The present invention provides a DNA vaccine, which comprises a DNA construct comprising an expression vector which is expressible in a eukaryotic cell, and a nucleotide fragment which comprises an IL-6-encoding sequence and an HPV E7-encoding sequence. In addition, the present invention also provides a pharmaceutical composition and a method... Agent: Bacon & Thomas, PLLC

20090169635 - Pharmaceutical compositions and use thereof: Colloidal compositions, loaded with non-covalently bonded antibiotics, can be efficiently used for the treatment of severe bacterial pneumonia and other serious lung infections such as tuberculosis. Such formulations, comprised of biodegradable nanoparticles or nanocapsules with incorporated antibiotics, show a significant increase in antibacterial activity, extended and sustained drug release and... Agent: Alpharx Inc.

20090169640 - Compositons for nasal administration of pharmaceuticals: Compositions for nasal administration, which comprise a pharmaceutical, a physiologically active peptide, or a peptide-related compound, and as the carrier thereof, crystalline cellulose with a specific particle diameter and/or partially pregelatinized starch are provided. Such compositions improve the in vivo absorption efficiency of pharmaceuticals.... Agent: Wilson Sonsini Goodrich & Rosati

20090169638 - Inhibitors of ribonucleotide reductase subunit 2 and uses thereof: The present application relates to inhibitors of ribonucleotide reductase subunit 2 (R2), and methods and compositions related to the R2 inhibitors. In certain embodiments, the R2 inhibitors include nucleic acids, such as for example siRNAs.... Agent: Ropes & Gray LLP

20090169636 - Microparticles containing biodegradable polymer and cationic polysaccharide for use in immunogenic compositions: Immunogenic compositions are described herein which comprise microparticles that further comprise a biodegradable polymer. The microparticle compositions also comprise a cationic polysaccharide and an immunological species selected from an antigen, an immunological adjuvant and a combination thereof. Also described are methods of making such compositions and methods of administering such... Agent: Helen Lee Novartis Vaccines And Diagnostics

20090169637 - Nanocomposite particles: Nanocomposite particles having good solubility and redispersibility in water are provided. The nanocomposite particles include a sugar material and nanoparticles containing a drug to be delivered and a biodegradable polymer, the sugar material being disaccharide, and a mass ratio of the nanoparticles to the disaccharide being within the range of... Agent: Oliff & Berridge, PLC

20090169639 - Particles for injection and processes for forming the same: In accordance with one aspect of the invention, injectable particles are provided which comprise (a) a vinyl formal polymer, (b) a glucosamine polymer, and (c) an ionically or covalently bound agent selected from therapeutic agents, cell surface binding agents, and combinations thereof. Other aspects of the invention pertain to methods... Agent: Mayer & Williams PC

20090169641 - Compressible particles: Disclosed herein are methods that include providing a first particle having pores, the first particle having a first compression test value, and partially cross-linking the first particle to form a second particle having pores, the second particle having a second compression test value that is larger than the first compression... Agent: Fish & Richardson PC

20090169642 - Reconstructed living adipose tissue: The present invention relates to tissues and tissue sheets assembled from adipose-derived stromal cells. Particularly, it relates to reconstructed adipose tissues which comprise adipocytes as well as reconstructed conjunctive tissues which comprise adipose-derived stromal cells. The reconstructed tissues and sheets can be used, for example, in cosmetic applications for the... Agent: Dann, Dorfman, Herrell & Skillman

20090169643 - Composition for enhancing immune function: The present invention disclosed a composition for enhancing immune function comprising, as active ingredients, zinc and a saccharide having 3-O-α-D-glucopyranosyl-D-glucose as a structural unit. The composition for enhancing immune function according to the present invention exhibits a remarkably superior immunoenhancing effect to that achieved by the independent use of zinc... Agent: Wenderoth, Lind & Ponack, L.L.P.

20090169644 - Antidandruff shampoo: Surfactant-containing cleansing compositions contain hydrogenated castor oil for stabilizing an antidandruff component that is insoluble in the cleansing composition. As a result, thorough and gentle cleansing of skin and/or of hair with simultaneous antidandruff effect is ensured, without phase separation, change in viscosity, or reduction in the foaming ability during... Agent: Ratner Prestia

20090169645 - Iron sulfate-based phosphate adsorbent: The present invention relates to a process for the preparation of a novel composition, and to the use of the composition as a phosphate adsorbent, in particular for administration in humans or animals.... Agent: Rankin, Hill & Clark LLP

20090169646 - Methods of treating cystic fibrosis: A method of treating and/or managing cystic fibrosis in a patient by administering an electrolyzed saline solution containing hypohalous acid. Preferably, the hypohalous acid is hypochlorous acid. Also provided is a method of treating and/or managing cystic fibrosis by administering an electrolyzed saline solution at specific pHs such as between... Agent: Cooley Godward Kronish LLP Attn: Patent Group

20090169647 - Liquid antiseptic compositions containing iodine and a sugar and/or sugar alcohol: The present invention relates to compositions that contain iodine intended primarily for tissue antisepsis, particularly skin antisepsis.... Agent: 3m Innovative Properties Company

20090169648 - Compositions to reduce blood glucose levels and treat diabetes: The invention discloses compositions that effectively reduce and stabilize glucose levels in the blood of mammals, specifically in pre-diabetic patients and patients with type 2 diabetes mellitus (T2DM). Composition 1 (Comp1) reinforces efficacy of Mg salt to reduce glucose level by the combination of Mg salt with anti-inflammatory agents konjac-glucomannan... Agent: Seed Intellectual Property Law Group PLLC

20090169649 - Treatment of neurodegenerative diseases: The present invention relates to the use of selenate or a pharmaceutically acceptable salt thereof in methods and compositions for enhancing the activity of the protein phosphatase PP2A. Methods of reducing phosphorylation of tau protein, inhibiting activity of GSK3 and treating or preventing neurodegenerative diseases are also described.... Agent: Knobbe Martens Olson & Bear LLP

20090169650 - Food compositions incorporating stearidonic acid: The present invention relates to the improvement of food items through the increased utilization of plant-derived stearidonic acid. Many long chain fatty acids have been classified as being Omega 3 and have been shown to provide several health benefits, including heart health. According to the current invention plant-derived stearidonic acid... Agent: Monsanto Company

20090169651 - Anti-skin damage compositions with complimentary dual mode of action: Disclosed are skin care compositions exerting a novel complementary dual mode of action in protecting the skin from day-to-day insults. The skin care compositions of the present invention comprise the extract from the liquid endosperm of Cocos nucifera as the principle ingredient along with one or more actives including the... Agent: Sabinsa Corporation

20090169652 - Personal care compositions: Personal care compositions comprising an active component, use of such compositions, and methods of marketing such compositions. The personal care compositions can be applied topically, ingested orally, injected, or used as part of a regimen.... Agent: The Procter & Gamble Company Global Legal Department - Ip

20090169653 - Composition for prophylaxis or treatment of urinary system infection and method thereof: The present invention relates to a composition for prophylaxis or treatment of urinary system infection, comprising a matrix metalloproteinase inhibitor. The present invention also relates to a method for prophylaxis or treatment of urinary system infection, comprising administering to a patient in need of such treatment an effective amount of... Agent: Wpat, PC Intellectual Property Attorneys

20090169654 - Tea composition and process for the manufacture thereof: A composition comprising tea, 0.1 to 15% by weight of herb selected from Shankhpushpi, Shatavari, Vidarikhand, Arogyapacha or a mixture thereof; and 0.01 to 0.5% by weight of a flavouring agent is disclosed. Also disclosed is a process for manufacturing the composition.... Agent: Unilever Patent Group

20090169656 - Insect repellent concentrate formulation: A non-toxic insect repellent concentrate formulation utilizing a plurality of all natural active components has been proven to be effective in repelling mosquitoes for periods of between six to eight weeks, with one application. The insect repellent concentrate formulation includes a plurality of natural essential oils comprising at least one... Agent: Malloy & Malloy, P.A.

20090169655 - Insect repellent formulation: A non-toxic insect repellent formulation utilizing a plurality of all natural active components in solution has been proven to be effective in repelling mosquitoes for periods of between six to eight weeks, with one application. The insect repellent formulation includes a plurality of natural, essential oils in an aqueous solution... Agent: Malloy & Malloy, P.A.

20090169657 - Phaseolus vulgaris extracts, their use, and formulations containing them: Extract obtainable by extraction from Phaseolus sp. with mixtures of ethanol and water, characterised by an α-amylase inhibitor content in between 1,000 and 1,600 USP/mg (HPLC titre between 6 and 14% w/w) and a phytohaemagglutinin content in between 8,000 and 30,000 HAU/g, and a process for its preparation.... Agent: Mathews, Shepherd, Mckay, & Bruneau, P.A.

20090169658 - Toona sinensis extract for suppressing proliferation and inducing apoptosis of osteosarcoma cells: Toona sinensis extract for suppressing the proliferation and inducing apoptosis of osteosarcoma, but not normal human osterblasts. The extraction process comprises: extracting Toona sinensis with water to obtain a first extract, and filtering the first extract by a membrane to obtain a filtrate, and the Toona sinensis extract of the... Agent: Thomas, Kayden, Horstemeyer & Risley, LLP

20090169659 - Purification and endotoxin-removal process: A process for purifying an aqueous composition including a water-soluble contaminant having lipid groups, e.g. an endotoxin, comprises contacting the composition with a lipophilic component that forms a complex with the contaminant; a first removal step, of material having a size larger than the complex; and a second removal step,... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20090169660 - A composition of radix codonopsis and radix astragali, a method for preparation thereof and its application: The invention relates to a composition of Radix Codonopsis and Radix Astragali of which the main component is prepared according to a certain weight ratio of Radix Codonopsis and Radix Astragali. The invention also provides a method of preparing the pharmaceutical composition and its applications in the preparation of an... Agent: Dickstein Shapiro LLP